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Summary
The type II transmembrane serine proteases (TTSP) are cell surface proteolytic 
enzymes that mediate a diverse range of cellular functions, including tumour invasion 
and metastasis. Matriptase-2 is a relatively newly identified member of the TTSP 
family whose role in cancer is currently poorly understood. Sanders et al 2008 
investigated the effect of matriptase-2 in PC3 and DU145 prostate cancer cells. This 
study aims to further elucidate the role of matriptase-2 in cancer development and 
progression. The relationship between matriptase-2 and p-catenin was examined as 
previous preliminary data (unpublished) showed P-catenin to be a protein of interest 
from a screen of molecules associated with cell.cell and celhmatrix adhesion performed 
during previous studies.
To build on the data gained from Sanders el al 2008, normal prostate cell lines PZHPV7 
and PNT2C2 had matriptase-2 stably knocked down and were used in assays to asses 
cell functionality. Knock-down of matriptase-2 did not alter the growth or adhesion of 
PZHPV7 or PNT2C2 cells but did however; cause a significant reduction in their motile 
and invasive capabilities. HECV cells were also used to examine the effect of 
matriptase-2 on angiogenesis. The over-expression of matriptase-2 in these cells had no 
effect on growth and adhesion but significantly reduced the motile and tubule formation 
abilities of the HECV cells. This is a similar effect to that seen in the PZHPV7 and 
PNT2C2 cells.
PC3 and DU145 cells over-expressing matriptase-2 were also used to examine possible 
mechanisms of matriptase-2 action. Examination into the possible relationship between 
matriptase-2 and p-catenin revealed that a knockdown of matriptase-2 increased the p- 
catenin levels and conversely, over-expression decreased the P-catenin levels in PC3 
cells. In DU 145 cells the P-catenin levels increased. This may be due to the differing 
expression levels of key molecules such as E-cadherin. The HECV cells appeared to 
show no change in p-catenin levels. Angiogenesis factor MMP-7 was found to be 
altered in response to p-catenin levels. Additionally matritpase-2 over-expression was 
found to reduce uPA and the converse with matriptase-2 knockdown in all cell lines 
examined.
These results indicate that matriptase-2 may have a regulatory function over p-catenin 
and uPA in prostate cells. This is possibly two mechanisms by which matriptase-2 
protects against cancer metastasis and angiogenesis in normal cells and tissues. 
However, due to the differences seen in the p-catenin experiments, there are obviously 
other possible mechanisms to be considered. This study provides a valuable insight into 
how this poorly understood protease functions in prostate cancer.
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Chapter X  
Introduction
1
1.1 Introduction to prostate cancer
1.1.1 Prostate cancer incidence, risk factors
Prostate cancer is the most commonly diagnosed cancer in men in the UK. 
Approximately a quarter of new cancer cases diagnosed in men are prostate cancer. 
In 2007 around 36,000 men were diagnosed with prostate cancer in the UK. In 2008, 
there were 37,051 new cases of prostate cancer diagnosed in the UK, which is 
around 101 men every day or one man every 15 minutes. The lifetime risk of being 
diagnosed with prostate cancer is 1 in 9 for men in the UK. This was calculated in 
January 2011 using incidence and mortality data for 2008 (CRUK 2010). Although 
prostate cancer incidence rates appear to be rising, this is thought to be attributed to 
the advancement in detection methods, such as the advancement in PSA serum 
testing and ultrasound imaging.
The strongest known risk factor for prostate cancer is age, with very low risk in 
men under 50 and rising risk with increasing age thereafter. Very few cases are 
registered in men under 50 and around three-quarters of cases occur in men over 65 
years. The largest number of cases is diagnosed in those aged 70+ (Figure 1.1). It is 
estimated from post-mortem data that around half of all men in their fifties have 
histological evidence of cancer in the prostate, which rises to 80% by age 80, but 
only 1 in 26 men (3.8%) will die from this disease (Sakr et a l , 1996). It is 
commonly believed that more men die with prostate cancer than from  it. Another risk
factor is familial history. A family history of prostate cancer is one of the strongest 
known risk factors for this disease. It has been estimated that 5-10% of all prostate 
cancer cases and 30-40% of early-onset cases (men diagnosed <55 years) are caused 
by inherited susceptibility genes (Bratt, 2002). If a first degree family member is 
diagnosed with prostate cancer the risk of developing the disease increases two to 
three times, which further increases as the person ages.
It has been noted that incidence rate vary round the world suggesting that risk is 
associated with ethnicity. In the UK, black Caribbean and black African men have 
around two to three times the risk of being diagnosed or dying from prostate cancer 
than white men, while Asian men generally have a lower risk than the national 
average (Wild et al., 2006).
Due to the large variations in the incidence of prostate cancer between different 
cultures and their diet there has been interest in the potential risks involved. It has 
been suggested that the ‘western’ diet may increase risk compared to that of the 
lower incidence ‘asian’ diet, though there is little evidence supporting this. A recent 
review of the evidence concluded that foods containing lycopenes and selenium 
probably have a protective effect while diets high in calcium may increase risk. 
Other risk factors that are being considered are alcohol, smoking, body weight, 
endogenous hormones and diabetes mellitus.
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Figure 1.1 Number of deaths and age-specific mortality rates, prostate 
cancer, UK (taken from CR-UK, 2007).
1.1.2 Anatomy and histology of the prostate
The prostate is a tubuloalveolar walnut sized gland of the male reproductive 
system, which is situated within the pelvis at the base of the bladder, and surrounds 
the urethra. The prostate is also surrounded posteriorly by the rectum, through which 
it can be felt during rectal examination. The prostate is believed to be enclosed by a 
capsule composed of collagen, elastin, and large amounts of smooth muscle. 
Although this capsule may be partially transgressed by normal glands making the 
determination of extracapsular disease problematic. The prostate is mainly composed 
of glandular epithelium which is deposited in a fibromuscular stroma. This non- 
glandular fibromuscular stroma makes up around a third of the gland, and stretches 
from the bladder neck to the striated sphincter. It comprises of fibroblasts, smooth 
muscle, nerves and lymphatics. The stroma is immediately continuous with the
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capsule, and progressively lengthens into fibrous tissue that terminates in loose 
connective, and adipose tissue. Although the prostate lacks discernible lobes, it is 
characterised as having a zonal architecture as defined by McNeal (McNeal, 1969, 
1981, 1981). There are four major zones within the normal prostate: the peripheral 
zone, the central zone, the transition zone and the anterior fibromuscular stroma 
(Figure 1.2).
The peripheral zone extends posterolaterally around the prostate from the apex 
to the base and has the largest volume, accounting for around 70% of the gland. The 
central zone accounts for around 25% of the prostate gland and surrounds the 
ejaculatory duct apparatus and constitutes the majority of the prostatic base. Finally 
the transition zone, which is the smallest zone and accounts for 5% of total prostate 
volume; comprises two small lobules that adjoin the prostatic urethra. The peripheral 
zone is the most common site for the development of prostatic carcinomas whereas 
the transition zone is region where benign prostatic hyperplasia (BPH) more 
commonly originates. The prostate is believed to be enclosed by a capsule composed 
of collagen, elastin, and abundant smooth muscle. Although this capsule may be 
partially transgressed by normal glands making the determination of extracapsular 
disease problematic.
On the whole, the prostatic glands are simply branched and tubuloalveolar in 
structure, lined with both cuboidal and columnar secretory epithelial cells androgen- 
dependant for their growth. These terminally differentiated columnar cells are rich 
in secretory granules, keratin and enzymes such as prostatic acid phosphatase,
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leucine amino peptidase and PSA. They are tightly packed together via cellular 
adhesion molecules (CAMS), and attached to a basement membrane through integrin 
receptors which connect them to the stromal cells via an extracellular matrix, 
enhancing epithelial cell growth. The prostate also contains a pseudostratified 
epithelium with three differentiated epithelial cell types: luminal, basal, and 
neuroendocrine (Foster et al., 2002; Hudson, 2004; Peehl, 2005). The luminal 
epithelial cells form a continuous layer of polarised columnar cells that produce 
protein secretions and express high levels of the androgen receptor (AR). Basal cells 
are located beneath the luminal epithelium and above the basement membrane, 
express AR at much lower levels. Neuroendocrine cells are rare cells of unknown 
function that express endocrine markers such as chromogranin A, but are AR 
negative.
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Figure 1.2 Zonal anatomy of the prostate: the three glandular zones of the 
prostate and the anterior fibromuscular stroma (Cancer medicine 6th edition 2000)
1.1.3 Biology of prostate cancer
The majority of prostate cancers are classified as adenocarcinomas that originate 
from the prostatic epithelium (-95%). The other 5% is composed of other categories 
such as ductal adenocarcinoma, mucinous carcinoma, and signet ring carcinoma, and 
are all extremely rare. The most significant histological variant is the neuroendocrine 
prostate cancer, which is generally classified as either small cell carcinoma or a 
carcinoid tumour, and represents <2% of prostate cancer cases (Grignon, 2004). The
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development of solid tumours is generally thought to be a multi-step process in 
which successive genetic events occur in a normal cell to render it increasingly 
malignant. In prostate cancer the genetic and epigenetic processes that result in 
cancer are poorly understood. It is believed that the occurrence of pre-malignant 
lesions may pre-date the development of cancer by many years (Figure 1.3).
The umbrella term ‘prostatic intraepithelial neoplasia’ or ‘PIN’ describes the 
heterogeneous morphologic lesions prostatic dysplasia or atypia. PIN is generally 
characterised at the histological level by the appearance of luminal epithelial 
hyperplasia, reduction in basal cells, enlargement of nuclei and nucleoli, cytoplasmic 
hyperchromasiam and nuclear atypia (Bostwick and Foster, 1999). These 
abnormalities are generally found within architecturally benign-appearing glands and 
acini. PIN is graded depending on the degree of basal cell layer disruption (with 
more disruption being present in high grade PIN): grade 1 is a mild manifestation; 
grade 2 is moderate, and grade 3 is severe. Grades 2 and 3 are often combined as 
‘high grade’ PIN. PIN is presumed to be a pre-malignant lesion due to its common 
presence adjacent to prostate adenocarcinomas.
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1.1.4 Prostate cancer detection
The probability of developing prostate cancer rises with age, with an incidence 
percentage of over 30% in men over the age of 50, and up to 80% by the age of 80. 
As prostate cancer is typically a slow growing cancer, most never grow to the point 
of causing symptoms. Because of this the majority of men die with prostate cancer 
rather than of it. Due to this lack of symptoms, prostate cancer is often diagnosed in 
an already advanced state. Around 75% of patients exhibit locally extensive or 
metastatic disease, resulting in a poor prognosis of less than 15% surviving over 5 
years (Foster, 1990). The patients that do present with symptomatic prostate cancer 
experience bladder outlet obstruction resulting in reduced urinary flow, and bladder 
emptying. However, these symptoms are also present in those with benign prostate 
hyperplasia which makes the correct diagnosis of a malignant disease more 
important. This also adds to the difficulties in managing the disease. Other 
symptoms of prostate cancer include a feeling of pain in the pelvis and bones, fatigue 
or blood in the urine, are usually associated with advanced or metastatic prostate 
cancer (Foster and Abel, 1992).
Three main strategies exist in the detection of prostate cancer; serum prostate 
specific antigen (PSA) analysis, digital rectal examination (DRE), and trans-rectal 
ultrasound (TRUS) detection. It has been shown that a higher rate of detection can be 
achieved if a combination of these methods is used in diagnosis. PSA in combination 
with DRE for example, leads to a doubling in detection rates, in comparison to DRE 
alone (Littrup and Goodman, 1994).
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1.1.4.1 Serum PSA test
PSA is a glycoprotein, serine protease that is produced by the prostatic 
epithelium and periurethral glands and is present in large amounts in prostatic 
secretions. Although PSA is not cancer specific, a rising serum PSA level can 
indicate the potential presence of prostate cancer. PSA was first described in 1966 
and has revolutionised the diagnosis and management of prostate cancer. It is now 
the most common screening test used for the detection of prostatic disease (Elgamal 
e ta l, 1994).
A serum PSA level of 4-10 ng/ml indicates the presence of prostate cancer and 
patients presenting with a serum PSA in this range usually have a needle biopsy to 
confirm the presence of the disease. Around 2-3% of men screened for prostate 
cancer using the PSA serum test will have prostate cancer. It is reported that a PSA 
level of greater than 4ng/ml has a sensitivity of 80% in detecting prostate cancer in 
asymptomatic men (Catalona et a l, 1994).
PSA exists in several forms in the circulation, and although most is complexed 
to protease inhibitors, a small fraction remains unbound. The percentage of free-PSA 
(free:total PSA ratio) is lower in men with prostate cancer. A cut off value of less 
than 25% free-PSA yielded a 95% cancer detection rate in men with total serum PSA 
levels between 4 and lOng/ml (Catalona et a l, 1998).
Although PSA testing is used worldwide, questions have been asked involving 
limitations that reduce the accuracy of the test. This is mainly due to data from
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several groups which showed that a significant number of men with PSA levels 
within the ‘normal range’ actually had prostate cancer, some even of a high grade. In 
addition, as BPH, prostatis, and ejaculation can also cause an increase in PSA levels, 
patients who have PSA levels in the range of 4ng/ml-10ng/ml, sometimes have to 
undergo unnecessary and painful biopsies (Thompson et a l, 2005; De Angelis et al., 
2007).
Because of these limitations, attempts have been made to improve the specificity 
of the PSA test. As PSA production from benign epithelium rises with age, age- 
specific PSA cutoff points were developed (Oesterling et a l, 1993). Another 
modification is PSA density. The serum concentration of PSA appears to be 
influenced by total prostate volume. The PSA concentration is divided by the total 
gland volume as measured by TRUS. A PSA density of >0.15ng/ml increased the 
specificity of detection of prostate cancer compared with total PSA, although the 
optimal cut-off point is debated (Ohori et a l, 1995). Another common modification 
is the monitoring of PSA velocity. This involves monitoring the rate of change (PSA 
velocity) of serum PSA levels rather than PSA level. An increase of 0.75ng/ml per 
year has reported a specificity of over 90% in distinguishing prostate cancer from 
BPH (Carter e ta l, 1992)
1.1.4.2 Digital Rectal Examination (DRE)
Digital rectal examination (DRE) is the oldest detection test for prostate cancer 
and was common before the development of PSA testing. It is still used today
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alongside PSA testing and has the benefit of detecting non-PSA secreting tumours. 
The process involves a physician inserting a gloved, lubricated finger into the rectum 
in order to inspect the size, shape, and texture of the prostate, and any lumps or 
nodules that may be present. Areas deemed irregular then go through further 
evaluation to determine whether they are cancerous or not. The sensitivity of this test 
is limited as the examining finger can only palpate the posterior and lateral aspects 
of the prostate gland. Studies suggest that 25-35% of tumours occur in portions of 
the prostate that are inaccessible to DRE (McNeal et al., 1986). Prostate cancer 
tumours that are detected via DRE are often at a more pathologically advanced state 
of disease compared to those found by PSA testing. Before PSA testing was 
introduced most men diagnosed with prostate cancer ultimately died of their disease 
(Smith and Catalona, 1995). Due to these limitations DRE is rarely used as the sole 
diagnostic indicator of prostate cancer, rather in conjunction with other more reliable 
tests.
1.1.4.3 Trans-rectal Ultrasonography (TRUS)
Trans-rectal ultrasonography was presented over 20 years ago and is the 
preferred method by which to obtain prostate needle biopsies. The process involves 
inserting an ultrasound probe into the rectum of the patient, and using the resulting 
image to direct spring loaded 18-gauge biopsy needles into abnormal areas of the 
prostate. Although TRUS is not recommended for the detection of early-stage 
prostate cancer, it can however, image the outline of the prostate, identify cysts, 
abscesses and calcifications within the prostate, and can be used to determine 
prostate volume. The most commonly used biopsy technique is the six-core or
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sextant biopsy, with 10 to 12 being carried out to sample the prostate as it leads to 
significantly improved cancer detection rates (Borley and Feneley, 2009).
1.1.5 Tumour grading systems
To tailor the treatment of prostate cancer to a specific person the tumour first 
needs to be graded and classified using well established cancer grading systems such 
as the Gleason grading system and the TNM classification system.
1.1.5.1 The Gleason grading system
The Gleason grading system for prostate carcinomas is the dominant method 
used around the world and was first described by Gleason and Mellinger in 1974. 
The grading is based on the histological pattern of the distribution and growth of the 
tumour cells in the prostatic stroma, as well as the degree of glandular differentiation 
in H&E stained prostatic tissue samples from either a biopsy, or if after radical 
prostatectomy, a whole prostate (Gleason and Mellinger, 1974).
The various growth patterns (shown in Figure 1.4) are combined to form 5 basic 
grade patterns ranging from 1 (least aggressive) to 5 (most aggressive). This enables 
the generation of a histological score ranging from 2-10, by the addition of the 
primary grade pattern; the prevailing one in that area, to the secondary pattern, which 
is the subsequently most widespread pattern. However, if only one grade is present, 
or if the second grade covers less than 3% of the total tumour, its value is doubled in 
order to give a corresponding Gleason score.
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The cell arrangement seen in each Gleason pattern is described in Table 1.1 and 
ranges from the closely packed well-differentiated carcinoma cells seen in pattern 1, 
to smooth rounded masses of necrotic and very poorly differentiated carcinoma cells 
in pattern 5 (Humphrey, 2004).
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Figure 1.4: Schematic drawing of Oleason histological grading (Taken from 
(Humphrey, 2004).
PROSTATIC ADENOCARCINi
(Histologic Grades)
B.F.SIuMn.M.D:
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1 Nodular, well-defined 
and smooth edges
Pushing Single, round to oval, closely 
packed, but separate glands
Medium
2 Masses less well defined 
and less well-confined
Some gland 
separation at 
tumour edge
Single, separate, round to oval 
glands, with more variation in 
gland size and shape
Medium
3A ill-defined infiltrating 
edges
Irregular
extension
Single separate glands of variable 
shape and size, with elongated, 
angular and twisted forms with 
wide stromal separation
Medium
3B Ill-defined infiltrating 
edges
Irregular
extension
Same as 3A but glands are smaller Small to 
very small
3C Masses and cylinders 
with smooth rounded 
edges
Expansile Papillary and cribriform 
epithelium, without necrosis
Medium to 
large
4A Raggedly infiltrative Diffusely
permeative
Fused glands, creating masses, 
cords or chains
Small, 
medium or 
large
4B Raggedly infiltrative Diffusely
permeative
Similar to 4A but cells have cleared 
cytoplasm (hypemephromatoid)
Small, 
medium or 
large
5A Smooth, rounded 
cylinders
Expansile Papillary, cribriform or solid 
masses with central necrosis 
(corned ocarcinoma)
Variable
5B Diffusely infiltrative Diffusely
permeative
Masses and sheets of anaplastic 
carcinoma, with few tiny glands or 
signet ring cells
Small
Table 1.1. Gleason grading system adapted from (Humphrey, 2004).
1.1.5.2 Tumour Nodal Metastasis (TNM) classification
The TNM classification of the prostate was first developed in the 1940s by 
Pierre Denoix, but was updated by the American Joint Committee on Cancer and 
International Union against Cancer (UICC), in 2002. The system is based on primary 
tumour (T), lymph node (N), and metastases (M) categories, with each one being 
built on a series of clinical examinations, radiological imaging, biopsies, and 
biochemical analyses (Greene and Sobin, 2002). Clinical T staging is the most
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important prognostic factor for clinically localised prostate cancer, and is usually 
carried out using DRE. Regional lymph node metastases meanwhile are strong 
predictors of progression, and imaging using nomograms is essential for men who 
have a greater risk of developing metastases. Finally, staging for bone metastases has 
been widely used as the established norm for distinguishing outlying metastases of 
the axial skeleton, with MRI being the most reliable means of detection (Borley and 
Feneley, 2009). The TNM staging is fully described below in Table 1.2, and 
represented in diagram form in Figure 1.5.
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Figure 1.5: Diagram showing the three categories of TNM classification 
(Cancer Update 2005).
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! Primary tumour (T)
TX Primary tumour cannot be assessed
TO No evidence of primary tumour
T1 Clinically inapparent tumour, neither palpable or visible by inaging
Tla Tumour (non-palpable) as incidental histological finding at transurethral resection 
of prostate in 5% of tissue resected
Tib Tumour (non-palpable) as incidental histological finding at transurethral resection 
of prostate in >5% of tissue resected
T ic Tumour (non-palpable) identified by needle biopsy (for elevated serum PSA): 
includes bilateral non-palpable tumour needle biopsy
T2 Tumour confined within prostate (including prostatic apex, prostate capsule) that 
is either palpable or visible on imaging or (with p-prefix) demonstrated in radical 
prostatectomy specimen
T2a Tumour involving one-half of one lobe or less
T2b Tumour involving more than one half of one lobe but not both lobes
T2c Tumour involving both lobes
T3 Tumour extends through prostatic capsule
T3a Extra-capsular extension (ECE)
T3b Invasion of seminal vesicle(s)
T4 Tumour fixed or invades adjacent structures: bladder neck, external sphincter, 
rectum, levator muscles and pelvic wall
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
NO No regional lymph node metastases
N1 Regional lymph node metastases within true pelvis, below’ common iliac artery 
bifurcation, either unilateral or bilateral
! Metastases (M)
MX Distant metastases cannot be assessed
MO No distant metastases
M ia Non-regional lymph node metastasis
Mlb Metastasis to bone(s)
M lc Other site(s) of metastasis
Table 1.2: The 2002 TNM classification of adenocarcinoma of the prostate 
(adapted from (Borley and Feneley, 2009).
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1.1.6 Prostate cancer treatment and management
Treatment for prostate cancer may involve active monitoring, surgery, radiation 
therapy including brachytherapy and external beam radiation, chemotherapy, 
hormonal therapy, or a combination of these therapies. Which treatment is chosen 
depends on the stage of the disease, the Gleason score and serum PSA level. Also to 
be considered are the age and general health of the patient and his feelings about 
possible treatments and their side effects.
1.1.6.1 Active monitoring
Active monitoring refers to the process of observing and monitoring without 
invasive treatment. This is the standard treatment for those with T la early stage 
tumours as most men never develop metastases within 10-15 years. It is also used 
when risks of surgery, radiation therapy, or hormonal therapy outweigh the benefits. 
Active surveillance entails strict monitoring of a patient’s progression by carrying 
out PSA serum tests, DREs, and tissue biopsies, until further action is carried out, if 
required (Wu et al., 2004). The age of the patient at the time of diagnosis must also 
be taken into account when considering active monitoring. As most tumours remain 
localised for up to 10 years, those with a life expectancy of less than 10 years may 
view active monitoring as a preferred option to invasive treatment. In younger men a 
period of three years of active monitoring is more common as the risk of metastasis 
increases. This treatment delay would allow younger patients to avoid the quality of 
life impact of invasive treatment until such treatment became necessary.
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1.1.6.2 Radical prostatectomy
Radical prostatectomy, which involves the complete removal of the prostate 
gland, is currently the most common treatment in patients that have organ confined 
prostate cancer (Bracarda et al., 2005). Previously radical prostatectomy was 
associated in loss of sexual potency and incontinence. However, developing surgical 
techniques have reduced the likelihood of patients encountering these complications 
(Gamick, 1993).
1.1.6.3 Androgen ablation therapy
The male sex hormones, androgens, are essential for the development of the 
prostate gland and for the growth of early stage hormone-dependent prostate cancer. 
Locally confined tumours are able to be treated with surgery or radiation but 
disseminated disease presents a more difficult problem. Early metastatic prostate 
cancer is usually hormone dependant; this means that it can be treated with androgen 
ablation treatments that would slow the continued spread of the cancer. Prostate 
cancer survival depends on the signalling initiated by the androgen receptor in the 
nucleus of the cells. If androgen receptor activation is prevented then the cell is 
unable to survive. Unfortunately, androgen ablation therapy rarely cures prostate 
cancer. This is due to the development of androgen insensitive cancer cells that are 
able to survive without the presence of androgens. These hormone insensitive cancer 
cells then continue to disseminate and further treatment measure must be utilised.
21
Androgen ablation therapy must take into account the complex negative 
feedback loop that stimulates the production of androgens and their subsequent 
translocation in to the prostate cell nucleus to initiate transcription of cell survival 
factors. The majority of androgens are produced by the testes (95%) and the rest is 
produced by the adrenal glands (5%). Androgens bind to androgen receptors (AR) 
present in the hypothalamus and stimulate production of luteinising hormone 
releasing hormone (LHRH). LHRH travels to the pituitary where it interacts with 
LHRH-receptors. This stimulates the release of luteinising hormone (LH) which is 
released by the pituitary to bind to LH-receptors in the testes, inducing the 
production of testosterone, which is synthesised from cholesterol. The testosterone 
enters the prostate cell and is converted to dihydrotestosterone (DHT) by the enzyme 
5a-reductase. DHT has an even higher affinity for the AR than testosterone, and 
binds tightly to the AR. The binding of DHT causes the AR to be released from the 
heat shock proteins (HSP) that hold it inactive in the cytoplasm. AR then dimerises 
and is translocated to the nucleus where is activates the transcription of genes that 
promote cell survival and growth. Increased testosterone levels can also decrease 
LHRH and LH production through a negative feedback loop. This maintains the 
serum testosterone at a physiological level. The testosterone that is produced by the 
adrenal gland enters the feedback loop alongside the testosterone produced by the 
testes (Lytton, 2001; Denmeade and Isaacs, 2002).
There are currently two methods to achieve androgen ablation: chemical and 
physical castration. Physical castration (orchiectomy) involves the removal of one or 
both (bilateral orchiectomy) of the testes. As the testes produce 95% of testosterone,
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orchiectomy results in a massive drop in serum testosterone levels. This in turn 
results in the atrophy of the tumour. However, due to the psychological effects of 
orchiectomy, chemical castration is the preferred method (Fan, 2002).
The first method of chemical castration was developed by Huggins and Hodges 
in 1941. They developed the synthetic oestrogen diethylstilbestrol (DES) for use as a 
reversible form of chemical castration. DES inhibits the release of luteinising 
hormone releasing hormone (LHRH) from the hypothalamus. However, this drug 
induced significant side effects including cardiovascular complications (Blackard et 
al, 1970) and new drugs were developed. The most commonly used drugs are 
LHRH agonists, these include goserelin, leupolide and buserelin. Treatment with 
these agonists causes LHRH receptor desensitisation and inhibition of LH and 
testosterone production. LHRH agonists initially cause in increase in LH production 
which in turn causes increased production of testosterone (Tammela, 2004). This 
testosterone ‘flare’ can result in severe bone pain, obstructive renal failure, spinal 
cord compression and fatal cardiovascular problems (Heidenreich et a l, 2008) for 
some patients for the first 1-2 weeks of treatment. However, with continued use, 
after around 2-3 weeks, the high levels of testosterone act to down-regulate LHRH 
receptors of the pituitary, resulting in a reduction in LH and testosterone levels 
(Vilchez-Martinez et a l, 1979). Side effects are rather mild and include; hot flashes, 
fatigue, reduced libido, impotence, and weight gain. This method therefore proves to 
be a successful form of chemical castration, and results compare to surgical and DES 
castration with significant reductions in PSA levels in 70-80% of patients, and a 
decrease in pain in 60-80% (Tolis et a l, 1982).
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Another form of drug affecting LHRH is the LHRH antagonists such as, 
abarelix, degarelix and cetrorelix. These antagonists occupy the LHRH receptors on 
the anterior pituitary and prevent LHRH binding. This causes a major and rapid 
reduction of LH and serum testosterone levels. LHRH antagonists also have the 
advantage of not inducing a testosterone flare that is present with LHRH agonists 
(Kirby et a l, 2009).
The final type of androgen ablation drugs are the anti-androgens such as, the 
non-steroidal Flutamide, Bicalutamide, and Finasteride. These drugs function by 
competitively inhibiting the binding of testosterone and DHT to the AR and by 
inhibiting the activity of 5-a reductase. This prevents the activation of the AR and 
subsequent transcription of growth and survival factors (Vis and Schroder, 2009). 
However, these drugs have the ability to cross the blood-brain barrier raising the LH 
secretions and, therefore testosterone secretion in the testes making monotherapy 
with anti-androgens a less preferable method of androgen ablation (Tammela, 2004).
Also important for the achievement of total androgen blockade is the removal of 
adrenal androgens. The removal of the adrenal glands, adrenalectomy, is often 
performed along with chemical or surgical castration to produce total androgen 
blockade. This offers the complete removal of serum testosterone and offers a 
survival benefit to those with only a testicular androgen blockade (Samson et al, 
2002). See figure 1.6 for a diagrammatical overview of androgen ablation therapy.
24
A d re n a l g lan d
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Figure 1.6: Schematic diagram detailing methods of androgen ablation therapy. 1.
LHRH agonists and antagonists prevent release of luteinising hormone (LH) which 
inhibits the production of testosterone in the testes. 2. Chemical and surgical castration 
prevents release of androgens into blood circulation. 3. Finasteride is a synthetic anti­
androgen that acts by inhibiting type II 5-alpha reductase, the enzyme that converts 
testosterone to dihydrotestosterone (DHT). 4. Bicalutamide acts as a pure anti­
androgen by binding to the androgen receptor (AR) and preventing the activation of the 
AR and subsequent up-regulation of androgen responsive genes by androgenic 
hormones. Adapted from (Gamick, 1993).
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1.1.6.4 Radiation therapy
Radiation therapy is used to treat all stages of prostate cancer and uses 
ionising radiation to cause DNA damaging in the cells receiving the radiation. 
Cancer cells are less able to repair the damage and subsequently have a higher rate of 
death. There are two main types of radiation therapy: external beam radiotherapy and 
brachytherapy. External beam radiotherapy involves targeting the prostate and 
immediately surrounding tissue with a high level radiation beam. This allows a 
specific area to be treated, although inflammation of the bladder and rectum is 
inevitable due to the placement of the prostate gland. Treatment occurs over a 
number of weeks during which time the inflammation to surrounding structures 
occurs. Brachytherapy involves inserting a number of small radioactive ‘seeds’ 
directly into the prostate, guided by TRUS imaging, under either general or spinal 
anaesthesia. These seeds emit lower-level radiation that only travels a short distance 
enabling the radiation to be confined to the prostate. This method minimises the 
damaging effects on the bladder and rectum that are caused by external beam 
radiation therapy (Gamick, 1993).
1.1.6.5 Chemotherapy
While many patients initially respond well to androgen ablation therapy, in 
time the patients develop hormone refractory disease. This form of disease does not 
depend on androgen for survival and therefore is immune to conventional hormone 
ablation therapy and is often fatal. Chemotherapy is the last resort for those with 
hormone refractory disease, although treatment with cytotoxic compounds will only 
extend the life of the patient for a number of months. A combination of compounds
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is often used in treatment, such as estramustine, vincristine, etoposide, doxorubicin 
and the taxanes paclitaxel and docetaxel (Pienta et a l , 1994; Sella et al., 1994; 
Hudes et a l, 1997; Savarese et a l, 2001).
1.1.6.6 Angiogenesis inhibitors
Angiogenesis is a necessary requirement for the metastasis of cancer. As 
cancer growth is dependent on the diffusion of nutrients and waste, establishing a 
blood supply is crucial for the continued enlargement of the tumour. Investigation 
into the mechanisms that initiate angiogenesis has led to the development of novel 
therapies that target the angiogenic pathway. There is some possible advantage to 
using angiogenesis inhibitors over cytotoxic chemotherapy. As most cells are not 
actively relying on angiogenesis, treatment with angiogenesis inhibitors will be more 
accurately targeted to cancer cells than a cytotoxic compound and will have a lower 
level of toxicity to normal non-cancerous cells. Some of the angiogenesis inhibitors 
that are currently being investigated are Bevacizumab, Sorafenib, Sunitinib, 
Thalidomide and Imatinib (Hwang and Heath, 2010).
1.2 Cancer metastasis
The metastasis of cancer to secondary sites in the body is responsible for the 
majority of cancer related deaths. There is however, no curative treatment for cancer 
metastasis. Due to this fact metastasis is the subject of intense research in the hope of 
producing treatments to delay or even prevent the process of metastasis. Prostate
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cancer metastasis is a complex multi-stage process that involves several crucial steps 
that facilitates the spread of the cancer cells to secondary sites. The steps involve 
mutation of cells, epithelial to mesenchymal transition (EMT), degradation of the 
extracellular matrix (ECM), invasion, angiogenesis, intravasation, extravasation and 
colonisation of secondary sites.
1.2.1 Metastatic process
Metastasis has long remained poorly understood due to its increasing 
complexity. In order for cancer cells to metastasis they must undergo several 
epigenetic changes that facilitate their spread around the body. In order for the 
primary tumour to arise it must accumulate genetic changes that drive the cell toward 
a cancerous phenotype from which the cells can progress to metastasis. An overview 
of this process is given in figure 1.7.
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Figure 1.7 The metastatic process. Diagram detailing the process through which cancer 
arises and metastases.
Local invasion is a crucial step in early metastasis. Without the ability to 
invade through surrounding tissues, metastasis cannot occur. In order to begin the 
process of local invasion the cells must acquire an invasive and motile phenotype by 
down-regulating cell-cell, and cell-matrix adhesion. A major mechanism in the loss 
of adhesion is the loss of the tumour suppressor gene, E-cadherin. The loss of E- 
cadherin induces cell detachment and invasive potential (Frixen et a l, 1991). The 
loss of E-cadherin can also potentially indicate outcome for cancer patients (Hong et 
a l , 2011). E-cadherin also plays an important role in epithelial to mesenchymal 
transition (EMT). Cells are required to undergo this process to become metastasising 
cells. The transition involves the loss of cell polarity, and cell-cell binding, as the 
cells take on a mesenchymal phenotype and increase their expression of N-cadherin, 
granting them with the ability of invading the extracellular matrix (ECM) and 
breaking through the basement membrane (BM). It does this by using degrading 
enzymes such as those in the matrix metalloprotease (MMP) family (Overall and 
Lopez-Otin, 2002). Over-expression of MMP-21 is associated with poor survival of 
colorectal cancer patients (Huang et a l, 2011).
Cell motility is also a key factor in the metastasis of many types of cancer 
cells. Cell motility and migration depend on GTP-binding proteins such as Ras and 
Rho, which are involved in processes such as cytoskeletal construction, intracellular 
signalling, as well as whole cell, and cell membrane movement (Oxford and 
Theodorescu, 2003). Ras for example, regulates cell proliferation, gene transcription, 
apoptosis, and invasion. Rho GTPases act downstream of Ras, and regulate actin 
dynamics to lead cell growth and movement, important during cell migration and
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prostate metastasis. Their importance was proven when the use of inhibitors to the 
Rho-Ras pathway resulted in a reduction of the migratory and motile capacity of 
prostate cancer cells, suggesting that the pathway is activated during metastasis 
(Sequeira et al., 2008). RhoC especially has been highly implicated in the 
development, invasion and metastasis of prostate cancer (Iiizumi et al., 2008; Bu et 
a l, 2011).
As a primary tumour grows, it requires more oxygen and nutrients in order to 
progress. In order to overcome this problem, it starts to develop new blood vessels 
through the secretion of angiogenic factors such vascular endothelial growth factor 
(VEGF), reviewed in (Saharinen et a l, 2011), allowing a greater flux of resources to 
build up, and the tumour to grow. In addition, these blood vessels offer a means of 
escape for the cancer cells to leave the primary tumour, penetrate into the vessel, and 
shed into the blood’s circulatory system through a process called intravasation. This 
process involves multiple adhesive interactions, and is facilitated by the loss of 
CD82, normally responsible for anchoring tumour cells to the endothelium 
(Bandyopadhyay et a l, 2006).
Alternatively, some tumour cells might also enter the circulation through the 
lymphatic system. Cancer cells can invade the lymphatics in the primary site, where 
they are drained into the lymph nodes, and enter the blood circulation either via 
efferent lymphatic vessels that end up in the venous system, or by newly formed 
blood vessels serving the lymph node metastases (Paget, 1989). Tumour cells are 
then disseminated throughout the body, where the vast majority are destroyed during 
cellular clearance from the circulation, mainly due to their large size. The 0.1% that
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do survive, probably do so by aggregating with platelets in the blood, concealing 
them from immune surveillance through the production of chemokines, cytokines, 
and growth factors (Im et al., 2004). These cells need to survive long enough in 
order to colonise a distant site of preference.
The idea that metastasising cancer cells can ‘home’ to a specific organ was first 
recognised by Paget over a hundred years ago with the proposal of the ‘seed and 
soil’ hypothesis. This states that certain cancer cells (seeds) will only capably grow 
in a specific site (soil) (Paget, 1989). The specificity of certain cancers to metastasise 
to a specific organ is often seen in the propensity of prostate and breast cancer to 
spread commonly to the bone. However, more recent research has proposed that this 
propensity is likely due to the ability of a particular cancer type to grow in the 
microenvironment of a specific organ, so ‘the compatibility of the ‘seed’ with the 
‘soil’.
Upon arrival at the distant site, the cancer cells arrest on the endothelial 
surface of the blood vessel and undergo transendothelial migration, a process 
involving numerous adhesive interactions initially involving selectins and stabilised 
by integrin binding (1995). Once within the secondary site, the new micro­
environment surrounding the metastatic cells is initially hostile and the survival of 
the cells depends on their molecular features and the ability to successfully engage in 
cross-talk with their surrounding environment. In addition, growth-factor receptor 
ligand interactions between the cancer cells and host cells result in an interactive 
signalling loop, thereby up-regulating survival pathways and angiogenesis (Derynck
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et al., 2001). These processes allow the cells to survive and establish themselves in 
their new environment, developing a secondary tumour.
1.3 Prostate cancer metastasis
Advanced prostate cancer has a very high tendency to metastasise. This presents a 
huge clinical challenge in treating the disease. The most common sites of prostate 
cancer metastasis are the bone, lymph nodes, liver, lungs and dura (Edwards et a l , 
2003; Taplin et a l , 2003). Bone metastases are most common in the red bone 
marrow of the axial skeleton and occur in approximately 90% of patients with 
advanced disease and are a leading cause of morbidity (Bubendorf et a l , 2000). 
Once the tumours spread to the bone they are virtually incurable and lead to several 
complications such as severe pain, pathological fractures, hypercalcaemia and 
compression syndromes. Due the almost incurable nature of these metastases the 
treatments currently available are mostly palliative.
1.3.1 Bone metastases
As stated above the bone is the most common site of prostate cancer metastasis. 
Bone metastasis initiates in the same manner as in section 1.2.1 but undergo several 
genetic and phenotypic changes that enable the metastasising cells to interact with 
the bone micro-environment. One theory for the propensity of bone metastasis is the 
placement of the Batson’s Plexus. This is a collection of veins that surround the 
prostate and connects to the venous drainage of the spine and may provide a short­
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cut for metastasising tumour cells (Batson, 1995). Elevated expression of BMPs and 
TGF-p in prostate cancer cells has been implicated in bone metastases (Paget, 1989; 
Autzen et a l , 1998; Shariat et al., 2001). Vascular endothelial growth factor (VEGF) 
secreted by the tumour cells may also contribute to bone metastasis because of the 
promotion of angiogenesis and activation of osteoblasts (Chen et a l, 2004; Dai et 
a l, 2004). These features can direct the metastases to the bone. Another theory that 
was proposed over a century ago is the ‘seed and soil’ theory by Steven Paget. He 
compared the distribution of cancer cells to the dispersal of plant seeds. He proposed 
that osteotropic cancer cells possess certain attributes that enable them to grow in a 
particular environment and the bone micro-environment provides a fertile soil in 
which the cancer cells can thrive (Paget, 1889).
1.3.1.1 Bone micro-environment
The bone micro-environment is as important to facilitating bone metastases as the 
metastasising cancer cells themselves. Bone is a highly mineralised tissue that 
provides mechanical support and metabolic functions to the skeleton. It can be 
formed by either intramembranous ossification or endochondral ossification. 
Intramembranous ossification occurs when mesenchymal precursor cells 
differentiate directly into bone-forming osteoblasts, a process utilised in adding new 
bone to the outer surfaces of long bones as well as in generating the flat bones of the 
skull. In comparison, endochondral bone formation involves the conversion of an 
initial cartilage template into bone. This process is responsible for generating the 
majority of the bones of the skeleton (Erlebacher et a l, 1995).
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The bone itself is an organic matrix that is strengthened by deposits of calcium salts. 
Type-1 collagen constitutes approximately 90-95% of the organic bone matrix and 
non-collagenous proteins comprise the remaining 5-10%. Crystalline salts deposited 
in the matrix are primarily calcium and phosphate in the form of hydroxyapatite 
(Erlebacher et a l , 1995). The non-collagenous proteins can be sub-divided into 1) 
cell attachement proteins, 2) proteoglycans, 3) y-carboxylated (gla) proteins, and 4) 
growth factors (Robey et a l , 1993). Adult bone is being constantly remodelled in a 
process that ensures that the rate of bone formation is in equilibrium with bone 
resorption. Most bones have a centre that consists of spongy bone or a bone cavity, 
which are lined by endosteal cells. These spaces are occupied by red or yellow bone 
marrow. The bones containing red bone marrow are the flat bones, such as the iliac 
crest and sternum, and at the proximal ends of the long bones femur and humerous. 
These bones are the most often affected by cancer metastases indicating the red bone 
marrow may have a role in cancer metastasis (Galasko, 1986).
1.3.2 Osteoblastic metastases
Prostate cancer predominantly produces osteoblastic metastases. Osteoblasts are 
derived from mesenchymal cells and their growth and differentiation are regulated 
by complex signalling pathways mediated by growth factors such as bone 
morphogenetic proteins (BMPs), insulin-like growth factor (IGF)-I and IGF-II, 
transforming growth factor-pl (TGFpl) and TGFp2, fibroblast growth factor (FGF), 
platelet-derived growth factor (PDGF), and Wnt (Canalis, 1980; Hauschka et al, 
1986; Globus et a l, 1988; Wang et a l, 1990). The cells secrete a collagen-
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proteoglycan bone matrix known as osteoid, capable of binding calcium salts which 
induces its mineralisation, converting it to bone. This bone matrix deposition occurs 
in both intramembraneous and endochondral bone formation, and is regulated with 
spatiotemporal coordination by a variety of endocrine, paracrine, and autocrine 
factors (Ducy et al., 1999).
Analysis of prostate cancer bone metastases has typically shown that a large number 
of osteoblasts adjacent to the prostate cancer cells. This is in contrast to other cancer 
metastases, which usually contain a large number of osteoclasts (Logothetis and Lin, 
2005). tases from other cancers (such as breast, lung, and kidney), which largely 
contain osteoclasts. The increase in prostate cancer bone-forming activity gives rise 
to a woven bone, characterized by an osteosclerotic appearance distinct from the 
typical lamellar structure seen in normal bone. These lesions are associated with an 
increase in bone mass at the lesion site, and often have an elevated osteoid surface 
area, osteoid volume, and mineral apposition rate. An increase in serum levels of 
osteoblast proliferation markers, such as bone-specific alkaline phosphatise and 
type-1 protocollagen C-propeptide, has been observed in patients with metastatic 
prostate cancer (Jung et al., 2004). Several studies have confirmed the involvement 
of osteoblast cells in prostate cancer metastasis. One study showed that factors 
secreted by bone fibroblasts, but not other cells, accelerated prostate cancer growth 
(Gleave et al., 1991)and the stimulation of prostate cancer cells grown in osteoblast­
like cell culture medium (Fizazi et al., 2003).
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Figure 1.8 The vicious cycle of osteoblastic bone metastasis is shown. (A) Prostate cancer 
cells secrete osteogenic growth factors, activating osteoblasts to deposit new bone matrix. 
(B) Osteoblasts secrete a range of additional factors such as insulin-like growth factor (IGF), 
fibroblast growth factor (FGF), and transforming growth factor-p (TGFP). (C) These factors 
attract prostate cancer cells, further enhancing their proliferation and growth. ET1 indicates 
endothelin 1; PDGF, platelet-derived growth factor; BMP, bone morphogenetic protein; 
RANK, receptor activator of the nuclear factor-jB; RANKL, RANK ligand; OPG, 
osteoprotegerin. Taken from (Ibrahim et al., 2010)
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1.3.3 The role of p-catenin in prostate cancer
The nuclear signalling molecule P-catenin has long been widely accepted as an 
oncogene in human cancer. It acts a co-factor for the AR which further substantiates the 
ability of p-catenin to promote cancer development and progression (Mulholland et a l,
2002). The downstream targets of p-catenin, such as cyclin-Dl and c-myc, play a large 
role in the development of prostate cancer which adds to the evidence of the importance 
of P-catenin in human cancer.
In normal epithelial cells, P-catenin is found at the plasma membrane where it provides 
a mechanical linkage between cell-to-cell junctional proteins (e.g., E-cadherin) and 
cytoskeletal proteins (e.g., a catenin and actinin-4) (Morin, 1999). By contrast, in 
tumour cells, p-catenin is often found in the cytoplasm and nucleus where it associates 
with TCF family members to form a complex, which activates transcription of pro- 
mitotic proteins including c-Myc and cyclinDl (Figure 1.9). Nuclear transduction of P- 
catenin also occurs as part of the epithelial-mesenchymal transition (EMT) process, 
which is essential to organ development in the embryo. The importance of EMT in the 
progression of prostate cancer is widely known. As p-catenin plays a central role in 
EMT this reiterates the importance of p-catenin in prostate cancer progression.
A great deal of current biomedical research is directed towards determining the signal 
transduction pathways that modulate p-catenin localisation, degradation, and function. 
It has been recently established that phosphorylation of P-catenin by Src is necessary 
for its dissociation from E-cadherin (Coluccia et al., 2006). p-catenin is additionally 
phosphorylated by the glycogen synthase kinase 3-p: adenomatous polyposis coli
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(GSK:APC) complex leading to its ubiquination and proteosome-mediated degradation. 
Significantly, GSK3 activity is decreased by the canonical Wnt signaling pathway, 
which involves the growth factor Wnt, the Wnt receptor Frizzled, and associated 
regulatory proteins such as Disheveled and Frat (Krishnan et al., 2006). Thus, increased 
Wnt signaling results in diminished phosphorylation and reduced degradation of P- 
catenin, and accumulation of p-catenin in the cytoplasm and nucleus.
Downstream components of the p-catenin signalling pathway have been implicated in 
several human cancers, not just in prostate. Abberant up-regulation of p-catenin nuclear 
activity is possibly due to APC deficiency or P-catenin mutations that prevent its 
degredation and leads to accumulation of p-catenin in the cytoplasm. This accumulation 
subsequently results in increased nuclear transduction and therefore to increased p- 
catenin target gene transcription. Because of this there has been huge interest in 
developing therapeutics to block the signalling of P-catenin for treatment of cancer. To 
date many therapeutics aim to disrupt TCF/ p-catenin interaction and to stabilise axin as 
this promotes the degredation of P-catenin.
There is very little information regarding the involvement of p-catenin with serine 
proteases. The TTSP family members are in an ideal location to affect the signals that 
are passed across the plasma membrane. As the regulation of p-catenin is dependent on 
signalling cascades initiated from the cell membrane, TTSP family members are ideally 
located to affect signals that originate on the extracellular surface, p-catenin was 
selected to be examined in this study based on unpublished data from a previously 
conducted study. As matriptase-2 was found to affect the migratory and adhesive
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capabilities of PC3 and DU145 cells a screen of molecules involved in cellxell and 
cell:matrix adhesion was performed in an attempt to determine if any of these 
molecules had been altered by the presence of matriptase-2. P-catenin was identified as 
a molecule of interest from this panel of molecules. Due to the fact that p-catenin is 
already a well known oncogene and has already been shown to be highly deregulated in 
prostate cancer it was felt that the involvement of matriptase-2 with the regulation of p- 
catenin warranted further investigation.
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Figure 1.9 Signal transduction pathways modulating P-catenin localization and 
degradation (Adapted from ValaSciences).
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1.4 Type II Transmembrane Serine Proteases (TTSP)
Cell surface proteolysis has become known as an important mechanism for the 
activation of proteins involved in managing a wide range of cellular functions. The 
chymotrypsin (SI) fold group, of which trypsin and chymotrypsin are prototypic 
members, are one of the largest subfamilies of the serine proteases, one of the largest 
and most conserved (Rawlings and Barrett, 1994) family of proteases. Recently, a 
group of SI serine proteases has been recognized that possess domains which anchor 
them directly to cell membranes. These are the type I and type II serine proteases. Type 
I serine proteases are anchored to the cell membrane with a carboxy-terminal 
transmembrane domain (Wong et al., 1999) . The type II transmembrane serine 
proteases (TTSPs) are anchored to the membrane via an amino-terminal transmembrane 
domain with a cytoplasmic extension (Netzel-Arnett et al., 2003). Members of the 
TTSP family include enteropeptidase (Maestracci et al., 1975) matriptase/MT-SPl (Lin 
et a l, 1999), matriptase-2/TMPRSS6 (Velasco et a l, 2002), matriptase-3/TMPRSS7 
(Szabo et a l, 2005), TransMembrane PRoteaSe Serine 1 (TMPRSS1) /Hepsin (Leytus 
et al., 1988), TransMembrane PRoteaSe Serine 2 (TMPRSS2) (Paoloni-Giacobino et 
al., 1997), TransMembrane PRoteaSe Serine 3 (TMPRSS3) (Scott et al., 2001), 
TransMembrane PRoteaSe Serine 4 (TMPRSS4) (Wallrapp et al., 2000), 
TransMembrane PRoteaSe Serine 5 (TMPRSS5)/spinesin (Yamaguchi et a l, 2002), 
TransMembrane PRoteaSe Serine 9 (TMPRSS9)/polyserase-l (Hayama et al., 2007), 
Corin/TMPRSSIO (Yan et a l, 1999), Differentially expressed in squamous cell 
carcinoma gene 1 (DESC1) (Lang and Schuller, 2001) and Human airway trypsin-like 
(HAT) (Yamaoka et al., 1998) (See Table 1.3 for summary) (Figure 1.10).
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Based on the phylogenetic analysis of the serine protease domains and the domain 
structure of the extracellular stem region, the TTSPs have been divided into four 
subfamilies (Szabo et al., 2003). The largest of these is the HAT/DESC subfamily 
which consists of HAT, DESC1-4 and HATL3, 4 and 5. The second subfamily is the 
Hepsin/TMPRSS family which is comprised of TMPRSS2-5, hepsin and 
enteropeptidase. The next family is the matriptase subfamily which includes matriptase, 
matriptase-2, matriptase-3 and polyserase-1. The final subfamily is the corin subfamily 
of which the only member is corin.
Matriptase-1 MT-SP1/TADG-15 Ilq25 95
Matriptase-2 TMPRSS6 22ql2-13 89
Matriptase-3 TMPRSS7 3ql3 .ll 101
TMPRSS9 Polyserase-1 19pl3.3 114
Hepsin TMPRSS1 19ql3.1 51
TMPRSS2 Epitheliasin 21q22.3 53.8
TMPRSS3 TADG-12 21q22.3 49
TMPRSS4 TMPRSS3 1 lq23.3 68
TMPRSS5 Spinesin llq23.3 52
Enteropeptidase Enterokinase 21q21 156
Corin TMPRSS10 4pl2-13 116
HAT - 4ql3.2 48
DESC1 - 4ql3.3 47
DESC2 - 4ql3.3 46.2
DESC3 - 4ql3.3 44
Table 1.3. Summary of human membrane anchored serine proteases
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Figure 1.10 Multi-domain structures of human type II transmembrane serine proteases.
Structures are grouped according to phylogenetic analysis. Adapted from (Netzel-Amett et 
al., 2003)
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1.4.1 General structure and function
The TTSPs are characterized by a single pass transmembrane domain which 
separates the short intracellular region from the larger, more variable, extracellular 
section of the protease. The extracellular section is composed of a stem region of 
variable length and a C-terminal serine protease domain containing histidine (H), 
aspartate (D), and serine (S) residues essential for catalytic function (Hooper et al., 
2001; Szabo et a l, 2003; Choi et al., 2009). The N-terminal cytoplasmic domain of 
TTSPs may allow signal transduction across the plasma membrane and effect changes 
within the cell (Fig. 1.11).
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Figure 1.11 Potential for intracellular signalling through membrane bound 
proteases.
Metalloproteases (MTMMPs, ADAMs), membrane anchored serine proteases 
(SPs), TTSPs, and the plasminogen/plasmin system are adequately positioned at 
the plasma membrane to participate in a cascade of protease activation, to activate 
receptors, growth factors, and cytokine/chemokines, to shed cell surface 
molecules, and to participate in extracellular matrix (ECM) remodelling. Taken 
from Noel et al (Noel et al., 2004).
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The stem region of TTSPs is believed to regulate diverse processes and contain as 
many as 11 structural domains that may serve as regulatory and/or binding domains 
(Hooper et al., 2001; Choi et a l, 2009)(Figure 1.11). These include a low density 
lipoprotein (LDL) receptor domain class A, which binds Ca2+ and is involved in the 
binding of lipoproteins (van Driel et al., 1987; Esser et al., 1988), Cls/Clr urchin 
embryonic growth factor (CUB) domain, a (SEA) domain named after the first three 
proteins it was identified in (sperm protein, enterokinase and agrin), a group A 
scavenger receptor domain (SR), frizzled (FRZ) and meprin, A5 antigen and receptor 
protein phosphatise ji domain (MAM) in various combinations in each of the TTSPs 
(Hooper et al., 2001; Netzel-Amett et al., 2003; Szabo and Bugge, 2008). The catalytic 
activity of the serine protease domain is dependent on the presence of the previously 
mentioned residues histidine, aspartate and serine (Szabo and Bugge, 2008). This 
domain activates or degrades protease activated receptors (PARs) (Choi et a l, 2009), 
cytokines, growth factors and components of the extracellular matrix (Del Rosso et al., 
2002; Lopez-Otin and Matrisian, 2007). Soluble forms of several TTSPs have been 
detected. This suggests that the extracellular domains of these proteases may be shed 
from the cell surface (Louvard et a l, 1973; Yamaoka et a l, 1998; Lin et al., 1999; Afar 
et al., 2001). The mechanisms involved in the regulated release of these extracellular 
domains and whether release may occur in response to specific cellular signals or 
environments have yet to be fully characterized.
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Although the functional purpose of these proteases is largely unknown, the TTSPs 
have gained intense attention from the field of cancer research. This interest in TTSPs 
stems from the observation that many of them are aberrantly expressed in tumours 
compared to normal tissue. Increasing evidence demonstrates that this aberrant 
expression of TTSPs is a hallmark of several cancers and recent studies have attempted 
to define the molecular mechanisms underlying TTSP-promoted carcinogenesis. Loss 
of the basement membrane is a mandatory step that occurs during local invasion early 
in the metastatic process (Abate-Shen and Shen, 2000; Robinson et al., 2004). To 
accomplish local invasion, tumour cells use extracellular and cell surface proteolytic 
enzymes to degrade the basement membrane proteins (Chang and Werb, 2001; Del 
Rosso et al., 2002). The TTSP family is ideally located to perform this crucial task. 
Many recent studies have focused on the expression of specific TTSPs during 
tumourigenesis and their potential to influence tumour cell proliferation, motility and 
invasion (Szabo and Bugge, 2008).
1.4.2 Matriptase subfamily
1.4.2.1 Matriptase/MT-SPl
Matriptase, also known as MT-SP1, has been identified in the epithelial components 
of the prostate, stomach, small intestine, colon, lung, kidney, placenta and peripheral 
blood leukocytes (Takeuchi et al., 2000; Oberst et al., 2003). Matriptase protein is 
95kDa in length and is composed of a short cytoplasmic extension with unknown 
function, a transmembrane domain, a SEA domain, two CUB domains, four tandem 
repeats of a LDLA domain and a C-terminal active serine protease (Netzel-Arnett et al.,
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2003; Szabo et al., 2003; Uhland, 2006) (Figure 1.10). Matriptase is expressed as a 
zymogen that has to be activated by proteolytic cleavage to gain its biological function. 
The activation site is located directly N-terminal to the catalytic domain. Once 
processed, the active catalytic domain stays attached to the membrane by a disulfide 
bond linking the pro-domain to the catalytic domain (Lin et al., 1999; Takeuchi et al., 
2000) unless it is shed at either of the shedding sites at residues 190 or 205 (Oberst et 
al., 2003; Oberst et al., 2003). Shed matriptase has been found in a complex with 
hepatocyte growth factor activator inhibitor (HAI-1) in human milk, indicating that 
HAI-1 might be a cognate inhibitor of the protease. Paradoxically, HAI-1 has not only 
inhibitory function, but is also required for matriptase activation (Oberst et al., 2003). 
This is thought to ensure that matriptase can be quickly inactivated once it is set free 
from the membrane to protect the cells from uncontrolled matriptase activity (Uhland, 
2006). However, a recent study by Miyake et al using stably transfected canine kidney 
cells, proposes that matriptase activation does not require HAI-1 (Miyake et a l, 2010).
Due to its notably consistent expression in tumours of epithelial origin, matriptase 
has received significant attention in the field of cancer biology. This protease was first 
described as a matrix degrading enzyme with major gelatinolytic activity in breast 
carcinoma (Shi et a l, 1993; Lin et al., 1997), and was later found to be expressed in a 
wide variety of other benign and malignant tumours of epithelial, but not mesenchymal, 
origin. In most carcinomas, tumour progression is associated with a significant increase 
in matriptase mRNA and protein expression. Matriptase has been found to be up- 
regulated in many epithelial tumours, including breast, colon, kidney, liver, lung, 
mesothelioma, ovarian and prostate cancers, and is a potential diagnostic and prognostic
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biomarker (Jin et a l , 2006; Uhland, 2006; Kobel et a l, 2008; Szabo and Bugge, 2008; 
Tsai et a l , 2008; Darragh et a l , 2010).
It is suggested that matriptase is able to promote cancer development and 
progression by processing the pro-forms of urokinase-type plasminogen activator (pro- 
uPA) and hepatocyte growth factor (pro-HGF), both of which are known to promote 
invasive tumour growth (Lee et a l , 2000; Takeuchi et a l , 2000; Uhland, 2006). In 
addition, matriptase might promote tissue invasion by modulating cell-cell adhesion via 
degradation of components of the extracellular matrix (Jin et a l, 2006) or by activating 
PAR-2 (Takeuchi et a l, 2000; Bocheva et a l, 2009), a regulator of inflammation and 
cell-cell adhesion. However, involvement of any of these targets in matriptase- 
dependent tumourigenesis has yet to be tested and further investigation will be needed 
to validate matriptase as a novel biomarker, a predictor of patient outcome, and as a 
possible therapeutic target for at least some types of carcinoma.
A direct role for matriptase in tumourigenesis has been demonstrated with transgenic 
mice that over-express the protease in skin. This study found that increased protease 
expression in the epidermis induced strong proliferation of keratinocytes and squamous 
cell carcinoma formation (List et a l, 2005). By contrast, double transgenic mice, which 
expressed both matriptase and a cognate inhibitor, HAI-1, did not develop carcinomas. 
Importantly, both the epidermal hyper-proliferation and the formation of matriptase- 
induced skin tumours was completely abolished by co-expression of the cognate 
inhibitor of matriptase, HAI-1, providing further evidence of matriptase proteolytic 
activity being the underlying causative agent in the formation of these lesions.
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Interestingly stable knockdown of HAI-1 was shown to mimic the epithelial to 
mesenchymal transition (EMT) in both pancreatic and lung cancer cell lines. Over- 
expression of HAI-1 in these cell lines re-established epithelial morphology (Cheng et 
al., 2009). There is also increasing evidence that an altered ratio of matriptase and HAI- 
1 might have a role in cancer development. Indeed, increased matriptase expression 
relative to HAI-1 expression has been demonstrated in several studies (Oberst et a l, 
2002; Vogel et al., 2006). It appears that matriptase is involved in both the development 
and progression of diverse cancers and may be a viable biomarker and therapeutic 
target. However, further characterization of this protease will be necessary to fully 
elucidate its potential in the field of cancer therapy.
1.4.2.2 Matriptase-2
See section 1.5 below for full description of matriptase-2.
1.4.3 Hepsin/TMPRSS subfamily
1.4.3.1 Hepsin/TMPRSSl
Hepsin is a transmembrane serine protease that was originally identified from a 
human hepatoma HepG2 cell library using a homology-based cloning strategy (Leytus 
et al., 1988). Expression and characterization of recombinant hepsin show that the 
protein is synthesized as a single-chain zymogen with an apparent molecular mass of 
5lkDa (Netzel-Arnett et al., 2003). Hepsin expression is highest in the liver but has also 
been indentified in several tissues including thymus, thyroid, lung, pancreas, pituitary
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gland, prostate and kidney (Szabo and Bugge, 2008). Hepsin consists of a short 
cytoplasmic amino terminal extension, a transmembrane domain, a SR domain and an 
active serine protease at the carboxy terminal (Netzel-Amett et al., 2003; Szabo and 
Bugge, 2008; Choi et al., 2009) (Figure 1.10).
Hepsin has become a high interest topic because of its marked over-expression in 
prostate and ovarian cancer (Tanimoto et al., 1997; Dhanasekaran et al., 2001; Luo et 
al., 2001; Magee et al., 2001; Stamey et al., 2001; Welsh et al., 2001; Rhodes et al., 
2002; Chen et al., 2003; Adib et al., 2004; Huppi and Chandramouli, 2004; Lai et a l, 
2004; Herter et a l, 2005; Wu and Parry, 2007), renal cell carcinoma (Zacharski et al., 
1998; Betsunoh et a l, 2007) and endometrial cancer (Matsuo et al., 2008). Hepsin has 
also been shown to be a potential biomarker for the presence of prostate cancer (Parekh 
et al., 2007; Sardana et al., 2008; Leman et al., 2009; Talesa et a l, 2009; Huang et al, 
2010) and to be associated with poor patient outcome (Betsunoh et al., 2007; Matsuo et 
al., 2008). The physiological function of hepsin remains unknown, but within the 
carcinogenesis pathway it appears to play a role in cancer cell migration/invasion rather 
than cell proliferation (Holt et al., 2010). The effect of deregulated hepsin has been 
shown to promote cancer progression and metastasis in mouse models by causing 
disorganization of the basement membrane (Klezovitch et a l, 2004).
Although it is clear that hepsin plays a role in cancer progression, the possible 
mechanisms that may be responsible for this remain largely undetermined. However, 
studies have begun to elucidate routes through which hepsin could exert its pro- 
tumourigenic effect. It has been suggested that hepatocyte growth factor (HGF) is a
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possible substrate for hepsin with high degree of specificity (Herter et al., 2005; Qiu et 
al., 2007; Owen et al, 2010). Herter et al 2005 showed that hepsin can cleave sc-HGF 
and that hepsin cleaved sc-HGF is biologically active in ovarian cancer cells, and may 
influence tumourigenesis through inappropriate activation and/or regulation of the HGF 
receptor c-met (Herter et a l, 2005). Laminin-332 (Ln-332) is an ECM macromolecule 
associated with prostate cancer cell motility, and its expression is lost in cancer 
progression. Hepsin has been shown to cleave Ln-332, possibly aiding cancer 
progression by increasing the motility of cancer cells. Cleavage is specific, since it is 
both inhibited in a dose-dependent manner by a hepsin inhibitor (Kunitz domain-1) and 
does not occur when catalytically inactive hepsin is used (Tripathi et al, 2008; Li et al., 
2009). Hepsin has also been shown to efficiently activate pro-uPA, suggesting it may 
initiate plasmin-mediated proteolytic pathways at the tumour/stroma interface that 
could lead to basement membrane disruption and tumour progression (Moran et a l, 
2006). In light of the evidence gained, hepsin appears to be a promising therapeutic 
target for slowing or even preventing the development and progression of cancer.
1.4.3.2 TMPRSS2
TMPRSS2 is expressed widely in the epithelia of the gastrointestinal, urogenital and 
respiratory tracts, with the highest levels detected in prostate luminal epithelial cells 
(Szabo and Bugge, 2008). TMPRSS2 was originally cloned in 1997 and consists of a 
short cytoplasmic amino terminal extension, a transmembrane domain, a LDLA 
domain, a SR domain and an active serine protease at the carboxy terminal and forms a 
protein of 53.6kDa in length (Paoloni-Giacobino et al., 1997) (Figure 1.10). Activation 
of the serine protease requires its cleavage, which is autocatalytic. The active serine
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protease with trypsin-like specificity is then shed into the extracellular space, where it is 
predicted to interact with other proteins on the cell surface, as well as soluble proteins, 
matrix components and proteins on adjacent cells (Afar et a l, 2001).
TMPRSS2 is a TTSP that has gained significant interest owing to its highly localized 
expression in the prostate and its over-expression in neoplastic prostate epithelium 
(Wilson et a l, 2005). The detection of chromosomal abnormalities in tumours is not a 
recent discovery but their significance has only recently become clear. A central aim in 
cancer research is to identify recurrent chromosomal rearrangements that play a vital 
role in cancer development. These rearrangements are of two general types. In the first, 
the promoter and/or enhancer elements of one gene are aberrantly juxtaposed to a proto­
oncogene, thus causing altered expression of an oncogenic protein (Rabbitts, 1994). In 
the second, the rearrangement fuses two genes, resulting in the production of a fusion 
protein that may have a new or altered activity (Rowley, 1973; de Klein et a l, 1982). 
Fusion proteins formed after chromosomal translocations are common in a range of 
tumour types; these are unique tumour antigens and are therefore potentially valuable 
targets for therapy design.
Recently a small number of fusion transcripts, specific to prostate cancer have been 
discovered (Scheble et al, 2010), that were the result of a chromosomal rearrangement 
involving two genes. The first gene, TMPRSS2, is secreted by prostate epithelial cells 
in response to androgen exposure (Afar et a l, 2001). TMPRSS2 was fused to either 
ERG or ETV1, two members of the ETS family of oncogenes. It had earlier been 
reported that the ERG gene was the most commonly over-expressed proto-oncogene in
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prostate cancer (present in about 72% of cases of prostate cancer) (Petrovics et al.,
2005). It was discovered that both intra-chromosomal and inter-chromosomal genetic 
rearrangements led to the creation of a fusion transcript called TMPRSS2-ETS 
(Tomlins et ah, 2005), it results in the translocation of an ETS (E26 transformation 
specific) transcription factor (ERG or ETV1) to the TMPRSS2 promoter region, which 
contains androgen responsive elements. ETS is a family of transcriptional activators and 
inhibitors and their activity is regulated by phosphorylation and protein-protein 
interactions (Seth and Watson, 2005). The TMPRSS2:ERG genetic rearrangement has 
been reported to occur in approximately 40% of primary prostate tumours (ETV1 
genetic rearrangements occur at a much lower frequency), and it results in the aberrant 
androgen-regulated expression of ERG and could be a mechanism whereby the ETV1 
or ERG oncogenes are over-expressed, leading to prostate cancer.
TMPRSS2:EGR fusion gene transcripts were found to promote proliferation, 
motility and invasion of PNT1A cells (Wang et ah, 2008) and Tomlins et ah concluded 
that ETS genetic rearrangements are sufficient to initiate prostate neoplasia. However, 
Carver et al. have shown that ETS genetic rearrangements may in fact represent 
progression events rather than initiation events in prostate tumourigenesis (Carver et al., 
2009). The role of TMPRSS2:ERG fusion protein in clinical outcome also remains 
unclear, with 10 studies receiving contradictory results (Huang and Waknitz, 2009). 
Another study, involving mice lacking TMPRSS2, showed no effect on the 
development, fertility, overall survival or function of the prostate (Kim et al, 2006). 
Despite the disparity in these findings there is promising evidence that TMPRSS2:ERG 
fusion proteins may be a useful biomarker, present in urine, for early detection of
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prostate cancer (Laxman et a l, 2006; Hessels et al., 2007; Han et al., 2008; Tomlins et 
al., 2009; Cao and Yao, 2010; Huang et a l, 2010; Rice et a l, 2010). There is also 
evidence to suggest that TMPRSS2 is capable of cleaving and thereby activating the 
PAR-2 receptor and this may be another method through which TMPRSS2 contributes 
to cancer progression (Wilson et a l, 2005). Thus, TMPRSS2 and the TMPRSS2:ERG 
gene fusion presents an exciting opportunity for use as a therapeutic target and drug 
development for the treatment of patients with TMPRSS2:ERG expressing prostate 
cancers.
1.4.33 TMPRSS3
The expression of TMPRSS3 was detected in several human tissues, including heart, 
lung, kidney, liver, placenta, pancreas, small intestine, colon, spleen, ovary, prostate, 
testis and thymus (Scott et a l, 2001). TMPRSS3 is expressed as a 49kDa polypeptide 
and consists of a short cytoplasmic extension, a amino terminal transmembrane domain, 
a LDLA domain, a SR domain and an carboxy terminal active serine protease (Netzel- 
Amett et a l, 2003) (Figure 1.10).
There is little information to date regarding the role of TMPRSS3 in the progression 
of cancer. A splice variant, TADG-12 has been shown to be over-expressed in ovarian 
cancer (Underwood et a l, 2000; Wallrapp et a l, 2000). TADG-12 was also found to be 
more highly expressed in advanced clinical stage ovarian cancer and this variant may be 
useful both as a molecular target for therapy and/or a diagnostic marker (Sawasaki et 
al, 2004). A study by Bellone et al identified potential immunogenic peptides derived 
from TADG-12 for immunotherapy of ovarian carcinoma. The TADG-12
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YLPKSWTIQV peptide is an immunogenic epitope in ovarian tumours and may 
represent an attractive target for immunotherapy of ovarian cancer (Bellone et al., 
2009). This discovery may allow the development of a TADG-12 peptide-derived cell- 
based therapy for the vaccination of ovarian cancer patients possessing chemotherapy- 
resistant or residual disease.
1.4.3.4 TMPRSS4
TMPRSS4 expression has been detected on the cell surface in oesophagus, stomach, 
small intestine, colon, kidney and bladder (Szabo and Bugge, 2008). It is also markedly 
up-regulated in gastric, liver, lung, ovarian, pancreatic, primary basal cell carcinomas, 
squamous cell carcinomas, thin melanomas and thyroid cancers (Jung et al., 2008; 
Riker et al., 2008) although its oncogenic potential and mechanism of action remain 
unclear. TMPRSS4 is expressed as a 68kDa protein which consists of a short 
cytoplasmic extension, a amino terminal transmembrane domain, a LDLA domain, a 
SR domain and an carboxy terminal active serine protease (Netzel-Amett et al, 2003) 
(Figure 1.10).
In pancreas cancer cells, TMPRSS4 is involved in the process of metastasis 
formation and tumour invasion, and its expression is correlated with the metastatic 
potential (Wallrapp et al., 2000). TMPRSS4 has also been identified as a possible 
diagnostic marker in thyroid cancer and to improve the accuracy of fine needle 
aspiration (FNA) biopsy (Jarzab et a l, 2005; Kebebew et al., 2005; Kebebew et al, 
2006). Although the mechanisms of action of TMPRSS4 remain unclear several studies 
have proposed potential pathways by which TMPRSS4 exerts its function. Dawelbait et
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al 2007 proposed that the interaction between the up-regulated TMPRSS4 and the 
down-regulated tissue factor pathway inhibitor 2 (TFPI2) in pancreas cancer cells could 
explain the mechanism of metastasis that makes pancreatic ductal adenocarcinoma 
(PDAC) a very aggressive type of cancer. TFPI2 is an extracellular protein that belongs 
to the small Kunitz inhibitor family. TFPI2 plays a major role in extracellular matrix 
degradation during tumour cell invasion and metastasis, wound healing and 
angiogenesis and is known to be down-regulated in PDAC (Dawelbait et al., 2007). 
Dawelbait et al hypothesized that TFPI2 acts as a natural inhibitor of TMPRSS4. Since 
TFPI2 is down-regulated, the up-regulated TMPRSS4 is no longer inhibited and might 
facilitate tissue invasion and metastasis.
Jung et al 2008 proposed that TMPRSS4 mediates the invasive and metastatic 
potential of human cancer cells by facilitating an epithelial-mesenchymal transition 
(Jung et a l , 2008). Kim et al. 2010 further explored the mechanisms by which 
TMPRSS4 mediates EMT and invasiveness in tumour cells. TMPRSS4 mediated FAK 
signalling pathway activation and extracellular signal-regulated kinase (ERK) activation 
via integrin a5 up-regulation, resulting in epithelial-mesenchymal transition (EMT) and 
invasiveness. Furthermore, TMPRSS4 over-expression in human colorectal cancer 
tissues correlated with enhanced expression of integrin a5. These observations implicate 
integrin a5 up-regulation as a molecular mechanism by which TMPRSS4 induces 
invasion and contributes to cancer progression (Kim et a l, 2010). To further implicate 
TMPRSS4 in EMT, Cheng et al 2008 suggests that interactions between HAI- 
1/SPINT1 and TMPRSS4 contribute to transcriptional and functional changes involved 
in EMT in certain carcinoma cells (Cheng et a l, 2009). Although a specific substrate
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molecule of TMPRSS4 that initiates the EMT stimulatory pathway is still not defined, 
recent studies have contributed to discovering the pathways through which TMPRSS4 
may exert its function. Regulation of EMT by proteases such as TMPRSS4 may provide 
novel therapeutic targets for the treatment of cancer metastasis.
1.4.4 HAT/DESC Subfamily
1.4.4.1 HAT
Human airway trypsin-like (HAT) protease was originally identified in the human 
trachea and bronchi (Yasuoka et a l, 1997; Yamaoka et a l, 1998) and subsequently 
found in diverse tissues including brain, spinal cord, skin, tongue, testis, prostate, 
urinary bladder and the organs of the gastrointestinal tract (Hansen et a l, 2004; Iwakiri 
et a l, 2004; Hahner et a l, 2005; Szabo and Bugge, 2008). HAT protein is 48kDa in 
length and consists of a short cytoplasmic extension, a amino terminal transmembrane 
domain, a SEA domain and a carboxy terminal active serine protease (Yamaoka et a l, 
1998) (Figure 1.10). Proposed physiological roles of HAT include mucus production 
(Chokki et a l, 2004), deposition of fibrin in the airway lumen (Yoshinaga et a l, 1998), 
proteolytic activation of hemagglutinin antigen of influenza virus (Bottcher et a l,
2006), activation of protease-activated receptor 2 (PAR2) (Miki et a l, 2003; Chokki et 
al, 2004; Iwakiri et al, 2004; Matsushima et a l, 2006) and proteolytic inactivation of 
the urokinase receptor (Beaufort et a l, 2007). HAT also appears to be released as a 
soluble protein from the surface of tracheal serous glands of patients with chronic 
airway disease (Yamaoka et a l, 1998). There are currently no studies investigating the 
possible involvement of HAT in tumourigenesis. A previous study even presented
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evidence against a role in adrenal tumourigenesis (Hahner et al., 2005). Further 
investigation is required to determine the role, if any, of HAT in cancer.
1.4.4.2 DESC1
Differentially expressed in squamous cell carcinoma gene 1 (DESC1) is expressed in 
a number of tissues derived from the head and neck, and in skin, prostate and testes. 
Cell line studies demonstrate that DESC1 expression is epithelial-specific (Lang and 
Schuller, 2001). The 47kDa DESC1 protein consists of a short cytoplasmic extension, a 
amino terminal transmembrane domain, a SEA domain and a carboxy terminal active 
serine protease (Szabo and Bugge, 2008) (Figure 1.10). DESC1 was first investigated in 
squamous cell carcinoma of the head and neck. A study by Lang et al 2001 (Lang and 
Schuller, 2001), compared DESC1 expression between primary squamous cell 
carcinoma and matched normal tissue and demonstrated that DESC1 expression was 
reduced or absent in 11/12 SCC tissue specimens when compared to specimens of 
matched normal tissue. A further study by Sedhgizadeh et al 2006 showed that down- 
regulation of DESC1 occurs during squamous cell carcinoma progression and up- 
regulation occurs during normal epithelial differentiation (Sedghizadeh et al., 2006). It 
has also been reported that DESC1 hydrolyses extracellular components such as 
fibronectin, gelatine and fibrinogen (Viloria et al., 2007). Madin-Darby canine kidney 
(MDCK) cells expressing exogenous human DESC1 acquire properties associated with 
tumour growth such as enhanced motility and an increase of tubular forms in a 3D 
collagen lattice following HGF treatment (Viloria et al., 2007). A study investigating 
the substrate specificities of a number of TTSPs demonstrated that DESC1 had a 
preference for small non-polar amino acids and that antithrombin III has robust
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inhibitory properties toward DESC1, whereas plasminogen activator inhibitor-1 and 
alpha(2)-antiplasmin inhibited DESC1 (Beliveau et al., 2009). In light of these findings 
it appears that DESC1 could be considered as a potential therapeutic target in some 
types of tumours.
1.4.5 CORIN Subfamily
1.4.5.1 Corin/TMPRSSIO
Human corin was first cloned in the search for novel serine protease genes in the 
cardiovascular system. The full-length human corin cDNA is approxiametly 5 kb in 
length and encodes a mosaic serine protease, which is named corin for its abundant 
expression in the heart (Yan et al., 1999). Independently, Hooper et al. (Hooper et a l, 
2000) also cloned human corin cDNA from a cancer cell line while studying novel 
serine protease genes in cancer. The human corin polypeptide is 116 kDa in length and 
consists of a short cytoplasmic extension at the N-terminus followed by an integral 
transmembrane domain, two frizzled-like cysteine-rich motifs, eight LDLA repeats, a 
SR domain, and a serine protease domain at the C-terminus (Wu et a l, 2005) (Figure 
1. 10).
Currently there are very few mentions of corin in the field of cancer research. Corin 
mRNA has been found in cancer cells derived from osteosarcoma, leiomyosarcoma, 
endometrial carcinoma, and small cell lung cancer (Hooper et al., 2000; Wu and Wu,
2003). It has been proposed that the ectopic expression of corin may contribute to the
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pathogenesis of the syndrome of inappropriate secretion of anti-diuretic hormone 
(SIADH) associated with certain cancers (Wu and Wu, 2003).
1.5 Matriptase-2
1.5.1 Discovery
Matriptase-2 was identified in 2002 when screening for sequences common to the 
TTSP family (Velasco et al, 2002). The matriptase-2 gene is found on chromosome 22 
and encodes an 88,901 kDa protein. In humans matriptase-2 expression is limited to the 
liver (Velasco et al., 2002), although expression in the kidney, uterus and nasal cavity 
was seen in mice (Hooper et al, 2003). Matriptase-2 consists of a short cytoplasmic 
extension with unknown function, a transmembrane domain, a SEA domain, two CUB 
domains, three LDLA domains and a C-terminal active serine protease (Hooper et a l, 
2003; Szabo and Bugge, 2008) (Figure 1.10). Matriptase-2 shares a high homology with 
matriptase, which is also over-expressed in different human cancers (Shi et a l, 1993). 
However, where the over-expression of matriptase leads to cancer progression (Uhland, 
2006; Tsai et a l, 2008), matriptase-2 over-expression significantly reduces breast and 
prostate cancer growth and reduced levels correlate with poor patient outcome (Parr et 
al, 2007; Sanders et a l, 2008). The molecular mechanisms involved in the activation of 
matriptase-2 remain largely unknown. Active matriptase-2 has been found in both 
membrane and soluble forms (Silvestri et a l, 2008; Ramsay et al, 2009). A recent 
study by Stimberg et al 2010 demonstrated shed matriptase-2 in a two-chain form that 
is highly active with a cleavage site located between ARG437 and Val438 within the 
second CUB domain of the non-catalytic stem region (Stimberg et a l, 2010).
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1.5.2 Substrate specificity
Velasco et al. examined the enzymatic function of matriptase-2 by producing a GST- 
matriptase-2 fusion protein. This fusion protein was found to degrade fibronectin, 
fibrinogen and type 1 collagen and to have limited action against pro-uPA but was 
unable to process MMP-2, MMP-9 and plasminogen. It was also found to be inhibited 
by serine protease inhibitors such as PMSF, leupeptin, aprotinin and plasminogen 
activator inhibitor-1 but not by inhibitors of cysteine or metallo protease inhibitors 
(Velasco et al., 2002; Beliveau et al, 2009). Recently, membrane bound hemojuvelin 
(m-HJV) has also been identified as a substrate of matriptase-2 (Silvestri et al., 2008), 
giving matriptase-2 a previously unrecognized, but important, role in iron metabolism.
In a recent study Maurer et al 2011 used site-directed mutagenesis, kinetic and 
molecular modelling studies to obtain insights into substrate/inhibitor-enzyme 
interactions. Based on the active site structure of the related enzyme matriptase, amino 
acids that enhanced (Phe665) or reduced (Asp 785, Tyr712) the affinity of peptide 
ligands for matriptase-2 were identified (Maurer et a l, 2011).
1.5.3 Expression of matriptase-2 in normal and cancerous cells
Altered expression of matriptase-2 in cancer has been reported in several studies. 
Matriptase-2 transcript was detected in mouse Leydig tumour cells (Odet et a l, 2006) 
and elevated levels of matriptase-2 have been reported in invasive ductal cell carcinoma 
(Overall et a l, 2004). Studies from within our laboratories showed that there were 
reduced levels of matriptase-2 immunostaining in cancerous breast tissue sections
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compared to normal tissue sections with the majority of matriptase-2 staining being 
confined to the epithelial sections (Parr et al., 2007). In contrast to this quantitative 
PCR showed that matriptase-2 levels were up-regulated in tumour compared to normal 
tissues, however matriptase-2 levels were significantly higher in lower NPI and TNM 
stages and correlated with positive patient outcome and the over-expression of 
matriptase-2 reduced aggressive in vitro and in vivo traits of MDA-MB-231 breast 
cancer cells (Parr et al., 2007). A study by Sanders et al 2008 described the effect of 
matriptase-2 over-expression in PC3 and DU145 cells. It showed that an increase in 
matriptase-2 caused PC3 growth to decrease but not that of DU 145. Also the adhesion 
of both cell lines was unaffected. The study also showed that matriptase-2 over­
expression also significantly reduced the migration and invasion of both cell lines. To 
further the investigation the PC3 cells over-expressing matriptase-2 were inplanted into 
nude mice. This caused a significant retardation of the normally highly tumourigenic 
PC3 cell ability to grow and develop into tumours. Also in the study enhanced 
matriptase-2 levels were seen to correlate with increased fluorescent staining of paxillin 
and FAK adhesion molecules, where a greater extent of these molecules were localised 
to the focal adhesion complexes (Sanders et al., 2008).
1.5.4 Role in iron homeostasis
Recently matriptase-2 has been found to have a role in iron homeostasis. The 
discoveiy was made by Du et al when examining mouse mutations caused by N-ethyl- 
N-nitrosurea. One phenotype exhibited low iron plasma levels and iron stores (termed 
Mask mutants) and was found to harbour splice variants of matriptase-2 lacking the 
protease domain. Du et al also noted that the low iron levels in Mask mice were paired
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with high levels of Hamp transcript, the gene from which hepcidin is produced. This 
suggested that matriptase-2 may play a role in iron homeostasis through the negative 
regulation of Hamp activation (Du et al., 2008). Another study has found that an 
increase in matriptase-2 protein in the liver from iron deficient rats was detected; 
suggesting that suppression of hepcidin expression in response to acute iron deprivation 
is mediated by an increase in matriptase-2 protein levels (Zhang et a l, 2011). It is 
believed that matriptase-2 proteolytically processes membrane hemojuvelin (also 
known as RGMc) which significantly reduces hepcidin transcription as hemojuvelin 
induces Hamp transcription (Silvestri et a l, 2008)(Figure 1.12). Hemojuvelin is 
produced as a membrane GPI linked protein that acts as a co-receptor for bone 
morphogenetic protein (BMP) -2, -4 and -6 (Babitt et a l, 2006; Xia et a l, 2008). It is 
likely that matriptase-2 exerts its effect directly by proteolytic processing of 
hemojuvelin and indirectly by creating an imbalance in levels of BMP co-receptor and 
antagonist (Ramsay et al, 2009). This is further corroborated by a study by Lenoir et al 
that showed that Tmprss6~'~ mice crossed with Bmp6~f' resulted in a correction of the 
haematological abnormalities brought about by a non-functioning matriptase-2 protein. 
This indicates that the elevated hepcidin levels in patients with familial iron-refractory 
iron anaemia are due to excess signalling through the BMP6/HJV pathway (Lenoir et 
al., 2010). A very recent study has proposed that matriptase-2 expression is regulated by 
BMP6 and iron levels. Maynard et al 2011 demonstrated that in vitro, treatment with 
BMP6 stimulates TMPRSS6 expression at the mRNA and protein levels and leads to an 
increase in matriptase-2 activity. And also that ID1, a negative regulator of basic-helix- 
loop-helix transcription factors, is the key element of the BMP-SMAD pathway to 
regulate TMPRSS6 expression in response to BMP6 treatment. Finally, they showed
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that in mice, TMPRSS6 mRNA expression is stimulated by chronic iron treatment or 
BMP6 injection, and is blocked by injection of neutralizing antibody against BMP6 
(Meynard et al., 2011). Although further elucidation of this pathway is required it is 
possible that due to the complex role of BMPs and their co-receptors in cancer that this 
novel pathway could partly be involved in the action of matriptase-2 in cancer 
progression.
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Figure 1.12 Matriptase-2 proteolytically processes mHJV (RGMc) negatively 
regulating HAMP expression. Matriptase-2 helps to maintain correct iron 
homeostasis by cleaving mHJV without which the transcription of HAMP cannot 
proceed.
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1.6 Aims and objectives
Cancer metastasis is an increasingly complex problem. Despite the increasing 
number of studies involving cancer metastasis and the knowledge already gained, there 
is still much that is unknown. Metastasis is a complex multi-stage process involving cell 
invasion, secretion of certain angiogenic factors, cell migration and changes in cell 
adhesive properties. To accomplish local invasion, tumour cells use extracellular and 
cell surface proteolytic enzymes to degrade the basement membrane proteins. This 
allows the cancer cells to invade into surrounding tissues. The TTSP family of cell- 
surface proteases is ideally located to perform this crucial task. Matriptase-1, which is 
highly homologous to matriptase-2, is known to increase the motile and invasive ability 
and to decrease the adhesive properties of prostate cancer cells. There is also the 
question as to whether some TTSPs may prevent the degradation of the basement 
membrane and therefore protect the surrounding tissues from invasion by the cancer 
cells. Many recent studies have focused on the expression of specific TTSPs during 
tumourigenesis and their potential to influence tumour cell proliferation, motility and 
invasion. Previous studies within this laboratory have already indicated that matriptase- 
2 is a possible tumour suppressor in breast and prostate cancer. Recent studies have also 
indicated that matriptase-2 cleaves RGMc, also known as Hemojuvelin, which is a 
BMP co-receptor. This presents the opportunity for a regulatory involvement of 
matriptase-2 in the BMP signalling pathway. This study will aim to further elucidate the 
involvement of matriptase-2 in the process of cancer progression.
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The specific aims of this thesis were:
• To produce and/or re-amplify plasmid constructs of matriptase-2, to force- 
express and knock-down its expression in prostate cancer cell lines, 
respectively. This would then allow for the effect that matriptase-2 has on 
biological properties of cancer cells including adhesion, invasion, proliferation, 
motility, and migration, to be studied.
• To examine the expression of p-catenin in the force-express and knockdown 
cells and determine if matriptase-2 affects the expression levels and patterns of 
P-catenin
• To investigate the potential involvement of matriptase-2 in angiogenesis using 
in vitro methods
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Chapter 2 
Materials and Methods
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2.1. General materials
2.1.1 Solutions for regular use
0.05MEDTA
lg KC1 (Fisons Scientific Equipment, Loughborough, UK), 5.72g Na2HP04, lg 
KH2P04, 40g NaCl and 1.4g EDTA (Duchefa Biochemie, Haarlem, The Netherlands) 
was dissolved in distilled water to make a final volume of 5L. The solution was
adjusted to pH 7.4 before autoclaving and storing for use.
Trypsin (25mg/ml)
500mg trypsin was dissolved in 20ml 0.05M EDTA. The solution was mixed 
and filtered through a 0.2pm minisart filter (Sartorius, Epsom, UK), aliquoted in 250pl 
samples and stored at -20°C until required. For use in cell culture one 250pl aliquot was 
diluted in a further 10ml of 0.05M EDTA solution and used for cell detachment
lOOx Antibiotic cocktail mix
5g streptomycin, 3.3g penicillin and 12.5mg amphotericin B in DMSO, were dissolved 
in BSS and filtered. 5ml was then added to a 500ml bottle of DMEM media.
Balanced Saline Solution (BSS)
79.5g NaCl, 2.2g KC1, 2.1g KH2PO4, and 1.lg Na2HPC>4 was dissolved in
distilled water to make a final volume of 10L. pH was adjusted to 7.2 before use.
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LB agar
lOg of tryptone, 5g yeast extract lOg NaCl and 15g agar was dissolved in 
distilled water to a final volume of 1L, the pH adjusted to 7.0 and the solution 
autoclaved. When necessary, the solution was heated to a liquid and cooled slightly 
before adding selective antibiotic (if required). The solution was then poured into 
10cm2 petri dish plates (Bibby Sterilin Ltd., Staffs, UK), allowed to cool and solidify, 
before being inverted and stored at 4°C.
LB broth
lOg of tryptone (Duchefa Biochemie, Haarlem, The Netherlands), 5g yeast 
extract (Duchefa Biochemie, Haarlem, The Netherlands) and lOg NaCl was dissolved 
in distilled water to a final volume of 1L and the pH adjusted to 7.0. It was autoclaved 
and allowed to cool before adding selective antibiotic (if required) and storing at room 
temperature.
DEPC water
250pl diethyl pyroncarbonate (DEPC) was added to 4750pl distilled water. 
Solution was then autoclaved before use.
5X Tris, Boric acid, EDTA (TBE)
540g of tris-Cl (Melford Laboratories Ltd., Suffolk, UK), 275g Boric acid 
(Duchefa Biochemie, Haarlem, The Netherlands) and 46.5g of disodium EDTA was 
dissolved in distilled water and made up to a final volume of 10L. Solution was stored
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at room temperature and diluted to IX concentrate prior to use in agarose gel 
electrophoresis.
Loading buffer (for DNA electrophoresis)
A stock solution was made by dissolving 25mg bromophenol blue and 4g 
sucrose in distilled water to a final volume of 10ml. Store at 4°C to avoid mould 
growing in the sucrose until use.
Ethidium bromide
lOOmg of ethidium bromide powder was dissolved in 10ml of distilled water. 
Container was wrapped in aluminium foil to protect solution from sunlight and stored 
safely before use.
Tris-Boric acid-EDTA (TBE)
For a 5xTBE buffer (1.1M Tris; 900mM Borate; 25mM EDTA; pH 8.3), 
dissolve 540g Tris-Cl (Melford Laboratories Ltd., Suffolk, UK), 275g Boric acid 
(Duchefa Biochemie, Haarlem, Netherlands) and 46.5g EDTA (Duchefa Biochemie, 
Haarlem, Netherlands) in 9.5 litres of distilled water. Adjust pH to about 8.3 using 
NaOH, and then make up to a final volume of 10 litres with distilled water.
Lysis Buffer
2mM CaCl2, 0.5% Triton X-100, 1 mg/ml leupeptin, 1 mg/ml aprotinin and 10 
mM sodium orthovanadate was dissolved in distilled water and stored at 4°C until 
required.
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10% Ammonium Persulfate (APS)
lg of ammonium persulfate was dissolved in 10ml of distilled water, separated 
into 2.5ml aliquots and stored at 4°C until required.
1 OX Running buffer
303g tris, 1.44Kg Glycine and lOOg SDS was dissolved in distilled water to a 
final volume of 10L. Solution was further diluted to IX concentrate before use.
Transfer buffer
72g of glycine, 15.15g Tris and 1L Methanol (Fisher Scientific, Leicestershire, 
UK) were dissolved in distilled water to a 5L final volume.
1 OX TBS
12lg of tris and 400.3g NaCl were dissolved in distilled water, made up to a 
final volume of 5L and adjusted to pH 7.4.
Sample buffer (for SDS-PAGE)
Supplied directly by Sigma.
Amido black stain
2.5g of amido black (Edward Gurr Ltd., London, UK) was dissolved in 50ml 
acetic acid (Fisher Scientific, Leicestershire, UK) and 125ml ethanol (Fisher Scientific, 
Leicestershire, UK). 325ml of distilled water was added and solution mixed well.
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Amido black destain
100ml of acetic acid and 250ml ethanol were added to 650ml distilled water.
Coomasie blue stain
lg coomassie blue, 400ml of methanol and 100ml of acetic acid were mixed and 
made up to a final volume of 1L in distilled water.
Coomasie blue destain
500 millilitres of methanol was mixed with 100ml of acetic acid and made up to 
a final volume of 1L in distilled water.
2.1.2 Cell lines/animals
The PC3 cell line is derived from a bone metastasis of a grade 6 prostatic 
adenocarcinoma from a 62 year old male in 1979. PC-3 cells are adherent and epithelial 
in morphology. The cell line is androgen insensitive and is highly tumourigenic.
The DU 145 cell line was derived from a brain lesion of a 69 year old male 
patient in 1978 with metastatic prostate carcinoma and a history of lymphocytic 
leukaemia. DU 145 is an adherent cell line with an epithelial morphology. The cell line 
is tumourigenic in nude mice where it forms tumours consistent with the primary 
prostate cancer originally described. The DU 145 cell line is androgen insensitive.
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CAHPV10 is a non-tumourigenic cell line originating from a prostatic 
adenocarcinoma. The cell line originated from the transfection of these prostate cells 
with HPVI8 DNA. The cell line is adherent and epithelial in morphology.
PZHPV-7 is a non-tumourigenic prostate cell line derived from the human 
prostate epithelium of the peripheral zone in a 70 year old male patient. The cell line 
was immortalised through transformation with Human Papilloma Virus 18 (HPV18).
PNT1A is a normal prostate epithelial cell line obtained from a 35 year old male 
patient. This cell line was established by immortalisation of normal adult prostatic 
epithelial cells by transfection with a plasmid containing SV40 genome with a defective 
replication origin.
PNT2C2 is a normal prostate epithelial cell line obtained from a 33 year old 
male patient. The normal prostate cells have been immortalised with SV40.
HECV is a human endothelial cell line obtained from the umbilical cord of a 
female patient.
The PC3, DU145, LNCaP, CAHPV10 and PZHPV7 cell lines were obtained 
from the American Type Culture Collection (ATCC, Rockville, Maryland, USA). The 
PNT1A and PNT2C2 cell lines were generous gifts from Professor Norman Maitland 
(University of York, England, UK).
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Athymic nude mice
The 4-6 week old CD-I athymic nude mice used in the in vivo tumour 
development model were obtained from Charles Rivers Laboratories (Kent, England, 
UK) and maintained in filter-hood cages under ethical conditions.
2.1.3 Antibodies
2.1.3.1 Primary antibodies
Anti-M atriptase-2  
(Stem region)
Rabbit
polyclonal 89 Abeam pic Ab28287
Anti-M atriptase-2 
(Cytoplasmic region)
Rabbit
polyclonal 89 Abeam pic Ab56180
Anti-GAPDH
Goat
polyclonal
^  Santa Cruz
Biotechnology Inc SC-20358
Anti-p-catenin Rabbitpolyclonal
Sigma-Aldrich Co. 
LLC C2206
Anti-E-cadherin Goatpolyclonal
120/135 Santa Cruz
Biotechnology Inc
SC -1500
Anti-N-cadherin Goatpolyclonal
Santa Cruz 
Biotachnology Inc SC -1502
Anti-M M P-7 Mousemonoclonal 28/19 Calbiochem IM71
Anti-uPA Rabbitpolyclonal
^  Santa Cruz
Biotachnology Inc Sc-14019
Table 2.5: Primary antibodies used during course of study 
2.1.3.2 Secondary antibodies
The secondary antibodies used for Western blotting were horseradish peroxidise 
(HRP) conjugated anti-goat IgG, goat anti-rabbit IgG, and rabbit anti-mouse IgG 
antibodies, all supplied by Sigma (Poole, Dorset, UK). Those used for 
immunofluorescent studies are either goat anti-rabbit IgG TRITC conjugated secondary
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antibodies (Sigma, Poole, Dorset, UK), or FITC conjugated sheep anti-mouse, and 
rabbit anti-goat IgG, supplied by Santa-Cruz Biotechnology (Santa-Cruz, California,
USA).
2.1.4 Primers
M atriptase-2
Matrip2F2 GAAAGAC AT AGCTGC ATT G
454
Matrip2R2 GT AGT AGCT GGGG AAGT ACG
GAPDH
GAPDHF10 AGCTTGTCATCAATGGAAAT
36
GAPDHR10 CTTCACCACCTTCTTGATGT
M atriptase-2
(QPCR)
Matrip2ZF A CTGAACCTGACCGTACAGCCGAGTA
CGAAGTGGAC 101
Matrip2R2 GT AGT AGCT GGGG AAGT ACG
GAPDH GAPDHZF ATGATATCGCCGCGCTCA
200(QPCR) GAPDHR8 CGCTCGGTGAGGATCTTCA
pEF6 T7F T AAT ACGACTC ACT AT AGGG Depends on 
insertplasmidspecific BGHR
CCTCGACTGTGCCTTCTAG
M atriptase-2 T7F T AAT ACG ACTC ACT AT AGGG A 700
(Cloning) M atrip2Rl T AGCTGT AGCGGT AAC AACC
Ribozyme
orientation
T7F T AAT ACG ACTC ACT AT AGGG A
Depends on 
insertRbToP CTGATGAGTCCGTGAGGACGAA
RbBM R TTCGTCCTCACGGACTCATCAG
P-catenin
BcateninF22 AAAGGCT ACTGTT GGATT G A
500
BcateninR22 TCCACCAGAGTGAAAAGAAC
uPA
uPA Fl GGTT GT GT GT GGGTT AGACT
500uPA R l GTGGCT ACC AGAC ATTGATT
E-cadherin
EcadF22 CAGGAGCCAGACACATTTAT
500EcadR22 TCTAAGGTGGTCACTTGGTC
N-cadherin
NcadF22 C AACGACGGGTT AGTC AC
500NcadR22 ATTGGGGTCTGGAGTTC
MM P-7
MMP-7F2 GCTATGCGACTCACCGTGCTGTG
500M MP-7R2 AGCGTGTTTCCTGGCCCATCAAATG
Table 2.2: Primers for conventional RT-PCR and Q-PCR (Primers were designed by 
Beacon Design programme (Palo Alto, California, USA) and were synthesised by 
Invitrogen (Paisley, UK)). These primers were subjected to BLAST search and were 
found to be unique to the molecule they were created to bind to.
Matriptase-2 Matrip2ExF4 ATGCCCGTGGCCGAGGMatrip2ExR3 GGTCACCACTTGCTGGATCCA
Table 2.3: Primers for amplifying Matriptase-2 coding sequence.
Matrip2RZlF CTGCAGCACTAGAGATTCCCGGCGGGTAAC
Matriptase-2 TGATGAGTCCGTCAGGA
Matrip2RZlr ACTAGTTGTACTCAATCGGCACTTCTCCCAGGATTTCGTCCTCACGGA
Matrip2RZf2 CTGCAGTTCGTACTCGGCCCTGTAGGGCTGATGAGTCCTGAGGAMatriptase-2 *
Matrip2RZr2 ACT AGT AAC AGCTCGGCTGCCGTTTCGTCCT CACGGA
Table 2.4: Primers used for ribozyme synthesis.
2.2 Methods of cell culture
2.2.1 Preparation of cell medium
Cells were routinely cultured in DMEM / Ham’s F12 with L-Glutamine medium 
(PAA Laboratories, Somerset, UK), supplemented with antibiotic cocktail and 10% 
foetal calf serum (PAA Laboratories, Somerset, UK). Transfected cell lines, containing 
the pEF6 plasmid, were cultured initially in selection medium containing 5pg/ml 
blasticidin S and then later were routinely cultured in a maintenance medium containing 
0.5pg/ml blasticidin S. All handling of was cells performed using class II hoods to 
maintain sterile conditions.
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1.6.1 2.2.2 Revival from liquid nitrogen
When required, cells were removed from liquid nitrogen and revived. Cells were 
allowed to thaw rapidly following their removal from liquid nitrogen. Once thawed, the 
cells were placed in a universal container containing 5ml of pre-warmed medium. The 
universal containers were centrifuged at 1800rpm for 6 minutes to form a cell pellet. 
The medium was then aspirated to remove all DMSO and the cell pellet was 
resuspended in 5ml of pre-warmed medium and placed into a sterile 25cm3 tissue 
culture flask placed in the incubator overnight at 37.0°C, 5% CO2 and 95% humidity. 
Following the overnight incubation, the flask was examined under the microscope to 
visually confirm sufficient healthy adherent cells had survived. The medium was 
changed to remove any dead cells. The flask was returned to the incubator and further 
standard sub-culture techniques carried out when necessary.
2.2.3 Maintenance of cells
Cells were maintained in supplemented DMEM medium prepared as described in 
section 2.2.1, and routinely sub cultured upon reaching 80 -  90% approximate 
confluency. Confluence was assessed by visually assessing the approximate coverage 
of cells over the surface of the tissue culture flask using a light microscope. Cells were 
maintained and grown in either 25cm3 or 75cm3 tissue culture flasks (Greiner Bio-One 
Ltd, Gloucestershire, UK), in an incubator at 37.0°C, 5% CO2 and 95% humidity. All 
tissue culture techniques were carried out following aseptic techniques inside of a class 
II laminar flow cabinet.
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2.2.4 Trypsinisation and determination of cell count
Upon reaching approximately 80 -  90% confluency the cells were prepared for 
Trypsinisation. Medium was aspirated and the cells rinsed briefly with EDTA to 
remove any traces of serum which inhibits the enzymatic action of trypsin. Following 
this, cells were detached from the tissue culture flask by incubating with trypsin/EDTA 
for several minutes. Once detached the cell suspension was placed in 20ml universal 
container (Greiner Bio-One Ltd, Gloucestershire, UK) and centrifuged at 1800rpm for 6 
minutes to pellet the cells. The cell pellet was resuspended, in an appropriate volume of 
fresh medium, before either determining cell number per millilitre (for use in cellular 
assays), or transferring a small volume of cell suspension into new tissue culture flasks. 
A Neubuaer haemocytometer was used to determine the cell density. Cells were 
counted on the haemocytometer counting chamber using an inverted microscope 
(Reichet, Austria) under 10 x 10 magnification. This allowed the number of cells per 
millilitre to be determined and accurate numbers of cells to be seeded in the in vitro and 
in vivo cellular functional assays. The dimensions of each 16 square area, containing 
cells to be counted, is 1mm x 1mm x 0.2mm which allowed the number of cells per 
millilitre to be determined using the following equation:
Cell number / ml = (number of cells counted in 16 squares ^ 2 ) x ( l  x 104)
Two 16 squared areas were counted to confirm consistent approximate cell density 
per millilitre between the two counts.
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\2.2.5 Storage of cells in liquid nitrogen
Stocks of low passage cells were stored in liquid nitrogen. Cells were detached from 
a large 75cm3 flask using EDTA/Trypsin as described in section 2.2.5 and placed in a 
centrifuge to form a cell pellet. These cells were resuspended in the required volume 
(dependent on the number of samples to be frozen) of a protective medium consisting of 
10% dimethyl sulphoxide (DMSO) in normal growth medium. Following resuspension, 
1 ml of cells was aliquoted into cryotubes (Nunc, Fisher Scientific, Leicestershire, UK), 
wrapped loosely in tissue paper and stored overnight in a -80°C freezer. Cells were then 
transferred to liquid nitrogen tanks for long term storage.
2.3 Methods for detecting mRNA
2.3.1 RNA isolation
Ribonucleic acid (RNA) is present within the nucleus, cytoplasm and 
mitochondria of all living eukaryotic cells and it is of particular importance as it carries 
the genetic information for protein formation. The presence of specific mRNA 
sequences indicates which protein is being produced by a cell at any given time. RNA 
isolation was completed using the ABgene Total RNA Isolation Reagent (TRIR) Kit 
and protocol (ABgene, Surrey, UK). Cells were grown until 85-90% confluent, the 
medium was removed and 1ml of TRIReagent (Sigma-Aldrich, Dorset, UK) was added 
to the cell monolayer. The cell lysate was then scraped from the flask and passed
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through a pipette several times before being transferred into a 1.8ml eppendorf. The 
homogenate was kept at 4°C for 5 minutes before adding 0.2ml chloroform and 
vigorously shaking the samples for 15 seconds, samples were centrifuged in a 
refrigerated centrifuge (Boeco, Wolf laboratories, York, UK) at 4°C and 12,000g for 15 
minutes. The homogenate will form two phases: the lower phase is the organic phase 
and the upper phase is the aqueous phase. DNA and protein are in the organic phase and 
in the interface while RNA is in the aqueous phase. The volume of the aqueous phase 
should be about 40-50% of the total volume of the homogenate plus chloroform. 
Following centrifugation, the upper aqueous phase containing RNA was carefully 
removed and added to a pre-labelled eppendorf containing an equal volume of 
isopropanol, the samples were then stored at 4°C for 10 minutes before centrifuging at 
12,000g and 4°C for 10 minutes. This causes any RNA present to precipitate which 
forms a white pellet at the bottom of the tube after the centrifugation. The supematum 
was discarded and the RNA pellet washed twice in 75% ethanol (prepared in a 3:1 ratio 
of absolute ethanol:DEPC water). Each wash consisted of the addition of 1ml of 75% 
ethanol, vortexing and subsequent centrifugation at 4°C and 7,500g for 5 minutes. 
Following the final wash, as much ethanol as possible was removed from the eppendorf 
before briefly drying the pellet in a Techne, Hybridiser HB-1D drying oven (Wolf 
laboratories, York, UK) at 50°C to remove any remaining ethanol. Finally the pellet 
was dissolved in 50 -  100pi (depending on pellet size) of DEPC water before 
proceeding to quantify the RNA present in the sample. DEPC water was used in RNA 
isolation to reduce the effects of any RNases that may be present. DEPC is a histidine 
specific alkylating agent and inhibits the action of RNases which rely on histidine 
active sites for their activity.
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2.3.2 RNA quantification
Following isolation, RNA was quantified using a UV1101 Biotech Photometer(WPA, 
Cambridge, UK), that had been configured to detect ssRNA (pg/pl) in a 1 in 10 dilution 
based on the difference in absorbance at 260nm wavelength to a DEPC blank. All 
samples were measured in a Stama glass cuvette (Optiglass limited, Essex, UK). The 
RNA samples were either stored at -80°C for later use or used immediately for reverse 
transcription (RT).
2.3.3 Reverse transcription polymerase chain reaction (RT-PCR) of RNA
RT-PCR is a simple, rapid and versatile method for the detection and analysis of 
mRNA. It provides a more sensitive approach than that of northern and southern 
blotting and requires smaller amount of RNA. Following RNA isolation and 
quantification, the RNA samples were normalised to 250ng. The volume of RNA 
required to make each sample 250ng depended on the concentration (pg/pl) of RNA in 
each sample. 250ng of RNA was converted into complementary DNA (cDNA) using an 
Enhanced Avian Reverse Transcriptase-PCR-100 kit (Sigma-Aldrich, Dorset, UK). RT- 
PCR was undertaken following the DuraScript Reverse Transcription for Two-Step RT- 
PCR protocol which is outlined below:
• X pi of RNA (volume depends on concentration)
• 1 pi of deoxynucleotide mix
82
• 1 |xl of anchored oligo (dT)23
• 8 pi (-volume of RNA) PCR H20
The tube was then mixed gently and centrifuged before placing the mix in a T-Cy 
Thermocycler (Creacon Technologies Ltd, The Netherlands) and heating at 70°C for 10 
minutes. This initial step may denature the RNA secondary structure and allow more 
effective reverse transcription. Once this initial incubation step had finished, the tubes 
were removed from the thermal cycler and placed on ice before centrifuging and adding 
the following to each tube:
• 6 pi -  PCR water
• 2 pi -  10X buffer for DuraScript RT
• 1 pi -  RNase inhibitor
• 1 pi -  Enhanced Avian Reverse Transcriptase (eAMVRT)
The tubes were mixed, centrifuged and placed back in the thermal cycler to be heated at 
42°C for 50 minutes. The cDNA generated was diluted 1:3 with PCR water and 
conventional PCR probing for GAPDH expression to confirm successful reverse 
transcription. Samples were stored at -20°C until further required.
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2.3.4 Conventional Polymerase Chain Reaction (PCR)
PCR was carried out using a REDTaq ReadyMix PCR Reaction mix (Sigma, 
Dorset, UK). Sixteen microlitre reactions were set up for each sample to be tested as 
follows:
• 8 pi - 2X REDTaq ReadyMix PCR Reaction mix
• 1 pi -  Specific forward primer
• 1 pi -  Specific reverse primer
• 5pl -  PCR water
• lpl - cDNA
Primers were designed using the Beacon Designer programme (Palo Alto, 
California, USA) and were synthesised by Invitrogen (Paisley, UK). Primers were 
diluted to a concentration of lOpM before being used in the PCR reaction. The PCR 
reaction was set up in a 200pl PCR tube (ABgene, Surrey, UK), mixed briefly and 
centrifuged before being placed in a T-Cy Thermocycler and subjected to the following 
temperature shifts:
• Step 1: Initial denaturing period -  94oC for 5 minutes
• Step 2: Denaturing step -  94oC for 1 minute
• Step 3: Annealing step -  reaction specific temperature for 1 minutes
• Step 4: Extension step -  72oC for 1 minute
• Step 5: Final extension period -  72oC for 10 minutes
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Steps 2 - 4  were repeated over 36 cycles. Specific reaction annealing 
temperatures together with primer sequence data is detailed in table 2.2. Primer binding 
sites and predicted product sizes were verified using the Primer3 (v.0.4.0) software 
available online (http://frodo.wi.mit.edu/). RT-PCR products which corresponded with 
this predicted size following electrophoresis and staining were taken as being accurate. 
Positive and negative controls were also tested to verify RT-PCR primers. A collection 
of mixed RNA extracted from a large number of prostate cancer tissue sections and 
subsequently converted to cDNA was used as the positive control for most of the primer 
pairs. The exception to this was the matriptase-2 primer pairs as matriptase-2 mRNA 
levels were found to be very low in prostate cancer samples. In these cases the 
PLC/PRF/5 liver cancer cell line was used as a positive control for matriptase-2. In all 
cases a negative control where PCR water replaced cDNA in the reaction was included.
2.3.5 Agarose gel electrophoresis
Agarose gel electrophoresis is the easiest and most common method to separate 
DNA fragments. Nucleic acid molecules are separated by applying an electric field to 
move the negatively charged molecules through an agarose matrix. Shorter molecules 
move faster and migrate farther than longer ones because shorter molecules migrate 
more easily through the pores of the gel. Once the samples had completed the sufficient 
number of cycles in the thermocycler, the amplified DNA was separated according to 
size using agarose gel electrophoresis. Dependent on the predicted size of the DNA 
produced, the samples were loaded into either 0.8% (samples greater than 
approximately 500bp), or 2% (samples less than 500bp), agarose gels. Agarose gels
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were made by adding the required amount of agarose (Melford Chemicals, Suffolk, 
UK) to TBE solution. This was then heated to fully dissolve the agarose, poured into 
the electrophoresis cassette and allowed to set around a plastic comb to create loading 
wells for approximately 30-40 minutes. Once set, the gel was submerged in TBE 
running buffer, 4pi of a 1Kb ladder (Invitrogen, Paisley, Scotland), or lOpl of sample 
was then added to the wells. The samples were then electrophoretically separated at a 
constant voltage of 100Y until the samples had run three quarters of the gel depending 
on the size of the PCR product. Once the electrophoresis was completed the gel was 
placed into ethidium bromide diluted in TBE with continuous agitation to ensure even 
staining of the agarose gel for 15 minutes. Once stained the gel was visualised under 
ultra violet light using a UV transilluminator (UVitech, Cambridge, UK).
2.3.6 Quantitative Polymerase Chain Reaction (Q-PCR)
Q-PCR, or real-time PCR, is a very sensitive technique which is used to amplify 
and simultaneously quantify a targeted DNA molecule. It enables both detection and 
quantification (as absolute number of copies or relative amount when normalized to 
DNA input or additional normalizing genes) of one or more specific sequences in a 
DNA sample. Due to its sensitivity this method allows the detection and quantification 
of very small quantities of cDNA in a sample. The cDNA for use in Q- PCR was 
generated as described above; this cDNA was then used to make up a master reaction 
mixture containing the following amounts of each component per reaction:
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• Forward Z primer -  0.3pl (lpmol/jil)
• Reverse primer -  0.3pl (lOpmol/pl)
• Q-PCR Master Mix -  5 pi
• Probe Ampiflour -  0.3pl (1 Opmol/pl)
• PCRH20-2.1pl
• cDNA -  2pl
In each reaction, one of the primer pairs (see table 2.2), will contain a Zsequence 
(ACTGAACCTGACCGTACA) at a 1/10 concentration of the other primer and the 
probe. The Amplifluor system was used to detect and quantify transcript copy number. 
The ampliflour probe consists of a region specific to the Z-sequence together with a 
hairpin structure labelled with a fluorescent tag (FAM). Whilst in the hairpin structure 
this fluorescent tag is effectively quenched and produces no signal. However, the 
specificity of the 3’ region of the ampilflour probe to the Z-sequence causes the 
incorporation of this uniprimer. Subsequent DNA polymerisation, following 
incorporation, results in the disruption of the hairpin structure and effective signalling 
of the fluorescent tag within this structure. The degree of fluorescence within each
sample compared to a range of standards of known transcript copy number allows the
calculation of transcript copy number within each sample. Detection of GAPDH copy 
number within these samples was subsequently used to allow further standardisation 
and normalisation of the samples. Figure 2.2 (A) and 2.2 (B) show the detection of a 
range of standard samples (108 to 102 copy number) and the subsequent generation of a 
standard curve from these samples. Sample cDNA was amplified and quantified over a 
large number of shorter
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cycles using an iCyclerlQ thermal cycler and detection software (BioRad laboratories, 
Hammelhempstead, UK) and experimental conditions are outlined below:
• Step 1: Initial denaturing period -  94°C for 5 minutes
• Step 2: Denaturing step -  94°C for 10 seconds
• Step 3: Annealing step -  55°C for 15 seconds
• Step 4: Extension step -  72°C for 20 seconds
Step 2 - 4  was repeated over 60 cycles. The camera used in this system is set to 
detect signal during the annealing stage. The experimental procedure was repeated 
twice and data representative of the expressional trends is presented. It should be noted 
that the high number of cycles was not necessarily needed to detect the product, as 
calculation of the transcript number arises based on when fluorescent detection reaches 
a certain threshold point. Furthermore, in this established method, approximately 20 
cycles are required for the generation of Z-tagged products (Nazarenko et al., 1997).
This is illustrated in figure 2.2 where the 108 sample was similarly run at a high 
number of cycles but reaches threshold relatively early on (approx 18 cycles). 
Subsequently, calculation of sample copy number will depend on point at which the 
sample reaches threshold cycle (TC) in comparison to the standards, automatically 
generated by the instrument software. Specific Q-PCR primers were verified using a 
positive control known to express the molecule of interest and a negative control, where 
PCR water replaced cDNA, was also included to rule out contamination of the reaction.
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Figure 2.1: Generation of Q-PCR standard curve (A) Detection of 
transcript levels from a range of standard samples (108 to 102 copy 
number) using the iCyclerIQ thermal cycler. (B) Subsequent generation 
of a standard curve from these samples.
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2.4 SDS-PAGE and Western Blotting
2.4.1 Cell Lysis and Protein Isolation
Upon reaching 85% confluency, the cell monolayer was removed from the flask 
using a disposable cell scraper; the detached cells were then transferred to a universal 
container. The cell suspension was centrifuged for 5 minutes at 1800 rpm to pellet cells 
and protein at the bottom of the universal container. Following centrifugation, the 
medium was aspirated and the cells were lysed in 200 -  250pl (depending on pellet 
size) of lysis buffer, before being transferred to a 1.8ml eppendorf (A Laboratories, 
Hampshire, UK) and placed on a Labinco rotating wheel (Wolf laboratories, York, UK) 
for 1 hour. The lysis solution was then spun at 13,000 rpm in a microcentrifuge for 15 
minutes to remove any insolubles and the pellet removed from the eppendorf tube. The 
protein samples were quantified and used in SDS-PAGE or stored at 20°C until needed.
2.4.2 Protein Quantification
Prior to use in Western blotting the protein samples were standardised to a 
specific concentration. Protein concentration was determined using a Bio-Rad DC 
Protein Assay kit (Bio-Rad laboratories, Hemmelhempsted, UK) and the supplied 
microplate protocol. A range of standard samples of known concentrations were 
produced using a serial dilution of lOmg/ml bovine serum albumin (BSA) standard 
(Sigma, Dorset, UK). The standard was serially diluted from lOmg/ml to 0.005mg/ml in 
the lysis buffer used in the previous protein extraction. Prior to quantification ‘working
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reagent A’ was prepared by adding 20pl reagent S to every millilitre of reagent A 
needed for the quantification. Five microlitres of either sample or standard was pipette 
into a well before adding 25pi ‘working reagent A’ followed by 200pi of reagent B. 
After the addition of reagent B the samples were mixed and incubated in the dark for 45 
minutes. Absorbance of samples and standards at 620nm was then read using an 
ELx800 plate reading spectrophotometer (Bio-Tek, Wolf laboratories, York, UK). 
Using the absorbances from the BSA standards a standard curve was produced and used 
to determine sample concentration. All samples were normalised to the chosen 
concentration by dilution in the appropriated amount of lysis buffer. The samples were 
then further diluted 1:1 with 2x Lamelli sample buffer concentrate. Samples were then 
boiled and used in SDS-PAGE or stored at 20°C for future use.
2.4.3 Sodium dodecyl sulphate polyacrilamide gel electrophoresis (SDS-
PAGE)
SDS-PAGE was used to detect the presence, or absence, of specific proteins. SDS- 
PAGE was undertaken using an OmniPAGE VS 10 vertical electrophoresis system 
(OminPAGE, Wolf Laboratories, York, UK). Resolving gels of a required percentage 
(depending on the predicted size of the protein of interest) were made up in a universal 
container. The amount of each ingredient required to make up 15ml (enough for two 
gels) for both 8% and 10% resolving gels is indicated below:
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Distilled water 6.9ml 5.9ml
30% acrylamide mix (Sigma- 
Aldritch, St Louis, USA)
4.0ml 5.0ml
1.5M Tris (pH8.8) 3.8ml 3.8ml
10% SDS 0.15ml 0.15ml
10% Ammonia persulphate 0.15ml 0.15ml
TEMED (Sigma-Aldritch, St 
Louis, USA)
0.009ml 0.006ml
Table 2.6 Components for resolving gel.
The resulting mixture was then poured in between two glass plates held in place 
by a loading cassette, until a level 1cm below the top of the plate, and in order to 
prevent gel oxidation, the top of the resolving gel was covered with a 0.1% SDS 
solution. The gels were then left to polymerise at room temperature for approximately 
30 minutes, or until fully set. The excess SDS solution was then poured off before 
adding a sufficient amount of stacking gel in its place, prepared as shown below:
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Distilled water 3.4ml
30%acrylamide mix (Sigma- 
Aldritch, St Louis, USA)
0.83ml
1.0M Tris (pH 6.8) 0.63ml
10% SDS 0.05ml
10% Ammonium persulphate 0.05ml
TEMED (Sigma-Aldritch, St 
Louis, USA)
0.005ml
Table 2.7 Components for stacking gel
Immediately after the addition of the stacking gel, a well forming Teflon 
comb is inserted before allowing the gel to polymerise at room temperature for 
around 20 minutes. Once set, the loading cassette was transferred into an 
electrophoresis tank and covered with IX running buffer before removing the 
well comb, and by use of a 50pl syringe (Hamilton), loading 6-8pl of 
ColorPlus Prestained Protein Marker (New England BioLabs Ltd., Herts, UK), 
followed by 10-15pi of the required protein samples. The gels were then run at 
125 V, 40mA, and 50W for a length of time appropriate for the size of the 
protein of interest, in order to separate the proteins according to charge and 
molecular weight.
2.4.4 Western Blotting
Once SDS-PAGE was completed, the protein samples were transferred to a 
nitrocellulose membrane using Western blotting. Gels were removed from the glass 
plates and the stacking gel cut away and discarded. The resolving gel was then placed 
on the bottom graphite base electrode in a SD20 SemiDry Maxi System blotting unit 
(SemiDRY, Wolf Laboratories, York, UK) on top of 3 pieces of lx transfer buffer pre­
soaked filter paper (Whatman International Ltd., Maidstone, UK), and 1 sheet of 
Hybond nitrocellulose membrane (Amersham Biosciences UK Ltd., Bucks, UK). An 
additional 3 sheets of pre-soaked filter paper were placed on top of the gel to form a 
sandwich arrangement of paper: membrane: gel: paper: as shown in Figure 2.2. 
Electroblotting was then carried out at 15v, 500mA, and 8W for around 1 hour. Once 
complete, membranes were removed and stored at 4°C in 10% skimmed milk, 0.1% 
polyoxyethylene (20) sorbitan monolaurate (Tween 20) (Sigma-Aldrich, St Louis, 
USA) in TBS until required for specific antibody probing.
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Figure 2.2 Diagram showing structure of Western blotting.
2.4.5 Staining of proteins
2.4.5.1 Staining membranes in Ponceau S
Ponceau S is a reversible and re-usable protein stain that does not interfere with 
any subsequent immune-probing. It is used to confirm transfer of proteins from the 
polyacrylamide gel to the nitrocellulose membrane. After the transfer was completed 
and before probing began, the membrane was immersed in Ponceau S solution for a few 
minutes at room temperature. The solution was then washed off with distilled water 
until the bands become visible. If required, the membrane was then cut into several 
sections using a sharp and clean scalpel. Once the Ponceau S was completely washed 
off it was placed in 10% milk solution.
95
2.4.6 Detection of proteins using specific antibody probing
Membranes were transferred to 50ml falcon tubes (Nunc, Fisher-Scientific, 
Leicestershire, UK) ensuring that the membrane surface that was in contact with the gel 
was facing upwards. The membranes were then placed in 10% milk blocking solution 
and left to rotate on a roller mixer (Stuart, Wolf Laboratories, York, UK) for 1 hour. 
After this blocking period was removed and a specific primary antibody at 1:200 in 3% 
milk solution (3% milk powder, 0.1% Tween 20 in TBS) was added to the falcon tube 
and the tube was placed on the roller mixer for 1 hour (See table 2.5 for full primer 
information). After 1 hour the primary antibody was removed and any remaining 
unbound antibody was washed off with three 15 minute washes with 3% milk solution. 
Once washing was completed, the membranes were incubated with 5ml of 1:1000 HRP 
conjugated secondary antibody (of the same species) diluted in 3% milk. The tubes 
were again placed on the roller mixer for a further hour. After this incubation two 15 
minute washes in 10ml of t-TBS were conducted to remove any unbound secondary 
antibody. A final two 15 minute washes with TBS alone were carried out to remove any 
residual detergent, before placing the membrane in weighing boats containing TBS 
solution, ready for chemiluminescent detection.
2.4.7 Chemiluminescent protein detection
Chemiluminescent protein detection was carried out using the Supersignal™ West 
Dura system (Pierce Biotechnology, Inc., Rockford, IL, USA), which contains a highly
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sensitive chemiluminescent substrate that detects the horseradish peroxidise (HRP) used 
during the western blot procedure. The two reagents provided were added in a 1:1 ratio 
into the weighing boat containing the membrane. After 5 minutes incubation the 
membrane was removed from the solution using forceps. Any excess solution was 
drained over a piece of tissue paper before being transferred to a new weighing boat. 
The chemiluminescent signal was detected using a UVTTech Imager (UVITech Inc, 
Cambridge, UK) which was linked to a computer to directly capture and store the 
resulting image. Each membrane was subjected to varying exposure times until the 
protein bands were sufficiently visible. These images were then captured and further 
analysed with the UVTband software package (UVITEC, Cambridge, UK), which 
allows for protein band quantification. In this study, GAPDH was used as a 
housekeeping gene and run alongside any other proteins to be detected, so as to allow 
for additional normalisation of the samples, and to compensate for any other negligible 
inaccuracies which may have occurred during the process. Because the GAPDH gene 
is often stably and constitutively expressed at high levels in most tissues and cells, it is 
considered a housekeeping gene. For this reason, GAPDH is commonly used as a 
loading control. In order to confirm reliability of the results, each Western blot was 
carried out three times and the protein bands quantified and standardised separately, 
followed by calculation of mean values and graphical presentation of the results.
2.4.8 Immunocytochemical staining
This study uses a previously reported method of Immunocytochemical staining 
(Jiang et al. 2005) and was carried out as follows:
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20,000 cells in 200pl DMEM media were seeded into chamber slides (Nalge, NUNC 
International, LAB-TEK®, USA) and left to incubate overnight at 37°C, with 5% CO2. 
The cells were then fixed in formalin for 30 minutes at 4°C, before being rehydrated 
with BSS for an hour at room temperature. This was followed by cell permeabilisation 
in 0.1% TritonXlOO in TBS for 5-10 minutes at room temperature. This causes the cell 
membranes to rupture, releasing intracellular proteins. Permeabilisation was followed 
by blocking of the cells with horse serum (Vector Laboratories Inc., Burlingame, USA) 
in OptiMax Wash Buffer (BioGenex, San Ramon, USA) for 30 minutes at room 
temperature. 1-2 drops of horse serum per 5ml of wash buffer was diluted 1:20 in 
distilled water and used as the blocking solution. After blocking, the cells were washed 
four times with wash buffer before being incubated for an hour at room temperature 
with primary antibody diluted 1 : 1 0 0  (depends on antibody used) in blocking solution. 
Any unbound antibody was subsequently washed off with wash buffer. This was 
repeated 4 times before incubating the cells for a further 30 minutes at room 
temperature, with the corresponding secondary antibody diluted 1 : 1 0 0 0  in blocking 
solution. After 4 washes with wash buffer, the cells were incubated with 200pi of 
working VECTASTAIN® Universal ABC complex (Vector Laboratories Inc., 
Burlingame, USA). The ABC complex was made up 30 minutes before use by mixing 
4 drops of the supplied reagent A, with 4 drops of reagent B. The ABC solution was 
subsequently removed by washing four times with wash buffer before a few drops of 
DAB chromogen (Vector Laboratories Inc., Burlingame, USA) were added to the cells 
and left to incubate for 5 minutes in darkness. DAB was made up as follows; 2 drops of 
the provided buffer (pH 7.5), 4 drops of DAB, and 2 drops of hydrogen peroxide diluted 
in 5ml of distilled water. Following DAB addition, the solution should turn brown and
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once this had occurred, the DAB was washed off using distilled water before the cells 
were counterstained with Mayer’s haemotoxylin for approximately 1 minute.
2.4.9 Immunoflourescent staining
The method used in this study for fluorescent staining was carried out as 
previously reported (Jiang et al., 1999). 20,000 cells in 200pl DMEM media were 
seeded into chamber slides (Nalge, NUNC International, LAB-TEK®, USA) and left to 
incubate overnight at 37°C, with 5% CO2.
After incubation the media was aspirated and the cells fixed with 200pi ice-cold pure 
ethanol for 20 minutes at 4°C. Following fixation, the cells were rehydrated with 200pi 
BSS for a minimum of 30 minutes at room temperature. The cells were permeabilised 
with 0.1% TritonxlOO in TBS for 5-10 minutes at room temperature before being 
blocked with horse serum in OptiMax Wash Buffer (BioGenex, San Ramon, USA) for 
30 minutes at room temperature as explained in section 2.4.7. Blocking was followed 
by four washes with wash buffer before the cells were incubated for an hour at room 
temperature with primary antibody diluted 1 : 1 0 0  (depending on antibody used) in 
blocking solution. After a further four washes with wash buffer, the cells were 
incubated with the corresponding secondary antibody labelled with either FITC or 
TRITC diluted 1:100 in blocking serum. The secondary antibodies were subsequently 
washed off twice using wash buffer before the slides were mounted with Flouro-Save 
(CalBiochem, Nottingham, England) and viewed under a fluorescent microscope 
(Olympus). Photos were taken and analysis carried out using the Cell Analyser 
software (Olympus).
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2.5 Alteration of Matriptase-2 gene expression
2.5.1 Knocking down gene expression using Ribozyme Transgenes
In order to knockdown the expression of Matriptase-2, it was targeted at the mRNA 
level using hammerhead ribozyme transgenes that specifically target and cleave the 
Matriptase-2 mRNA transcript. This method of knockdown is used within the 
laboratory instead of siRNA because the ribozyme method proved to be consistently 
more reliable and stable than the siRNA method. The hammerhead ribozyme was first 
described by Forster and Symons in 1987 as a self-cleaving region in the RNA genome 
of various plant viroids and virusoids. The hammerhead motif was subsequently 
integrated into short synthetic oligonucleotides, transforming it into a turnover catalyst 
capable of cleaving various RNA targets (Uhlenbeck, 1987; Haseloff and Gerlach, 
1988).
Hammerhead motifs contain a conserved secondary structure that consists of three 
helical stems (I, II, and III) enclosing a junction known as the catalytic core, typified by 
various invariant nucleotides. The best codons demonstrated to be suitable for cleavage 
are AUC, GUC and UUC (Figure 2.3a). In order to generate a ribozyme transgene 
specific to Matriptase-2, primers were designed using Zuker’s RNA mFold programme 
(Zuker, 2003) according to the secondary structure of the gene. Subsequently, an 
appropriate GUC ribozyme target site was chosen from within matriptase-2’s secondary 
structure (Figure 2.3b) and the ribozyme created to specifically bind the sequence 
adjacent to this GUC codon. This made it possible for the hammerhead catalytic region
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of the ribozyme to bind to and specifically cleave the GUC sequence within the target 
mRNA transcript.
Following ribozyme design, the sequences were ordered from invitrogen as 
sense/antisense strands (as shown in Table 2.4) and joined to the transgene by carrying 
out touchdown PCR under the following conditions:
• Step 1: Initial denaturing period -  94°C for 5 minutes
• Step 2: Denaturing step -  94°C for 10 seconds
• Step 3: Various annealing steps -  70°C for 15 seconds, 65°C for 15 seconds,
• 60°C for 15 seconds, 57°C for 15 seconds, 54°C for 15 seconds and 50°C for 
15seconds.
• Step 4: Extension step -  72°C for 20 seconds
• Step 5: Final extension period -  72oC for 7 minutes
• Step 2 - 4  was repeated over 48 cycles, each different annealing temperature 
comprising 8  cycles.
Once combined, the transgenes were run electrophoretically on a 2% agarose gel to 
confirm presence and correct size before being inserted into the pEF6  plasmid in the 
TOPO cloning reaction, as described in a later section.
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Figure 2.3a: Secondary structure of hammerhead ribozyme with bound substrate.
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Matriptase-2
Figure 2.3b The predicted secondary structure of human matriptase-2 mRNA
2.5.2 Matriptase-2 gene over-expression
In addition to generating ribozyme transgenes against matriptase-2, the full 
sequence of matriptase-2 was also cloned into the pEF6 plasmid and used to transform 
mammalian cancer and human endothelial cells. Prior to the initiation of this PhD 
study, a pEF6 plasmid, containing the full sequence of matriptase-2, had been generated 
by Dr C. Parr. This cloning work has been recently fully described in Parr et al 2007 
(Parr et al., 2007). It is unkown if the original creator of the expression plasmid 
intended to utilise the V5/His tagged pEF6 vector for purification or immunolabelling 
procedures. It does not appear that these tags affect matriptase-2 function although in 
depth examination should be conducted in the future. Briefly, matriptase-2 was found to
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be modestly expressed in the PLC/PRF/5 hepatocellular carcinoma cell line; cDNA 
from this cell line was subsequently used to generate the full matriptase-2 cDNA 
sequence for further use in cloning. In order to isolate the full matriptase-2 sequence 
expression primers (see table 2.1) were designed based on the Homo sapiens 
matriptase-2 mRNA sequence (PubMed accession number AJ319876). These primers, 
together with PLC/PRF/5 cDNA, were used in a PCR reaction (using an annealing 
temperature of 58°C over 35 cycles). Following electrophoretic separation on a 0.8% 
gel and staining, a band of approximately 2.5Kbp was revealed. This band corresponds 
with matriptase-2 sequence size listed in PubMed. This product was later inserted into 
the pEF6  plasmid using the TOPO cloning reaction described later. Prior to this current 
study, a study by Sanders et al 2008 used this matriptase-2 expression plasmid to 
extensively investigate the effect of matriptase- 2  over-expression on the cancerous cell 
lines PC3 and DU145 (Sanders et a l, 2008). Any further mention of the functional 
aspects of these two cell lines relating to matriptase- 2  expression status was derived 
from the Sanders et al study.
2.5.3 TOPO cloning reaction
Cloning of both the ribozyme and expression sequence was carried out using the 
pEF6/V5-His TOPO TA Expression Kit (Invitrogen, Paisley, UK), following the 
provided protocol. This protocol allows rapid five minute one step cloning of Taq 
polymerase amplified products for expression in mammalian cells. Once cloned, 
analysed, and transfected into a mammalian host cell line, the PCR product can be 
constitutively expressed (Figure 2.2). The reaction was performed in accordance with 
the manufacturers’ protocol which is outlined in the following sections.
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Figure 2.4: Schematic of the pEF6 plasmid (taken from pEF6/V5-His TOPO TA 
Expression Kit protocol).
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The following TOPO cloning reaction was set up for each ribozyme transgene or 
expression sequence used in a labelled PCR tube:
• PCR product (ribozyme or expression sequence) -  4pi
• Salt solution-1 pi
• TOPO vector -  1 pi
This reaction was gently mixed and incubated at room temperature for 30 minutes and 
stored in ice until proceeding to One Shot Chemical Transformation.
2.5.4 One Shot Chemical Transformation of chemically competent Escheria 
coli
Five microlitres of the TOPO cloning reaction from previously completed in
2.3.2 was added to a vial of One Shot Chemically Competent E. coli and mixed by 
stirring gently with the pipette tip as pipetting up and down may damage the bacteria. 
The vial was then incubated on ice for 30 minutes. After this incubation, the cells were 
heat-shocked for 30 seconds at 42°C without shaking and immediately placed back on 
ice. Two hundred and fifty microlitres of room temperature SOC medium was added to 
each tube, which were then capped tightly and shaken horizontally at 2 0 0  rpm on a 
horizontal orbital shaker (Bibby Stuart Scientific, UK), at 37°C for 1 hour. Following 
this incubation period, the contents of each tube were spread onto two pre-warmed 
selective agar plates (containing lOOpg/ml ampicillin). One plate was seeded at a high 
concentration and the other at a low concentration. The plates then were incubated
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overnight at 37°C to allow the E. coli to grow and form colonies. The pEF6  plasmid 
contains two antibiotic resistance genes that allow cells containing the plasmid to grow 
under ampicillin and blasticidin S selection, a schematic of the plasmid is shown in 
figure 2 .1 .
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Figure 2.5 Flow chart detailing the process of TOPO TA cloning reaction
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2.5.5 Selection and orientation analysis of positive colonies
Correct insertion and orientation of the ribozyme/expression sequence in the 
plasmid was analysed to ensure that the resulting product would be viable. The colonies 
were tested using PCR with primers specific to either the ribozyme/expression 
sequence, or the pEF6  plasmid. The size of the product obtained using the plasmid 
specific primers (T7F and BGHR) will give an indication of the inserted sequence size 
and can then be used to check that the full sequence had been inserted without 
degradation. Although T7F vs. BGHR indicate if the complete sequence has inserted it 
does not give an indication of the orientation of the insert. Therefore, in order to check 
correct size and orientation of the sequence, a mixture of plasmid specific and sequence 
specific primers were used. To check the ribozyme sequences a combination of T7F vs. 
RbToP and T7F vs. RbBMR were used. RbToP and RbBMR recognise and bind to 
sequences within the ribozyme transgene that are common to all of the ribozymes used. 
There are approximately 90bp between the T7F promoter and the beginning of the 
insert. Thus, correct orientation and ribozyme size (based on approximate ribozyme size 
of 50bp), would be confirmed by a band of approximately 140bp in the T7F vs. 
RbBMR reaction. Likewise, a band of approximately 140bp in the T7F vs. RbToP 
would indicate incorrect orientation of the sequence.
Following overnight incubation, the plates were examined for colony growth. 
Ten colonies were randomly selected for orientation analysis and marked and labelled 
on the plates. For each colony, two PCR reactions were carried out as follows (full 
primer sequences are given in table 2 .2 ):
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Ribozyme orientation reaction 1
• 8 pl - 2X REDTaq ReadyMix PCR Reaction mix
• lfxl — T7F plasmid specific forward primer
• 1 pi -  Ribozyme specific forward primer (RbToP)
• 6  pi -  PCR water
Ribozyme orientation reaction 2
• 8 pl - 2X REDTaq ReadyMix PCR Reaction mix
• lp.1 -  T7F plasmid specific primer
• 1 pi -  Ribozyme specific reverse primer (RbBMR)
• 6 pl -  PCR water
In order to test the DNA present in the colonies, a sample was picked from the 
plate using a sterile pipette tip and inoculated into both mixes before the addition of the 
specific primers. Each reaction mix was then placed in a thermal cycler and subjected to 
the following conditions:
• Step 1: Initial denaturing period -  95°C for 10 minutes
• Step 2: Denaturing step -  94°C for 1 minute
• Step 3: Annealing step -  55°C for 1 minute
• Step 4: Extension step -  72°C for 1 minute
• Step 5: Final extension period -  72°C for 10 minutes
The mixture was run on a 2% agarose gel and visualized under ultra violet light. 
Colonies showing correct orientation of the insert were picked off the plate and used to 
inoculate 10ml of ampicillin selective LB broth and incubated overnight whilst being 
horizontally shaken at 225 rpm.
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Orientation checking for the larger matriptase-2 expression sequence products 
follows the same basic theory and principle. As mentioned earlier, the generation of a 
pEF6  plasmid containing the matriptase-2 expression sequence had been previously 
completed by Dr C. Parr prior to the initiation of this PhD study and is outlined in Parr 
et al, 2007 (Parr et al., 2007). Thus correct orientation of this molecule had already 
been confirmed by Dr Parr using the following PCR reactions T7F vs. BGHR 
(indicating full sequence) and T7F vs. matrip2Rl (indicating correct orientation). A 
sample of the matriptase-2 expression plasmid was generously donated by Dr Parr for 
use in the prostate study conducted in this thesis. This plasmid was then used to 
inoculate fresh One Shot TOP 10 Chemically Competent E. coli and subsequently 
subjected to further orientation and size checks before being used to transfect the 
prostate cancer cell lines. Additional information, together with results of orientation 
checking, is outlined in chapter 3.
2.5.6 Plasmid extraction, purification and quantification
Plasmid extraction was performed using the Sigma GenElute Plasmid MiniPrep 
Kit according to the provided protocol. Five millilitres of the LB broth previously 
inoculated with the chosen colony and cultured overnight was centrifuged at 3,000 RCF 
to obtain a pellet of bacteria. The supematum was removed and the bacterial pellet was 
resuspended in 200pl of resuspension solution (containing RNase A) and mixed by 
pipetting. Two hundred microlitres of lysis solution was then added and the container 
and inverted 5 - 6  times. This stage was completed within 5 minutes before adding 
350pl of the neutralisation solution, inverting 4 - 6  times and centrifuging at 12,000 x g
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in a micro centrifuge. Plasmid DNA was bound to the column by transferring the 
cleared lysate to a Mini Spin Column placed inside a collection tube, spinning at 12,000 
x g for 30 seconds to 1 minute and discarding the flow through. Seven hundred and fifty 
microlitres of wash solution (containing ethanol) was added to the column before 
spinning at 12,000 x g for 30 seconds to 1 minute and again discarding flow through. 
The column was spun at 12,000 x g for 30 seconds to 1 minute to remove any 
remaining flow through before transferring the Mini Spin Column to a fresh collection 
tube. Plasmid DNA was eluted through the addition of 1 OOjliI of elution solution and 
spinning the column at 12,000 x g for 1 minute. The eluted plasmid solution was then 
electrophoretically run on a 0 .8 % agarose gel to confirm presence and correct size of 
the plasmid.
2.5.7 Transfection of plasmid using electroporation
In order to introduce the plasmid DNA to the mammalian cells the method of 
electroporation was used. This involves using electricity to induce pores in the cell 
membrane to allow plasmid DNA to enter the cell. Following plasmid purification and 
quantification, l-3pg of the extracted plasmid was used to transfect the mammalian 
cancer cell lines. Near confluent wild type cells were detached from tissue culture flasks 
using trypsin/EDTA, pelleted and counted following resuspension as previously 
described. One million cells in 1 OOOjliI were added to an electroporation curvette 
(Eurgenetech, Southampton, UK) together with the purified plasmid. This was briefly 
mixed before being subjected to an electrical pulse of 310V and 1500 capacitance from 
an electroporator (Easyjet, Flowgene, Surrey, UK). Following this pulse, the cell and
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plasmid suspension was quickly transferred into 5ml of pre warmed medium and placed 
in an incubator to allow any surviving cells to recover from the electroporation process.
2.5.8 Selection and maintenance of transfected cell lines
The pEF6/V5-His-TOPO plasmid used to transform the cells, encodes two 
antibiotic resistance genes. As previously described, the ampicillin resistance gene 
allows initial selection of prokaryotic bacterial cells containing the plasmid. The 
plasmid also contains a blasticidin S resistance gene. Blasticidin S is a potent microbial 
antibiotic that inhibits protein synthesis in both prokaryotes and eukaryotes and is used 
to specifically select for mammalian cells containing the pEF6  plasmid. The use of two 
antibiotic resistance genes allows more accurate selection of the plasmid throughout the 
cloning process. Following electroporation the cells were incubated overnight. The cells 
were then subjected to an intense 5 day period of blasticidin S selection. During this 
period the cells were cultured in medium supplemented with 5ug/ml of the blasticidin S 
antibiotic to kill any cells that did not harbour the pEF6  plasmid. After this initial 5 day 
period the cells were placed in to medium containing 0.5pg/ml of blasticidin S to place 
the cells under a selection pressure to maintain long term transformation of the cells. 
All cells were tested initially and following long periods of use, to estimate the efficacy 
and stability of both the transformation and the ribozyme transgene or expression 
sequence using RT-PCR and Western blot analysis.
113
2.6 In vitro cell function assays
2.6.1 In vitro cell growth assay
Cells were detached from the culture flask and cell density (per millilitre) was 
determined. Cells were then seeded into a 96 well plate (Nunc, Fisher Scientific, 
Leistershire, UK) at a seeding density of 3,000 cells in 200jil of normal medium per 
well. Four plates were set up to obtain a cell density reading following, 1, 3 and 5 day 
incubation periods at 37°C, 5% CO2 and 95% humidity. After the appropriate 
incubation period, the medium was aspirated and cells fixed in 4% formaldehyde in 
BSS for at least 10 minutes. The cells were then stained in 0.5% crystal violet solution 
in distilled water. The stain was then extracted from the cells using 10% acetic acid and 
cell density determined by measuring the absorbance at 540nm on a plate reading 
spectrophotometer (ELx800, Bio-Tek, Wolf Laboratories, York, UK) (Figure 2.4). Cell 
growth was presented as percentage increase and calculated by comparing the 
absorbance obtained for each incubation period. The following equation was used to 
perform this task:
Percentage increase = (day 1, 3 or 5 absorbance -  (day 1 absorbance/ day 1 
absorbance)) xlOO
Within each experiment at least twelve duplicate wells were set up and the entire 
protocol was repeated independently a minimum of three times (Smith et al., 2003).
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Figure 2.6 Sensitivity of crystal violet assay
Graph shows level of absorbance of crystal violet for a set number of cells.
2.6.2 In vitro cell Matrigel adhesion assay
Cells were detached from the culture flask and cell density (per millilitre) was 
determined. Five micrograms of Matrigel in lOOpl of serum free medium was added to 
wells of a 96 well plate and dried in an oven to form an artificial basement membrane. 
The membrane was then rehydrated in lOOpl of serum free medium for 40 minutes 
before cell seeding. Forty five thousand cells were seeded onto the Matrigel basement 
membrane in 200pl of normal medium and incubated for 40 minutes at 37°C, 5% CO2 
and 95% humidity. After incubation, the medium was aspirated and the membrane 
washed four times with 150pl of BSS solution to remove loosely attached cells. 
Adherent cells were then fixed in 4% formaldehyde in BSS for 10 minutes before being 
stained in 0.5% crystal violet solution in distilled water. Adherent cells were then
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visualised under the microscope under x40 objective magnification and random fields 
counted. At least 3 random fields per well were counted and a minimum of 3 duplicate 
wells were set up per sample. The entire experimental procedure was repeated 
independently a minimum of three times.
2.6.3 In vitro cell matrigel tubule formation assay
This assay was used to measure the ability of endothelial cells to form tubule 
structures in an artificial Matrigel basement membrane. These tubules are indicative of 
the cell’s ability to form new blood vessels. Cells were detached from the culture flask 
and cell density (per millilitre) was determined. Wells in a 96 well cell culture plate 
were coated in 250pg Matrigel in lOOpl serum free medium and allowed to set. Once 
the matrigel had set, 32,000 cells in 200pl normal medium were seeded into the wells 
and incubated for 6  hours at 37°C, 5% CO2 and 95% humidity. Following incubation, 
wells were visualised under x40 objective magnification and random fields counted. At 
least 5 random fields were counted per well and the whole experimental procedure was 
repeated 3 independent times. The total internal perimeter of all tubules per field was 
measured using Image J software. The arbitrary values obtained were converted into 
pm by multiplying the value by 2  as previously calibrated using a haemocytometer.
2.6.4 In vitro cell Matrigel invasion assay
The invasive capacity of the cells used in this study was determined using an in 
vitro Matrigel invasion assay. This assay measures the cells ability to degrade and
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invade through an artificial basement membrane and migrate through 8  pm pores. Cells 
were detached from the culture flask and cell density (per millilitre) was determined. 
Twenty four well cell culture plate inserts (BD Biosciences. Oxford, UK) containing 
8 pm pores were coated in 50pg of Matrigel (BD Biosciences, Oxford, UK) in lOOul 
serum-free medium and dried in an oven. Once dried, these inserts were placed into 
sterile 24 well plates and the artificial membrane was rehydrated with lOOpl of serum 
free media. The serum-free medium was then removed and 1ml of normal medium was 
added to the wells containing the insert in order to sustain any cells that may have 
invaded through the insert. 40,000 cells in 200pl of normal medium were then added to 
the insert over the top of the artificial basement membrane. The plate was then 
incubated for 72 hours at 37°C, 5% CO2 and 95% humidity.
After 72 hours, the inserts were removed from the plate and the inside of the 
insert (which was initially seeded with cells) was cleaned thoroughly with tissue paper. 
Any cells which had invaded through the membrane and passed to the underside of the 
insert were fixed in 4% formaldehyde in BSS for 10 minutes before being stained with 
0.5% crystal violet solution in distilled water. These cells could then be visualised 
under the microscope at x40 objective magnification and random fields counted. At 
least 3 random fields per insert were counted and duplicate inserts were set up for each 
test sample. The experimental procedure was repeated a minimum of three times 
(Engelhard et al., 1998).
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2.6.5 In vitro cell motility assay
This assays allowed the measurement of the motile capacity of the cells. Cells 
were detached from the culture flask and cell density (per millilitre) was determined.
500,000 cells for each cell type were incubated in 10ml of growth medium containing 
100pi of cytodex-2 beads (GE Healthcare, Cardiff, UK) for 3.5 hours to allow the cells 
to adhere to the beads. The beads were then washed twice in 5ml of normal medium to 
remove non-adherent or dead cells. After the second wash the beads were resuspended 
in 5 ml of growth medium. Three hundred microlitres of this solution was then added to 
a 96 well plate and incubated overnight at 37°C, 5% CO2 and 95% humidity. Following 
incubation, any cells that had migrated from the cytodex- 2  beads and adhered to the 
base of the well were fixed in 4% formaldehyde for 10 minutes, stained with 0.5% 
crystal violet. The cytodex-2 beads were removed through several extensive washes 
with BSS. Cells were then counted under x20 objective magnification, Three random 
fields were counted per well and 10 duplicate wells were set up per sample. The entire 
experimental procedure was repeated three independent times (Rosen et al., 1990).
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Chapter 3
Altering the expression of matriptase-2 in 
prostate cancer, prostate epithelial and 
endothelial cell lines
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3.1 Introduction
Recently the type II transmembrane serine proteases (TTSP) have attracted 
significant interest due to their various roles in cancer progression and development. 
Various studies involving the TTSPs have found them to be aberrantly expressed during 
cancer development and progression (Wallrapp et al., 2000; Magee et a l , 2001; Oberst 
et a l, 2001; Huang and Waknitz, 2009). These TTSPs are becoming one of the most 
intensively studied super families in the cancer field.
Matriptase-2 is a poorly studied protease in the field of cancer progression 
compared to other members of the TTSP super family. Matriptase-2 consists of a short 
cytoplasmic extension with unknown function, a transmembrane domain, a SEA 
domain, two CUB domains, three LDLA domains and a C-terminal active serine 
protease (Szabo and Bugge, 2008). It was originally presumed that matriptase-2 would 
drive cancer progression due to its high homology with matriptase-1. Due to previous 
work within the department it is now known that matriptase- 2  acts in to opposite 
manner to matriptase-1 .
Matriptase-2 over-expression significantly reduces breast and prostate cancer 
growth and reduced levels correlate with poor patient outcome (Parr et a l, 2007; 
Sanders et a l, 2008). The molecular mechanisms involved in the activation of 
matriptase-2 remain largely unknown. Also, little is known about the substrates of 
matriptase-2 , although it has been shown to degrade fibronectin, fibrinogen and type 1
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collagen and to have limited action against pro-uPA and to cleave mHJV (Velasco et 
al., 2002; Silvestri et a l, 2008).
No previous studies have investigated a possible role for matriptase-2 in prostate 
epithelial cells. Therefore, based on the established implications of previous studies 
within the laboratory investigating matriptase-2 , this study aims to establish a role for 
matriptase-2 , by altering its expression levels in two prostate epithelial cell lines. 
Therefore, by altering the endogenous expression levels of matriptase-2 in prostate 
epithelial cell lines, it was hypothesised that a loss of matriptase- 2  in these epithelial 
cell lines would result in a push towards a more aggressive phenotype more commonly 
seen in prostate cancer cell lines such as PC3 and DU145. The HECV endothelial cell 
line would also be used in another pioneering study to investigate the potential 
involvement of matriptase- 2  in angiogenesis.
In this study, matriptase-2 expression plasmid and ribozyme transgene were 
used to over-express and silence matriptase- 2  expression in several cell lines, 
respectively. Matriptase-2 expression was knocked-down in PZHPV7 and PNT2C2 
cells and over-expressed in PC3, DU 145, and HECV cell lines. Following transfection 
with the plasmids, matriptase-2 expression was verified using both mRNA and protein 
based methods. The remaining chapters in this study then aim to investigate the effect 
of altering matriptase- 2  expression on the biological properties of prostate cells in order 
to elucidate the function of matriptase-2 in this cancer. The transfection of HECV cells 
will also allow the investigation of the effect of matriptase- 2  in angiogenesis.
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3.2 Materials and methods
1.6.2 3.2.1 Cell lines
PZHPV7, PNT2C2, PC3, DU145, and HECV cell lines were used, cultured and 
maintained as described in sections 2.2.3.
3.2.2 Creation of over-expression and knock-down cell lines
Matriptase-2 expression plasmids were re-amplified, cloned and transfected into 
the PC3, DU145 and HECV cell lines. Ribozyme transgenes targeting matriptase-2 
mRNA were generated, cloned and transfected into PZHPV7 and PNT2C2 cell lines. 
Full details of the procedure used to generate the expression plasmid and ribozyme, 
insert it into the pEF6  plasmid, amplify the plasmid in E. coli, extract and electroporate 
the plasmid into mammalian cells are given in section 2.5. Full expression and 
ribozyme sequence data are shown in tables 2.2 and 2.3 in the general methods section 
(chapter 2 ).
3.2.3 RNA isolation, cDNA synthesis, and RT-PCR
RNA was isolated from the cells using the ABgene Total RNA Isolation 
Reagent (TRIR) kit (ABgene, Surrey, UK), and converted into cDNA by reverse 
transcription using the iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, 
California, USA), as described in section 2.4. This was then used as a template for RT- 
PCR, which was carried out at the following conditions; 94°C for 5 minutes, followed
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by 30 to 42 cycles of 94°C for 30 seconds, 56°C for 30 seconds, and 72°C for 1 minute, 
and a final extension of 7 minutes at 72°C. The products were run on an agarose gel and 
visualised using ethidium bromide.
3.2.8 Protein extraction, SDS-PAGE, and Western blot analysis
Protein was extracted following cell lysis, and was then quantified using the DC Protein 
Assay kit (BIO-RAD, USA). Following SDS-PAGE, the proteins were transferred onto 
nitrocellulose membranes which were blocked, and probed with the specific primary 
(anti-matriptase-2 ) and the corresponding peroxidise-conjugated secondary antibodies 
(1:1000). All of the antibodies used in this study are listed in Table 2.5. The protein 
bands were eventually visualised using the SupersignalTM West Dura system (Pierce 
Biotechnology, USA).
3.2.9 Immunocytochemistry (ICC)
Twenty thousand cells in 200pl DMEM media were seeded into chamber slides (Nalge, 
NUNC International, LAB-TEK®, USA) and left to incubate overnight at 37°C, with 
5% CO2 . After incubation the media was aspirated and the cells fixed with 200jil 
formalin for 20 minutes at 4°C. Following fixation, the cells were rehydrated with 
2 0 0 pi BSS for a minimum of 30 minutes at room temperature. Cells were permeabilsed 
and incubated with P-catenin primary antibody for 1 hour. After 4 washes with wash 
buffer, the cells were incubated with 200pl of working VECTASTAIN® Universal 
ABC complex (Vector Laboratories Inc., Burlingame, USA). The ABC solution was
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subsequently removed by washing four times with wash buffer before a few drops of 
DAB chromogen (Vector Laboratories Inc., Burlingame, USA) were added to the cells 
and left to incubate for 5 minutes in darkness. The DAB solution was washed off using 
distilled water before the cells were counterstained with Mayer’s haemotoxylin for 
approximately 1 minute. The slides were then viewed under a light microscope.
3.3 Results
3.3.1 Cell line screen for mariptase-2 expression
In order to determine which cell lines should be transfected with either the expression 
or ribozyme plasmid the expression levels of matriptase-2 in PC3, DU145, CAHPV10, 
PNT1 A, PZHPV7, PNT2C2 and HECV cell lines were examined using PCR. Figure 3.1 
shows that PC3, CAHPV10, PNT1A and HECV have minimal or no expression of 
matriptase-2. DU 145 appears to display a small amount of matriptase-2 mRNA. In 
contrast PZHPV7 and PNT2C2 display a high expression of matriptase-2 mRNA.
3.3.2 Generation of a pEF6 plasmid containing the matriptase-2 ribozyme
transgene
Figure 3.2 outlines the process in the generation of a pEF6 plasmid containing the 
matriptase-2 ribozyme transgene. The ribozyme was examined using touchdown PCR 
before being cloned into E.coli (figure 3.2 A). The plasmids were then checked to 
ensure that the ribozyme was in the correct orientation. Correct orientation of the 
ribozyme was indicated by a 140bp band in the T7F vs RbBMR lane and incorrect
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orientation was indicated by a band in the T7F vs RbToP lane (figure 3.2 B). From this 
orientation check, colony 2 was chosen as it contained minimal to no incorrect 
orientation. Following an overnight incubation of the E.coli, the plasmid from the 
chosen colony was extracted and purified. Figure 3.2 C shows the purified plasmid 
containing the transgene ready for transfection into the PZHPV7 and PNT2C2 cell 
lines.
3.3.3 Confirmation of knock-down of matriptase-2 mRNA in PZHPV7 and
PNT2C2
Once the PZHPV7 and PNT2C2 cells were transfected with the ribozyme plasmid, 
mRNA was isolated and quantitative PCR (q-PCR) was performed. Figure 3.3 A. q- 
PCR demonstrates that matriptase-2 mRNA has been successfully knocked-down in 
PZHPV7111312 nbl cells compared to its pEF6 control. Figure 3.3 B. q-PCR also confirms 
knock-down of matriptase-2 mRNA in PNT2C2 111312 nbl cells compared to the pEF6 
control.
3.3.4 Confirmation of knock-down of matriptase-2 protein in PZHPV7 cells
To ensure that the targeting of matriptase-2 mRNA has also resulted in a reduction in 
matriptase-2 protein, Western blots were performed to examine protein expression in 
the PZHPV7 transfected cells. Figure 3.4 A. Western blot showing knock-down of 
matriptase-2 protein in PZHPV7 111312 nbl cells when compared to control cells PZHPV7 
pEF6. Figure 3.4 B. Western blot performed 1 month after the blot in A showing that the
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matriptase-2 knockdown is stable over a long period of time. Figure 3.4 C. Western 
band quantification normalising matriptase-2 expression to the expression of the 
housekeeping gene GAPDH. Figure 3.4 D. ICC displaying increased brown staining in 
PZHPV7 111812 nbl cells when incubated with anti-matriptase-2 antibody. Staining also 
appears to be located at the cell membrane.
3.3.5 Confirmation of knock-down of matriptase-2 protein in PNT2C2 cells
To ensure that the malformation of matriptase-2 mRNA has also resulted in a reduction 
in matriptase-2 protein, Western blots were performed to examine protein expression in 
the PNT2C2 transfected cells. Figure 3.5 A. Western blot showing knock-down of 
matriptase-2 protein in PNT2C2 mat2 nbl cells when compared to control cells PNT2C2 
pEF6. Figure 3.5 B. Western blot performed 1 month after the blot in A showing that the 
matriptase-2 knockdown is stable over a long period of time. Figure 3.5 C. Western 
band quantification normalising matriptase-2 expression to the expression of the 
housekeeping gene GAPDH. Figure 3.5 D. ICC displaying increased brown staining in 
PNT2C2 Tma nbl cells when incubated with anti-matriptase-2 antibody. Staining also 
seems to be predominantly located at the cell membrane of the cells.
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Figure 3.1 Cell line screen for matriptase-2. Seven cell lines were screened for 
the mRNA expression of matriptase-2 using conventional PCR techniques.
Figure 3.2: Ribozyme transgene synthesis. A. The ribozymes were generated using 
touchdown PCR and run on an agarose gel (Expected band size 50bp). B. After 
transformation into E.coli cells, the colonies were analysed using PCR in order to verify 
correct orientation of the transgene (Expected band size 140bp). C. PCR confirming 
presence and correct size of plasmid after extraction from E.coli (Approx 5890bp).
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Figure 3.3. Confirmation of matriptase-2 knock-down at the mRNA level.
Quantitative PCR was carried out to determine the levels of matriptase-2 mRNA 
in the control and altered cell lines. A. Confirmation of mRNA knockdown of 
matriptase-2 mRNA in the PZHPV7 mat2 nbl. B. Successful knock-down of 
matriptase-2 in PNT2C2 mat2 nbl cell line compared to their pEF6 controls.
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Figure 3.4 Confirmation of knock-down of matriptase-2 protein levels in PZHPV7 
cells. A. Western blot showing reduced levels of matriptase-2 protein in the PZHPV7 mat2 
nbl cell line compared to the control PZHPV7 pEF6. B. Second Western blot 1 month after 
blot in A to demonstrate stable knockdown. C. GAPDH levels were not equal so band 
quantification was performed and matriptase-2 levels normalized to GAPDH and 
represented as a bar chart. D. ICC staining for matriptase-2 shows that matriptase-2 
staining appears to be predominantly seen at the cell membrane. It also appears reduced in 
the PZHPV7 mat2ribl cells. (,—  = 50pm).
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Figure 3.5 Confirmation of knock-down of matriptase-2 protein levels in PNT2C2 
cells. A. Western blot showing reduced levels of matriptase-2 protein in the PNT2C2 mat2 nbl 
cell line compared to the control PNT2C2 pEF6. B. Second Western blot 1 month after blot in 
A to show stable knockdown. C. GAPDH levels were not equal so band quantification was 
performed and matriptase-2 levels normalized to GAPDH and represented as a bar chart. D. 
ICC staining for matriptase-2 shows that matriptase-2 staining appears to be predominantly 
seen at the cell membrane. It also appears reduced in the PNT2C2 mat2 nbl cells. ( —  = 
50pm).
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3.3.6 Generation of a pEF6 plasmid containing the matriptase-2 expression 
sequence
The matriptase-2 expression plasmid was kindly donated by Dr. C Parr. The expression 
plasmid was re-cloned into E.coli to amplify the amount of plasmid. Figure 3.6 shows 
the orientation checking of the colonies chosen for examination. Correct orientation of 
the expression sequence was indicated by a band in the T7F vs BGHR lane and a 500bp 
band in the T7F vs Matript2Rl lane (figure 3.6 A). From this orientation check colony 
4 was chosen as it contained the the strongest expression of the correct bands. 
Following an overnight incubation of the E.coli in liquid broth, the plasmid from the 
chosen colony was extracted and purified. Figure 3.2 B shows the purified plasmid 
containing the expression sequence ready for transfection into the PC3, DU 145 and 
HECV cell lines.
3.3.7 Confirmation of over-expression of matriptase-2 mRNA
Once the PC3, DU 145 and HECV cells were transfected with the expression plasmid, 
mRNA was isolated and quantitative PCR (q-PCR) was performed. Figure 3.7 A. q- 
PCR demonstrates that matriptase-2 mRNA has been successfully over-expressed in 
PC3 10812 exp cells compared to its pEF6 control. Figure 3.7 B. q-PCR also confirms over­
expression of matriptase-2 mRNA in DU145 10812 exp cells compared to the pEF6 control. 
DU 145 also appears to have a higher basal level of matriptase-2 mRNA compared to 
PC3. This correlates with the small amount of signal seen in figure 3.1. Figure 3.7 C. 
Confirmation of mRNA over-expression in HECV10812 exp cells using q-PCR.
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3.3.8 Confirmation of over-expression of matriptase-2 protein in PC3 cells
Western blots were performed to examine protein expression in the transfected cells. 
Figure 3.8 A. Western blot showing over-expression of matriptase-2 protein in PC3 111312 
exp cells. Figure 3.8 B. Western blot performed 1 month after the blot in A showing that 
the matriptase-2 over-expression is stable over a long period of time. Figure 3.8 C. 
Western band quantification normalising matriptase-2 protein levels to the expression 
of the housekeeping gene GAPDH. Figure 3.8 D. ICC showing the increase in brown 
staining which is mainly seen at the cell membrane of the cells.
3.3.9 Confirmation of over-expression of matriptase-2 protein in DU145 
cells
Western blots were performed to examine protein expression in the transfected cells. 
Figure 3.9 A. Western blot showing over-expression of matriptase-2 protein in DU 145 - 
exp cejjs when compared to control cells DU145 pEF6. Figure 3.9 B. Western blot 
performed 1 month after the blot in A showing that the matriptase-2 knockdown in 
stable over a long period of time. Figure 3.9 C. Western band quantification 
normalising matriptase-2 expression to the expression of the housekeeping gene 
GAPDH. Figure 3.9 D. ICC displaying increased levels of brown staining in DU145 - 
man exp ce|js compared to control cells DU 145 pEF6 when incubated with anti-matriptase- 
2 antibody. Staining also appears to be mainly located at the cell membrane.
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3.3.10 Confirmation of over-expression of matriptase-2 protein in HECV
cells
Western blots were performed to examine protein expression in the transfected cells. 
Figure 3.10 A. Western blot showing over-expression of matriptase-2 protein in HECV 
111812 exp cells. Figure 3.10 B. Western band quantification normalising matriptase-2 
expression to the expression of the housekeeping gene GAPDH. Figure 3.10 C. ICC 
demonstrating enhanced level of matriptase-2 in cell containing the matriptase-2 over­
expression plasmid compared to control cells HECV pEF6. Staining also confirms 
location of matriptase-2 protein at the cell membrane.
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8300bp
2700bp
Figure 3.6: Expression plasmid cloning. A. After transformation into E.coli cells, 
the colonies were analysed using PCR in order to verily correct orientation of the 
transgene. B. PCR confirming presence and correct size of plasmid and expression 
sequence after extraction from E.coli.
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Figure 3.7 Confirmation of matriptase-2 over-expression at the mRNA 
level. Quantitative PCR was carried out to determine the levels of matriptase- 
2 mRNA in the control and altered cell lines. These graphs show the over- 
expression of matriptase-2 mRNA in the HECV 11X312 exp, PC3 1X1312 exp and 
DU145 1X1312 exp cell lines compared to their pEF6 controls. DU145 also shows 
a hieher basal level of matriotase-2 comoared to the other cell lines.
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Figure 3.8 Confirmation of over-expression of matriptase-2 protein levels in 
PC-3 cells.
A. Western blot showing higher levels of matriptase-2 protein in the PC3 mat2 exp cell line 
compared to the control PC3 pEF6. B. Western blot performed 1 month after the blot in A C. 
GAPDH levels were not equal so band quantification was performed and matriptase-2 levels 
normalized to GAPDH and represented as a bar chart. D. ICC staining for matriptase-2 also 
shows over-expression and reveals the majority of the staining is seen at the cell membrane. . (
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Figure 3.9 Confirmation of over-expression of matriptase-2 protein levels in 
DU145 cells.
A. Western blot showing higher levels of matriptase-2 protein in the DU 145 maa exp cell 
line compared to the control DU145 pEF6. B. Western blot performed l month after the 
blot in C. Bar chart representing the Western blot with matriptase-2 expression 
normalized to the control GAPDH. C. ICC staining for matriptase-2 also shows over­
expression and shows the majority if the staining is seen at the cell membrane. . ( i—  = 
50pm).
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Figure 3.10 Confirmation of over-expression of matriptase-2 protein levels 
in HECV cells.
A. Western blot showing enhanced levels of matriptase-2 protein in the HECV mat2 exp cell line 
compared to the control HECVpEF6. B. Western blot performed 1 month after the blot in A. C. 
GAPDH levels were not equal so band quantification was performed and matriptase-2 levels 
normalized to GAPDH and represented as a bar chart. C. ICC staining for matriptase-2 also 
shows over-expression and confirms the location of matriptase-2 at the cell membrane. . ( —  
= 50pm).
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3.4 Discussion
Matriptase-2 is a poorly studied protease in the field of cancer progression. 
What is known demonstrates that matriptase-2 behaves in an opposite manner to that of 
its closest homologue: matriptase-1. Matriptase-1 has been shown to drive cancer 
progression (Uhland, 2006; Tsai et a l, 2008), whereas, matriptase-2 appears to exert a 
protective function on breast and prostate cancer cells and is correlated with poor 
patient outcome (Parr et a l , 2007; Sanders et a l , 2008). Its expression in tissues shows 
that matriptase-2 is more highly expressed in non-cancerous epithelial tissues compared 
to cancerous tissue samples (Parr et a l, 2007). No other studies have attempted to 
define the function of matriptase-2 in prostate epithelial cell and its potential 
involvement in angiogenesis.
In the current study, we firstly demonstrated the presence of matriptase-2 
expression in six prostatic cell lines and one human endothelial cell line. The cell lines 
used here have extensively been used as models for in vitro studies on prostate cancer. 
PC3, DU145, are aggressive prostatic carcinomas derived from metastatic sites of the 
bone, and brain, respectively. CAHPV-10 meanwhile represents a less aggressive 
prostatic adenocarcinoma cell line immortalised with HPV-18. PZHPV7, PNT1A, and 
PNT2C2 meanwhile, are immortalised prostatic epithelial cell lines.
According to the mRNA levels of matriptase-2, its expression appears to be 
higher in the cell lines of non-cancerous origin, the prostatic epithelial cell lines 
PZHPV7 and PNT2C2. The only exception was PNT1A which appeared to have no 
matriptase-2 expression. The cancerous cell lines PC3, and CAHPV10 displayed little 
or no matriptase-2 expression. DU 145 cells appear to show a slight mRNA signal in the
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PCR screen and the Q-PCR confirmation of over-expression. When the protein levels 
were examined there appeared to be a minimal signal in the Western blot. This could 
mean that only a small amount of protein is produced from the mRNA in the DU 145 
cells. These results correlate with the literature in that the highest expression of 
matriptase-2 is seen in non-cancerous cells lines. The HECV human endothelial cell 
line displayed no detectable expression of matriptase-2 protein.
This screening process also aided in the determination of which cell lines to use 
for the remainder of the study. As previously mentioned, matriptase-2 is a cell surface 
serine protease with a possible role in intracellular signal transduction, as well as being 
in place to cleave other cell surface proteins. Therefore, in order to investigate the effect 
of on the biological functions of prostate cells, we altered matriptase-2 expression in 
PZHPV7, PNT2C2, PC3, DU145, and HECV cells. Due to previous studies within the 
laboratory, a ribozyme transgene targeting matriptase-2 mRNA and a mammalian 
expression vector containing the matriptase-2 coding sequence were already 
constructed. These constructs were re-cloned into E.coli, orientation checked and then 
extracted and purified before transfection into the selected cell lines.
As PZHPV7 and PNT2C2 expressed a high level of matriptase-2, these cell 
lines were selected as the cell lines to transfect with the ribozyme transgene in order to 
determine the consequences of knocking-down matriptase-2 on cellular functions. PC3 
and DU 145 were transfected with the matriptase-2 expression plasmid. As the HECV 
human endothelial cell line displayed minimal expression, it was also transfected with 
the expression plasmid to determine the effect, if any, of matriptase-2 on angiogenesis.
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The staining location of matriptase-2 was seen in all pictures to be located 
mainly at the cell membrane. As matriptase-2 is believed to be a cell membrane bound 
protease, the location of the staining appears to confirm this belief. Some of the images 
appeared to have a reduced confluency level. There appears to be no definitive reason 
for this apart from the well that the pictures result from may have received a fewer 
number of cells due to human error during seeding of the experiment.
In the PC3 and HECV Western blots above there seems to be the possibility that 
the transfection of the cells with the pEF6 plasmid appears to induce the expression of 
matriptase-2. This may be an artefact of the Western blots as the blots performed 1 
month after the initial Western do not seem to display this increase in the pEF6 
transfected cells.
The functional assays that have been used in this study were previously 
conducted on the PC3 and DU145 cells in Sanders et al 2008. Although the PC3 and 
DU 145 cells were re-transfected in this current study the functional assays were not 
repeated with the fresh cells. The assumption that the more recent transfections would 
behave in the same manner as the previous transfection was made. It was on this 
assumption that the functional assays were not repeated.
The ribozyme transgene proved effective at knocking-down the expression of 
matriptase-2 at both the mRNA and protein level. The expression plasmid was also 
successful at producing an over-expression of matriptase-2 at both the mRNA and
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protein level. These tools of genetic manipulation aid in the generation of useful in vitro 
models allowing for the investigation of the impact a single molecule has in a cell line. 
Subsequent functional assays carried out in the rest of this study, are based on both the 
matriptase-2 knock-out and over-expressing cells.
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Chapter 4
The role of Matriptase-2 in prostate 
epithelial cells
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4.1 Introduction
Cancer cells arise from normal cells via mutation. These mutations will allow 
the previously non-cancerous cells to gain characteristics that will allow the progression 
to an aggressive cancerous phenotype. A cancer cell relies on varying vital biological 
processes with which to establish itself in its environment, and to subsequently 
metastasise. The most important of these include changes in cell growth, adhesive and 
invasive capacity, motility, and migration. Cancer cells can influence these processes in 
several ways, most significantly by altering the expression of molecules that play key 
roles in controlling these cellular traits. Matriptase-2 has previously shown the ability to 
reduce the migration of PC3 and DU145 cells and the adhesion of PC3 cells. This 
chapter attempts to determine if a knockdown of matriptase-2 would drive a normal 
prostate cell lines toward a more cancerous phenotype.
In order to examine the possibility that matriptase-2 could prevent the 
progression to a cancerous phenotype in the normal prostatic epithelial cell lines 
PZHPV7 and PNT2C2. They possess a well differentiated morphology with the 
expression of cytokeratin 8, 18, and 19 with the latter being a feature of differentiated 
luminal cells of the glandular prostate and are non-tumourigenic in nude mice.
Chapter 3 describes how the expression of matriptase-2 in prostate cancer cells 
was altered by using a ribozyme transgene to knock-down matriptase-2 expression in 
the normal epithelial cell lines PZHPV7 and PNT2C2. This following chapter now
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goes on to investigate the effect, if any, that these changes in matriptase-2 expression 
have on these cells. The stable transfected cells were used in various in vitro cell 
function assays including; growth, adhesion, invasion, and motility. These assays are a 
well established and simple method of investigating the biological properties of cells in 
vitro. As an over-expression of matriptase-2 in PC3 and DU145 cancer cell lines was 
seen to reduce their aggressiveness it is hypothesised that a knock-down should 
therefore increase the aggressiveness of the PZHPV7 and PNT2C2 cells lines. This 
would confirm the fact that matriptase-2 likely prevents the progression of prostate 
cancer.
4.2 Methods
4.2.1 Cell lines
PZHPV7 and PNT2C2 prostate epithelial cell lines were used in this current chapter, 
including the wild-type control, empty plasmid control and transfected cell lines. Cells 
were continuously maintained in DMEM media with 10% FBS and antibiotics. The 
stable transfected cells were maintained in the same media but with 0.5pg/ml blasticidin 
following an initial ‘selection’ period with 5 jug/ml blasticidin.
4.2.2 In vitro cell growth assay
The cells were seeded into three 96 well plates, and incubated for 1, 3, and 5 days 
respectively, as described in section 2.7.1. Following incubation, the cells were fixed 
and stained with crystal violet before the absorbance was measured in order to
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determine cell number. Day 1 was used as an over night reference plate to which day 3 
and 5 were compared to in order to determine % increase in growth.
4.2.3 In vitro cell Matrigel adhesion assay
The cells were seeded into a 96 well plate coated with matrigel as described in section 
2.7.2. The cells were left to adhere for a period of 40 minutes, before being fixed and 
stained with crystal violet, and the cells counted.
4.2.4 In vitro cell motility assay
The protocol followed is described by Rosen and Jiang (Rosen et al., 1990; Jiang et al., 
1995b). The cells were incubated with cytodex-2 beads and left over night, by which 
time the cells will have adhered to the surface of the beads. The beads carrying the cells 
were then transferred into a 96 well plate, where the cells move from the beads onto the 
surface of the culture plate. These cells were then fixed and stained with crystal violet, 
and counted.
4.2.5 In vitro cell Matrigel invasion assay
The cells were seeded into transwell inserts with 8pm pores coated with 50 pg matrigel, 
in a 24 well plate and were incubated for a period of 3 days. Following incubation, the 
cells which had migrated through the matrigel to the other side of the insert were fixed 
in formalin, stained with crystal violet and counted.
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4.4 Results
4.4.1 Effect of matriptase-2 knock-down on PZHPV7 prostate epithelial cell 
growth
The cell lines displaying knock-down of matriptase-2 were used in an in vitro cell 
growth assay along with the wild type and empty plasmid controls. There was no 
significant difference in the growth of the PZHPV7 111812 nbl cells (Figure 4.1). The cell 
growth at 5 days was not significantly different in the PZHPV7 111812 nbl (478.20±72.27) 
compared to the control PZHPV7 pEF6 (495.88± 132.99) p=0.716.
4.4.2 Effect of matriptase-2 knock-down on PNT2C2 prostate epithelial cell 
growth
The PNT2C2 cells displaying knock-down of matriptase-2 were used in an in vitro cell 
growth assay along with the wild type and empty plasmid controls. Similarly there was 
also no significant difference in cell growth seen in the PNT2C2 cell line. There is no 
significant difference in the growth of the PNT2C2 111812 nbl cells. The cell growth at 5 
days was not significantly different in the PNT2C2 111812 nbl (367.65±71.54) compared to 
PNT2C2 pEF6 (347.14±115.04) p=0.711.
4.4.3 Effect of matriptase-2 knock-down on in vitro PZHPV7 cell adhesion
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The PZHPV7 cells were further analysed for their adhesive capacity in an in vitro 
matrigel adhesion assay. The cells with a knock-down of matriptase-2 displayed no 
difference in adhesion compared to its controls. Figure 4.3 A. Representative images of 
adhered PZHPV7 cells. Figure 4.3 B. There was no significant difference in cell 
adhesion with PZHPV7 matl nbl cells (29.36±4.90) compared to the control PZHPV7 pEF6 
(31.20±7.03) p=0.465.
4.4.4 Effect of matriptase-2 knock-down on in vitro PNT2C2 cell adhesion
As with the growth assay the PNT2C2 cells also showed no difference in cell adhesion 
with a knock-down of matriptase-2. Figure 4.4 A. Representative images of adhered 
PNT2C2 cells. Figure 4.4 B. There was no significant difference in cell adhesion with 
PNT2C2 ra“2 ribl cells (101.53±24.64) compared to the control PNT2C2 pEF6 
(100.33±27.25) p=0.900.
4.4.5 Effect of knock-down of matriptase-2 on PZHPV7 cell motility
The cells were further analysed for their motility using a cytodex-2 bead assay. The 
cells with knock-down of matriptase-2 displayed a significant difference in motility 
compared to control cells. Figure 4.5 A. Representative images of motile PZHPV7 
cells. Figure 4.5 B. There was a significant increase in cell motility with PZHPV7 111312 
ribl cells (188.33±12.02) compared to the control PZHPV7 pEF6 (61.20±9.05) p=<0.001.
4.4.6 Effect of knock-down of matriptase-2 on PNT2C2 cell motility
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The PNT2C2 cells were further also analysed for their motility using a cytodex-2 bead 
assay. Figure 4.6 A. Representative images of motile PNT2C2 cells. Figure 4.6 B. 
PNT2C2 cells also showed a significant increase in cell motility with a knock-down of 
matriptase-2. There was a significant increase in cell motility with PNT2C2111312 nbl cells 
(103.40±8.83) compared to the control PNT2C2 pEF6 (59.93±9.67) p=<0.001.
4.4.7 Effect of knock-down of matriptase-2 on in vitro PZHPV7 cell invasion
The cells were further analysed for their invasive capability. The cells with a knock­
down of matriptase-2 displayed a significant difference in invasion compared to its 
controls. Figure 4.7 A. Representative images of invaded PZHPV7 cells. Figure 4.7 B. 
There was a significant increase in invasion with PZHPV7 111312 nbI cells (21.50±0.70) 
compared to the control PZHPV7 pEF6 (7.00±0.00) p=0.001.
4.4.8 Effect of knock-down of matriptase-2 on in vitro PNt2C2 cell invasion
The matrigel invasion assay was used to assess the invasive capacity of the PNT2C2 
cells. PNT2C2 cells also showed a significant increase in invasion with a knock-down 
of matriptase-2. . Figure 4.8 A. Representative images of invaded PNT2C2 cells. 
Figure 4.8 B. There was a significant increase in invasiveness with PNT2C2 111312 nbl 
cells (55.00±10.71) compared to the control PNT2C2 pEF6 (33.25±6.18) p=0.007.
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Figure 4.1 Knock-down of matriptase-2 has no effect on the growth of PZHPV7 
prostate epithelial cells. After 5 days incubation there was no significant effect on the 
growth of PZHPV7 ™“2 ribl compared to the control PZHPV7 pEF6 (p= 0.716). Data 
shown is representative of at least 3 independent repeats. Error bars represent standard 
deviation. The 1 day time point was used as a baseline to normalise the data.
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Figure 4.2 Knock-down of matriptase-2 has no effect on the growth of PNT2C2 
prostate epithelial cells. After 5 days incubation there was no significant effect on the 
growth of PNT2C2 ribl compared to the control PNT2C2 pEF6 (p= 0.711). Data 
shown is representative of at least 3 independent repeats. Error bars represent standard 
deviation. The 1 day time point was used as a baseline to normalise the data.
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PZHPV7 wt PZHPV7 pEF6 PZHPV7 mat2ribl
PZHPV7 wt PZHPV7 pef PZHPV7 ribl
Mean 36 31.20 29.36
SD 3.35 7.03 4.90
Figure 4.3 Knock-down of matriptase-2 has no effect on the adhesion of PZHPV7 
prostate epithelial cells. A. Representative images of cells following staining. B. 
After 40 minutes incubation of the cells on an artificial matrigel basement 
membrane no significant difference in adhesion was seen between the PZHPV7 03312 
nbl cells compared to the control PZHPV7 pEF6 (p= 0.465). Data shown is 
representative of at least 3 independent repeats. Error bars represent standard 
deviation.
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PNT2C2 wt PNT2C2 pEF6 PNT2C2 mat2ribl
PNT2C2 wt PNT2C2 pef PNT2C2 ribl
Mean 94.87 100.33 101.53
SD 26.19 27.25 24.64
Figure 4.4 Knock-down of matriptase-2 had no effect on the adhesion of PNT2C2 
prostate epithelial cells. A. Representative images of cells after staining. B. After 40 
minutes incubation of the cells on an artificial matrigel basement membrane there 
was no significant difference in adhesion seen between the PNT2C2 111312 nbl cells 
compared to control PNT2C2 pEF6 (p= 0.988). Data shown is representative of at 
least 3 independent repeats. Error bars represent standard deviation.
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Mean 66.96 61.20 188.33
SD 17.57 9.05 12.02
Figure 4.5 Knock-down of matriptase-2 increased the motility of PZHPV7 prostate 
epithelial cells. Following an overnight incubation the cells that had migrated from 
the cytodex-2 beads to the base of the well were counted. A. Representative images 
of motile cells after staining. B. The knock-down of matriptase-2 caused a 
significant increase in the motility of the PZHPV7 111312 nbl when compared to control 
PZHPV7 pEF6 cells (**p= <0.001). Data shown is representative of at least 3 
independent repeats. Error bars represent standard deviation.
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Figure 4.6 Knock-down of matriptase-2 increases the motility of PNT2C2 prostate 
epithelial cells. Following an overnight incubation the cells that had migrated from 
the cytodex-2 beads to the base of the well were counted. A. Representative images 
of stained motile cells. B. The knock-down of matriptase-2 caused a significant 
increase in the motility of the PNT2C2 111312 nbl when compared to the control cells 
PNT2C2 pEF6 (**p= <0.001). Data shown is representative of at least 3 independent 
repeats. Error bars represent standard deviation.
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Figure 4.7 Knock-down of matriptase-2 increases the invasive ability of PZHPV7 
prostate epithelial cells. Following a 3 day incubation of the cells on an artificial 
matrigel basement membrane there was a significant increase in the invasion of the 
PZHPV7 mat2ribl cells compared to control PZHPV7 pEF6 cells (**p=0.006). Data shown 
is representative of at least 3 independent repeats. Error bars represent standard 
deviation.
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PNT2C2 pEF6
PNT2C2 wt PNT2C2 pEF6 PNT2C2 m at2 ribl
Mean 32 33.25 55.00
SD 4.24 6.18 10.71
Figure 4.8 Knock-down of matriptase-2 increases the invasive ability of PNT2C2 
prostate epithelial cells. A. Representative images of invaded cells stained with 
crystal violet. B. Following a 3 day incubation of the cells on an artificial matrigel 
basement membrane there was a significant increase in the invasion of the PNT2C2 
ma'2 nbl cells compared to control PNT2C2 pEF6 cells (**p=0.007). Data shown is 
representative of at least 3 independent repeats. Error bars represent standard 
deviation.
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4.5 Discussion
Several members of the TTSPs have been linked to cancer progression. Currently a lot 
of scientific attention is focusing on matriptase-1, which has been reported to play roles 
in cancer cell invasion and migration and display potential as a therapeutic target (Forbs 
et a l, 2005; Sanders et al., 2006). Matriptase-2 shows a 35% homology to matriptase-1 
and early studies implicated this molecule as a matrix degrading molecule potentially 
involved, as matriptase-1, in cancer progression (Velasco et a l, 2002). Due to this 
homology it was initially believed that matriptase-2 would act in the same manner as 
matripase-1 and drive cancer progression. As previously mentioned, the expression 
pattern of these two proteases are seen to be opposite in nature. This suggested that 
matriptase-2 would function quite differently from matriptase-1 and act as a possible 
tumour suppressing molecule. This hypothesis has now been shown to be true. 
Matriptase-2 has been shown to reduce the aggressive nature of breast and prostate 
cancer cells and to reduce the growth of tumours in vivo. It has also been reported to 
have a prognostic potential for breast cancer patients (Parr et al., 2007; Sanders et al.,
2008). This chapter will attempt to further elucidate the role of matriptase-2 in prostate 
cancer.
The role of matriptase-2 in cancer is a very elusive subject. There is still very 
little research into the role of matriptase-2 in cancer. This laboratory has previously 
shown that an over-expression of matriptase-2 in PC3 and DU 145 cells showed a 
reduction of the cells aggressive traits (Sanders et a l, 2008). Matriptase-2 has also been 
shown to be more highly expressed in normal breast tissue compared to cancerous
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breast tissue and to provide a possible prognostic advantage. Matriptase-2 also reduced 
the aggressiveness of breast cancer cells (Parr et al., 2007). The current study now 
shows that by altering the expression of endogenous matriptase-2 in prostate epithelial 
cells, that matriptase functions to prevent increased cell motility and invasion, 
suggesting an anti-tumourigenic role for matriptase-2 in cancer.
When matriptase-2 was knocked-down in the PZHPV7 and PNT2C2 cells lines 
they demonstrated no difference in cell growth compared to their controls. It appears 
that matriptase-2 knock-down has no effect on the cell growth of these non-cancerous 
cell lines. A similar effect was seen when examining the cellular adhesion of both cell 
lines. No significant difference was also seen in between cells with matriptase-2 knock­
down and the control cells. In a previous study within the laboratory a similar effect 
was seen. In Sanders et al 2008, an over-expression of matriptase-2 was seen to reduce 
the growth of PC3 cells but not DU145 cells. It was also shown that the over-expression 
had no effect on the cellular adhesion of either of these cells. The exact reason for the 
differential effect of matriptase-2 on the cell growth is currently unknown but is likely 
to be due to differences in the expression patterns of other proteins between PC3 and 
DU145. The study also states that the difference in growth in PC3 cells is not through 
increased rates of apoptosis (Sanders et al., 2008). It is likely that matriptase-2 plays no 
significant role in the growth or adhesion of prostate cells.
Interestingly the reduction in matriptase-2 expression resulted in a significant 
increase in the motility of both PZHPV7 and PNT2C2 cell lines. This correlates with 
the significant reduction in motility in PC3 and DU 145 cells over-expressing
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matriptase-2 in the Sanders et al 2008 study. Similarly matriptase-2 knock-down also 
resulted in a significant increase in the ability of the previously low-invasive PZHPV7 
and PNT2C2 cells to invade through an artificial basement membrane. In contrast, the 
over-expression of matriptase-2 caused the highly invasive cell lines PC3 and DU 145 to 
become less invasive. A similar effect was seen in the MDA-MB-231 breast cancer cell 
line, in which an over-expression of matriptase-2 also significantly reduced the 
invasiveness of these highly aggressive breast cancer cells (Parr et a l , 2007).
In the adhesion assays conducted with the PZHPV7 and PNT2C2 cells it was 
seen that the basal rate of adhesion is higher in the PNT2C2 cells compared to that of 
the PZHPV7. This effect is likely to be a characteristic of PNT2C2 cells. There is a 
possibility that this differential ability of PNT2C2 cells to adhere more quickly, or 
successfully, to matrigel could have an impact on the invasion assay which also uses 
matrigel as a part of the assay. This effect however, seems unlikely to affect the overall 
outcome of both the adhesion assay and the invasion assay. Within the adhesion assays 
of both cell lines the knockdown of matriptase-2 did not alter the adhesion of either cell 
line when compared to the control cell lines. Although PNT2C2 cells displayed a higher 
number of adherent cells the trend was conserved. Within the invasion assay the basal 
rate of invasion is seen to be higher in the PNT2C2 cells compared to the PZHPV7 
cells. This may in fact be a reflection of the adherent ability of the cell lines as the cells 
must first adhere to matrigel before invading through it. But again, within the invasion 
assay the knockdown of matriptase-2 increased the invasion of both cell lines compared 
to their respective controls. Therefore the the trend is conserved irrespective of the basal
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rate of invasion. In light of this, it is believed that differential rate of adhesion between 
to two cells lines does not affect the conclusions drawn from these assays.
Due to the scarcity of research involving the possible cellular functions 
matriptase-2 it is very difficult to hypothesize how the protease may be regulating the 
motility and invasiveness of prostate and breast cells. Further research may eventually 
uncover the pathways through which matriptase-2 exerts its effects on motility and 
invasion. It is however, likely that matriptase-2 exerts its effects on key regulators of 
motility and invasion to prevent the cells from progressing to a more cancerous 
phenotype. Although any possible future therapeutic must take into account the major 
role of matriptase-2 in iron homeostasis and the potential involvement of the BMP 
pathway.
Due to the potential tumour suppressive role that these results suggest for matriptase-2 
there is some discrepancy with the findings of Velasco et al 2002 who demonstrated the 
capacity of the matriptase-2 catalytic domain to degrade ECM components such as 
fibronectin, fibrinogen and type I collagen (Velasco et al., 2002). This would suggest 
that matriptase-2 should promote the degradation of the artificial matrigel basement 
membrane as it contains a large portion of collagen, laminin, and fibronectin. A 
possible explanation for the opposite trends demonstrated in this chapter may be that 
Velasco et al only examined the catalytic domain of matriptase-2. This domain shows a 
large degree of homology to the catalytic domain of matriptase-1 (approximately 50%) 
and contains motifs and sequences which are characteristic of all members of the serine 
protease family. This would indicate that the catalytic domain of matriptase-2 would
162
demonstrate the potential to degrade similar substrates to matriptase-1. However, the 
full length protein must be taken into account, not just the catalytic domain, as the large 
number of non-catalytic domains will undoubtedly contribute to protein folding and 
also interaction of the protease with substrates. Indeed the modular domains of the stem 
region of the TTSPs have been proposed to be involved in protease-substrate interaction 
(Netzel-Arnett et al., 2003).
To further implicate matriptase-2 in protecting against cancer development several 
other studies have reported findings that support this theory. Hartikainen et al found a 
SNP in the matriptase-2 gene on 22ql2-13 that has been implicated with breast cancer 
risk (Hartikainen et al., 2006). Studies have also shown that regions of chromosome 
22ql2-13, where the matriptase-2 gene is located, are frequently altered in breast and 
colorectal cancers (Allione et al., 1998; Hirano et al., 2001), oral squamous cell (SCC) 
carcinomas (Miyakawa et al., 1998), pancreatic endocrine cancer (Chung et al., 1998).
This study suggests that matriptase-2 is an important regulator of the biological 
properties of prostate cells, which possibly has the effect of preventing the progression 
from a normal to a cancerous phenotype. In order to further determine the role of 
matriptase-2 in cancer progression the following chapter attempts to examine the 
potential role of matriptase-2 in cancer angiogenesis.
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Chapter 5
The role of Matriptase-2 in angiogenesis
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5.1 Introduction
Angiogenesis is a crucial step that most cancers must take in order to progress 
down the metastasis path. Although angiogenesis is required for normal physiological 
development, such as wound healing, growth and fertility (Campbell, 1997; Los and 
Voest, 2001; Tuxhom et al., 2001), many cancers have the ability to force the growth of 
new blood vessels to bring enough nutrients to enable the progressive growth of cancer. 
The process of cancer acquiring the ability to promote blood vessel growth is termed 
the ‘angiogenic switch’. The observation of Dr. Folkman that tumours are unable to 
grow more than 2-3 mm in the absence of new blood vessel growth (Folkman, 1971) 
paved the way for the search for successful anti-angiogenic therapies.
Angiogenesis is a complex multi-step process involving close regulation of endothelial 
cells, extracellular matrix and soluble factors. This process can be divided into four 
stages: proteolytic degradation of the basement membrane and surrounding 
extracellular matrix, endothelial cell proliferation, endothelial cell migration and finally 
tube formation and structural reorganisation (Hanahan and Folkman, 1996). Every stage 
of the angiogenic process is tightly regulated using inhibitors and inducers of the 
molecules, such as MMPs, VEGF, FGF2, TGF-P and cyclooxygenase-2, involved in 
bringing about the stages of angiogenesis. Angiogenesis plays a major role in the 
progression of prostate cancer. It has been demonstrated that prostate cancer cells 
express VEGF, and that the expression of VEGF by neoplastic cells is greater that that 
found in normal prostate stromal tissue (Harper et a l, 1996; Ferrer et al., 1997). Also 
blood and urine VEGF levels hve been correlated with prostate cancer outcomes
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(Duque et a l , 1999; George et a l, 2001), with poorer patient outcomes associated with 
higher levels of VEGF. As a result of this VEGF inhibitors have been the subject of 
intense research for many years.
It recently been shown that matriptase-2 proteolytically processes membrane 
hemojuvelin (also known as RGMc) which significantly reduces hepcidin transcription 
as hemojuvelin induces Hamp transcription (Silvestri et a l, 2008). Due to the fact that 
RGMc is a BMP co-receptor, there could be further implications involving matriptase-2 
in angiogenesis. BMPs are essential in the regulation of angiogenesis as they are 
required for all mesodermally derived tissues, including blood vessels. BMPs also 
regulate the function of VEGF, a critical inducer of angiogenesis. The ability of 
matriptase-2 to cleave RGMc could affect the function of the BMP pathway, and 
therefore the regulation of critical angiogenic factors such as VEGF. This current study 
intends to elucidate any possible involvement of matriptase-2 in prostate cancer 
angiogenesis.
As angiogenesis is so important in the progression of cancer it was decided to 
investigate if matriptase-2 had any role to play in this crucial area of metastasis. As 
stated above there is a potential link between matritptse-2 and the BMP pathway. As 
BMPs are integral to the process of angiogenesis this could infer that matriptase-2 does 
indeed have a potential role in angiogenesis. In order to investigate the effect of 
matriptase-2 in angiogenesis, the well known angiogenesis cell model, HECV, was used 
in in vitro assays to determine cell functionality. The expression of matriptase-2 was 
forced in the HECV endothelial cell line, which has been found to display minimal
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matriptase-2 expression. A mammalian expression plasmid containing the matriptase-2 
gene was used to produce the over-expressed cell line. Following confirmation of over­
expression the cells were used in a number of in vitro experimental assays designed to 
investigate the angiogenic process in order to gain insight into the role of matriptase-2 
in angiogenesis.
5.2 Methods
5.2.1 Cell lines
The HECV cell line was used in the current chapter, including the wild-type control, 
empty plasmid control and transfected cell lines. Cells were continuously maintained in 
DMEM media with 10% FBS and antibiotics. The stable transfected cells were 
maintained in the same media but with 0.5pg/ml blasticidin.
5.2.2 In vitro cell growth assay
The cells were seeded into three 96 well plates, and incubated for 1, 3, and 5 days 
respectively, as described in section 2.7.1. Following incubation, the cells were fixed in 
formalin and stained with crystal violet before the absorbance was measured in order to 
determine cell number.
5.2.3 In vitro cell Matrigel adhesion assay
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The cells were seeded into a 96 well plate coated with matrigel as described in section 
2.7.2. The cells were left to adhere for a period of 40 minutes, before being fixed in 
formalin and stained with crystal violet, and the cells in random fields counted.
5.2.4 In vitro cell motility assay
The protocol followed is described by Rosen and Jiang (Rosen et al., 1990; Jiang et al., 
1995b). The cells were incubated with cytodex-2 beads and left over night, by which 
time the cells will have adhered to the surface of the beads. The beads carrying the cells 
were then transferred into a 96 well plate, where the cells move from the beads onto the 
surface of the culture plate. These cells were then fixed in formalin and stained with 
crystal violet, and counted in random fields.
5.2.5 In vitro cell matrigel tubule formation assay
Cells were seeded into a 96 well plate coated with 250 pg matrigel and incubated for 6 
hours. Following incubation, wells were visualised under x40 objective magnification 
and random fields counted. Using ImageJ the internal perimeter of each tubule was 
measured, combined, and the units converted into pm.
5.3 Results
5.3.1 Matriptase-2 has no effect on in vitro HECV cell growth
The effect of over-expression of Matriptase-2 on the growth of HECV cells was 
examined using an in vitro cell growth assay (Figure 5.1). This showed that at day 5
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there was no significant difference seen between HECV11*12 exp (788.79±91.50) 
compared to the control HECVpEF6 (820.12±79.20) p=0.423.
5.3.2 Matriptase-2 expression did not alter HECV cell adhesion to an 
artificial Matrigel basement membrane
The capacity of HECV endothelial cells to adhere to an artificial Matrigel basement 
membrane over a 45 min period was examined using an in vitro Matrigel adhesion 
assay (Figure 5.2). Over-expression of matriptase-2 in the HECV cells did not result in 
any noteworthy change in the adhesive properties of the HECV cell lines. There was no 
significant change in adhesive capacity seen between HECV™312 exp (66.67±26.98) and 
the control HECV pEF6(66.80±14.37) p=0.990.
5.3.3 Matriptase-2 greatly reduced the motile capacity of the HECV cells
The effect of matriptase-2 over-expression on cell motility was assessed using an in 
vitro cytodex-2 bead assay (Figure 5.3). Transfection with the matriptase-2 expression 
plasmid reduced HECV cells ability to move from the beads to the well surface. The 
HECV™312 exp cells (10.93±2.80) were significantly less able to move from the beads to 
the 96 well plate compared to the control HECV pEF6 (46.47±16.18) p= <0.001.
5.3.4 Over-expression of matriptase-2 diminished tubule formation capacity 
in HECV cells
The effect of matriptase-2 on the tubule forming ability of HECV endothelial cells in 
vitro was examined using a tubule formation assay (Figure 5.4). Over-expression of
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matriptase-2 caused a significant decrease in tubule formation in HECV mat2 exp cells 
(9817.83±933.85) compared to the control HECV pEF6 (23841.60±744.75) p= 0.026.
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Figure 5.1 Over-expression of matriptase-2 has no effect on the growth of human 
endothelial cells. After incubation for 5 days there was found to be no significant 
effect on the growth of HECV mat2 exp cells compared to its control HECV pEF6 (p= 
0.364). Data shown is representative of at least 3 independent repeats. Error bars 
represent standard deviation. The 1 day time point absorbance was used as a baseline 
in order to normalise the data.
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Figure 5.2 Over-expression of matriptase-2 has no effect on the adhesion of human 
endothelial cells. A. Representative images of stained adherent cells. B. Following 
incubation of the cells on an artificial matrigel basement membrane it was seen that 
over-expression of matriptase-2 has no significant effect on the adhesion of HECV Tma 
exp cells compared to its control HECV pEF6 p= 0.990. Data shown is representative of at 
least 3 independent repeats. Error bars represent standard deviation.
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Figure 5.3 Over-expression of matriptase-2 decreases the motility of human 
endothelial cells. A. Representative images of motile cells stained with crystal 
violet. B. Following an overnight incubation of the cytodex-2 beads it was seen that 
over-expression of matriptase-2 significantly decreased the motility of HECV 111312 exp 
cells compared to its control HECV pEF6 (**p= <0.001). Data shown is representative 
of at least 3 independent repeats. Error bars represent standard deviation.
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Figure 5.4 Over-expression of matriptase-2 decreases the ability of human 
endothelial cells to form tubules. A. Representative images displaying HECV 
tubules formed in matrigel. B. After a six hour incubation of the cells on an artificial 
matrigel basement membrane it appeared that over-expression of matriptase-2 
significantly decreases the tubule forming ability of HECV mat2 exp cells compared to 
its control HECV pEF6 (*p= 0.026). Data shown is representative of at least 3 
independent repeats. Error bars represent standard deviation.
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5.4 Discussion
Angiogenesis, the formation of new blood vessels from pre-existing ones, is 
essential for sustained tumour growth beyond a critical size of 2-3 mm. Moreover, 
increased angiogenesis promotes tumour cell penetration into the circulation and 
thereby metastatic dissemination. Tumour vessels can develop through different 
mechanisms, including sprouting or intussusception from pre-existing vessels, the 
mobilisation of circulating endothelial precursors from the bone marrow, and the 
recruitment of lymphatic vessels (lymphangiogenesis) (Carmeliet and Jain, 2000). 
Different proteolytic enzymes, including serine proteases (SPs) and matrix 
metalloproteinases (MMPs), have been implicated in angiogenesis (Pepper, 2001). The 
theory for the involvement of SPs and MMPs during cancer progression was that the 
degradation of extracellular matrix components should contribute to different events, 
such as provisional matrix remodelling, basement membrane breakdown, and cell 
migration and invasion. In addition to degrading extracellular matrix components, 
proteinases have also been implicated in the activation of cytokines, and in the release 
of growth factors within the extracellular matrix (Rifkin et a l , 1999; Egeblad and 
Werb, 2002; McQuibban et a l , 2002). Several TTSPs, such as hepsin, TMPRSS2 and 
matriptase, have been reported to be expressed during microvascular endothelial cell 
morphogenesis (Aimes et a l, 2003), suggesting that they have a function in 
angiogenesis. Membrane anchored SPs probably have complex functions because the 
upregulation and downregulation of their expression has been associated with cancer 
progression.
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Endothelial cells line the inner surface of all blood vessels in the body. They are 
essential in the formation of new blood vessels. HECV cells are a human endothelial 
cell line that has retained the ability of forming tubules in an artificial basement 
membrane. These tubules can indicate the level of angiogenic potential of the cells. The 
more tubules that are formed indicate that those particular cells are more angiogenic 
and therefore more capable of influencing metastasis. By manipulating the expression 
of matriptase-2 in these HECV cells the influence of matriptase-2 on tumour 
angiogenesis can be investigated. As seen in chapter 3 a mammalian plasmid construct 
containing the matriptase-2 sequence was successfully transfected into the HECV cells 
and over-expression was confirmed using several methods. Functional assays were used 
to determine the effect of matriptase-2 on the biological functions of the HECV cells.
The over-expression of matriptase-2 had no significant effect on the growth and 
adhesion of the HECV cells. This is the same effect seen with the PZHPV7 and 
PNT2C2 matriptase-2 knock-down cells in the previous chapter. It also correlates with 
DU 145 cells over-expressing matriptase-2. The only exception appears to be PC3 cells 
over-expressing matriptase-2 which had a reduction in growth although the adhesion 
had no difference (Sanders et al., 2008). This reduction in growth could be due to 
aberrant expression of cell cycle proteins arising from the cancerous nature of the PC3 
cells. The HECV 111812 exp cells were also used in a motility assay in which resulted in a 
significant decrease in cellular motility. Again this correlates with the increase in 
motility seen in the knock-down cells in chapter 4. It also mimics the reduction in 
motility seen in PC3 and DU 145 cells over-expressing matriptase-2 in Sanders et al. 
MDA-MB-231 cells over-expressing matriptase-2 were also seen to have a reduction in
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motility (Parr et a l, 2007). So far the effects of matriptase-2 on the biological functions 
of PC3, DU 145, PZHPV7, PNT2C2, MDA-MB-231, and HECV cells appear to be 
largely consistent throughout the three studies investigating the involvement of 
matriptase-2 in prostate and breast cancer.
The tubule formation assay can only be conducted with the HECV cells. It 
showed that an over-expression of matriptase-2 significantly reduced the number and 
size of tubules formed in an artificial matrigel basement membrane. Although the 
growth and adhesion didn’t change the reduced motility and tubule formation suggested 
that matriptase-2 may have a previously unrecognised role in tumour angiogenesis.
These results show that matriptase-2 possibly has a role in tumour angiogenesis. 
The results from this study clearly show a reduction in angiogenic potential in the 
presence of matriptase-2 over-expression. How matriptase-2 exerts its effect on the 
angiogenic process remains unknown. Several studies have suggested that fibrinogen 
and components of the uPA system can facillitate tumour angiogenesis and are possibly 
up-regulated in cancer (Bajou et al., 2001; Noel et a l, 2004; Morrissey et a l, 2008). As 
matriptase-2 has been shown to proteolytically process these proteins this may have 
some impact of the angiogenic ability of these cells. Also to be taken into account is the 
fact that matriptase-2 can cleave RGMc (m-HJV), a BMP co-receptor. This could alter 
the BMP signalling pathway and influence not only iron homeostasis but could have 
implications for preventing cancer development and/or metastasis. As BMPs are widely 
known for having a role in angiogenesis (Scharpfenecker et a l, 2007; David et a l,
2009) further investigation into the effect of matriptase-2 on BMP signalling will
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determine if the anti-angiogenic nature of matriptase-2 is mediated through the BMP 
signalling pathway. Further investigation into the role of matriptase-2 in tumour 
angiogenesis will be needed to elucidate its possibly important anti-angiogenic effects 
on prostate and to a lesser extent, breast cancer.
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Chapter 6
Matriptase-2 affects the protein expression 
of p-catenin which possibly facilitates the 
anti-metastatic properties of matriptase-2.
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6.1 Introduction
The p-catenin nuclear signalling molecule, a key component of the Wnt signalling 
pathway, has been widely implicated as an oncogene in human cancer and current 
research is greatly interested in deepening the understanding of the role of p-catenin in 
the development of cancer in the hope of providing possible therapeutic strategies for 
the treatment of cancer.
p-Catenin was first described as a structural component in adherens junction formation, 
a mechanism of cell-cell adhesion. p-Catenin is normally maintained at low levels in 
the absence of wnt stimulation due to its constitutive proteasomal degradation (Hart et 
a l , 1999). The regulators that confer this turnover, APC and Axin, position p-catenin 
for phosphorylation at its N-terminus (encoded by human exon 3) by glycogen synthase 
kinase-3p (GSK-3p). The targeted serine and threonine residues reside in an Ik B  
consensus destruction motif and upon their phosphorylation by GSK-3p prime p- 
catenin for ubiquitination and subsequent proteasomal degradation. De-repression of 
this post-translational regulation of P-catenin through inhibition of GSK-3p kinase 
activity is induced by the downstream formation of an appropriate wnt/fzd/LRP 
complex (Liu et a l , 2001).
The reduction of P-catenin degredation upon wnt stimulation leads to greater p-catenin 
participation in two major cellular processes, nuclear signaling and cell-cell adhesion, 
p-catenin accumulation results in its translocation into the nucleus and interaction with 
DNA-binding transcription factors, the most prominent of which are those of the 
TCF/lymphoid enhancer factor (LEF) family. Once localized to the nucleus, p-catenin
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complexed with its DNA-binding transcription factors, initiates the transcription of its 
target genes. These target genes are highly involved in the regulation of many proteins 
of importance in maintaining the proper cell functions. These target genes include c- 
MYC (He et a l , 1998), MMP-7 (Brabletz et a l , 1999; Crawford et a l , 1999), VEGF 
(Zhang et a l , 2001) and MET (Boon et a l , 2002). Due to the importance of these target 
genes in maintaining the correct function of the cell the balance between the 
degradation and activation of P-catenin must remain tightly controlled. Deregulation of 
this pathway plays a huge role in the progression and possibly the development of 
cancer.
An increase in cellular levels of p-catenin resulting from mutations of P-catenin itself, 
or of components of the destruction complex, is frequently observed in many cancer 
cells, including prostate cancer. Detection of P-catenin mutations in prostate cancer 
samples has been reported previously, with approximately 5% of samples revealing 
mutations at the serine ot threonine residues in the NH2-terminal of the p-catenin 
protein (Voeller et a l, 1998; Chesire et a l, 2000; Gerstein et a l, 2002). Examination of 
the p-catenin protein by immunohistochemical assays revealed aberrant localization of 
the protein in prostate cancer specimens (Chesire et a l, 2002; de la Taille et a l, 2003). 
Alterations of APC and b-TrCPl, which directly affect the degradation of p -catenin, 
have also been observed in prostate cancer samples (Gerstein et a l, 2002). The direct 
role of p-catenin in promoting prostate cancer cell growth has been examined recently.
As previously mentioned, p-catenin was selected to be examined in this study 
based on unpublished data from a previously conducted study. As matriptase-2 was 
found to affect the migratory and adhesive capabilities of PC3 and DU 145 cells a screen
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of molecules involved in cell:cell and cell:matrix adhesion was performed in an attempt 
to determine if any of these molecules had been altered by the presence of matriptase-2. 
p-catenin was identified as a molecule of interest from this panel of molecules. This 
presented the opportunity to investigate any link between matriptase-2 and p-catenin. 
As the expression and regulation of degradation of p-catenin and transcription of P- 
catenin target genes have already been shown to be highly deregulated in prostate 
cancer this seemed a good opportunity to investigate if matriptase-2 did have the ability 
to influence p-catenin in respect to preventing cancer progression.
Using the five cell lines with altered matriptase-2 from the previous chapters, this 
chapter will investigate the relationship between matriptase-2 and the expression of p- 
catenin as a possible mechanism of action for matriptase-2.
6.2 Methods
6.2.1 Cell lines
PZHPV7, PNT2C2, PC-3, DU-145, and HECV cell lines were used, cultured and 
maintained as described in sections 2.2.3.
6.2.2 RNA isolation, cDNA synthesis, and RT-PCR
RNA was isolated from the cells using the ABgene Total RNA Isolation 
Reagent (TRIR) kit (ABgene, Surrey, UK), and converted into cDNA by reverse 
transcription using the iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories,
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California, USA), as described in section 2.4. This was then used as a template for RT- 
PCR, which was carried out at the following conditions; 94°C for 5 minutes, followed 
by 30 to 42 cycles of 94°C for 30 seconds, 56°C for 30 seconds, and 72°C for 1 minute, 
and a final extension of 7 minutes at 72°C. The products were run on an agarose gel and 
visualised using ethidium bromide.
6.2.3 Western blot analysis of p-catenin expression
Cells stably transfected with either the matriptase-2 expression or ribozyme plasmid 
were lysed and the protein was extracted. This protein was used in SDS-PAGE Western 
blotting along with a p-catenin antibody to detect the expression of p-catenin in the 
altered cell lines and their controls.
6.2.4 Immuno-flourescent chemistry (IFC)
Cells were permeabilsed and incubated with p-catenin primary antibody for 1 hour. The 
primary antibody was then washed off and replaced with the corresponding FITC 
labelled secondary antibody, before the cells were viewed using a fluorescent 
microscope.
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6.3 Results
6.3.1 Over-expression of matriptase-2 decreased levels of p-catenin in PC3 
cells.
Forced expression of matriptase-2 cells resulted in a dramatic reduction in p-catenin 
protein levels in the PC3 111312 exp cells compared to the control cells PC3 ^  and PC3 pEF6 
Figure 6.1 A shows that alteration of matriptase-2 causes no change in p-catenin mRNA 
levels in PC3 cells. Figure 6.1 B depicts a Western blot showing a decrease in p-catenin 
protein levels in the PC3 111312 exp compared to PC3 and PC3 pEF6. Figure 6.1 C  further 
demonstrates the reduction in p-catenin protein using band quantification and 
normalisation against GAPDH expression. Figure 6.1 D revealed that through IFC 
staining, the reduction in P-catenin protein is form the cell membrane rather than 
globally throughout the cell.
6.3.2 Over-expression of matriptase-2 in DU145 cells increased levels of p- 
catenin
Forced expression of matriptase-2 resulted in an increase in P-catenin protein levels in 
DU145 111312 exp cells. Figure 6.2 A PCR reveals no change in p-catenin mRNA levels in 
DU145 cells. Figure 6.2 B shows a Western blot with increased levels of p-catenin in 
the DU145 111312 exp cells compared to DU145 WT and DU145 pEF6 control cells. Figure 6.2 
C further demonsrated the trend following band quantification and normalisation 
against GAPDH expression. Figure 6.2 D confirmed the increased the levels of p-
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catenin protein using IFC staining. The increase in p-catenin protein can clearly be seen 
in the DU145 exp cells.
6.3.3 Over-expression of matriptase-2 results in no change of p-catenin 
levels in HECV endothelial cells.
Forced expression of matriptase-2 caused no change in the protein levels of HECV 111812 
exp cells.PCR analysis showed no change in p-catenin mRNA levels in all HECV cells 
Figure 6.3 A. Western blot detection of p-catenin protein in transfected and control cell 
demonstrated little difference in p-catenin protein levels between HECV 111812 exp and 
HECV ** or HECV pEF6 control cells (Figure 6.3 B). Figure 6.3 C further demonsrates 
the trend following band quantification and normalisation against GAPDH expression. 
Figure 6.3 C confirms there is no change in p-catenin protein levels, although there may 
be a shift in P-catenin localisation, using IFC staining of P-catenin in the cells.
6.3.4 Knock-down of matriptase-2 results in an increase of p-catenin in 
PZHPV7 cells.
Knock-down of matriptase-2 caused a marked increase of p-catenin protein in PZHPV7 
01812 nbl cells when compared to the controls PZHPV7 wt and PZHPV7 pEF6. PCR analysis 
showed that there is no change in p-catenin mRNA levels regardless of matriptase-2 
expression status (Figure 6.4 A). Western blot analysis demonstrated a marked increase 
of p-catenin protein levels in the PZHPV7 111812 nbl cells compared to the PZHPV7 pEF6 
control cells (Figure 6.4 B). Figure 6.4C corroborates the trend following a band 
quantification of the Western blot and normalising against GAPDH expression. Figure
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6.4 D confirms there is a large increase in p-catenin protein levels at the cell membrane 
using IFC staining in the cells.
6.3.5 Knock-down of matriptase-2 results in an increase of p-catenin in 
PNT2C2 cells.
Knock-down of matriptase-2 caused a large increase of p-catenin protein in PNT2C2 
ma'2 ribl cells when compared to the controls PNT2C2 wt and PNT2C2 pEF6. PCR analysis 
revealed no change in p-catenin mRNA levels regardless of matritptase-2 expression 
status (Figure 6.5 A). Western blot analysis showed that there was a large increase in p- 
catenin protein in the PNT2C2 111842 nbl cells compared to the control cells PNT2C2 pEF6 
(Figure 6.5 B). Figure 6.5 C further demonstrates the trend using band quantification of 
the Western blot and normalising p-catenin protein expression against GAPDH. 
Following IFC staining, the increase in p-catenin protein was revealed to be at the cell 
membrane rather than throughout the whole cell (Figure 6.5 D).
Figure 6.3.6 Alteration of matriptase-2 expression affects the expression of 
E-cadherin and N-cadherin
EMT indicators E-cadherin and N-cadherin were investigated in all cells lines. Western 
blot analysis showed decreased levels of N-cadherin protein in PC3 1X1842 exp and DU145 
mat2 exp cells. However, there was no change in HECV 111842 exp cells. The Western blot also 
showed an increase in N-cadherin protein in the matriptase-2 knockdown cells PZHPV7 
111842 nbl and in PNT2C2 111842 nbl (Fig 6.6 A). On investigation of E-cadherin the Western 
blots displayed increased E-cadherin protein expression in PC3 111842 exp and DU 145 111842
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exp cells. The Western blot also showed a decrease of E-cadherin protein in matriptase-2 
knockdown cells PZHPV7111812 ribl and in PNT2C2 111842 ribl (Fig 6.6 B).
Figure 6.3.7 Alteration of matriptase-2 expression influences p-catenin 
target gene MMP-7
Expression levels of the p-catenin target gene MMP-7 were investigated in the 
matriptase-2 altered cells. PCR analysis showed clearly decreased MMP-7 mRNA in 
PC3 111842 exp and HECV 111842 exp cells. There was however, an increase in MMP-7 mRNA 
in DU 145 111842 exp cells. The PCR also showed an increase in MMP-7 mRNA in 
matriptase-2 knockdown cells PZHPV7 11,842 ribl and in PNT2C2 111842 ribl (Fig. 6.7 A). 
This trend was also investigated at the protein level. Western blots were conducted and 
revealed decreased MMP-7 protein expression in PC3 111842 exp and HECV 111842 exp cells. 
There was again an increase in MMP-7 protein in DU145 111842 exp cells. The Western also 
shows an increase of MMP-7 protein in PZHPV7 111842 ribl and in PNT2C2 111842 
nblmatriptase-2 knockdown cells (Fig 6.7 B).
Figure 6.3.8 Matriptase-2 appears to regulate the levels of ECM modulator 
uPA.
The levels of the potent angiogenic factor uPA were examined in all cell lines. PCR 
analysis displayed no change in uPA mRNA expression in any cell line regardless of 
matriptase-2 status (Fig 6.8 A). Western blots were then conducted to determine if uPA 
protein was affected. These revealed a reduction in uPA protein in the PC3 111842 exp,
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DU 145 111812 exp and HECV 111342 exp cells compared to the control pEF6 cells for each cell 
line. It also showed an increase in uPA protein in PZHPV7 111342 nbl and PNT2C2 111342 nbl 
cells compared to the control pEF6 cells for each cell line (Fig 6.9 B).
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Figure 6.1 Over-expression of matriptase-2 results in reduced p-catenin expression 
in PC3 cells
A. PCR showing no change in p-catenin mRNA levels. B. Western blot displaying 
reduced p-catenin protein levels in the PC3 exp cell line compared to the control PC3 
pEF6 C. Western blot band quantification showing P-catenin levels normalised to the 
levels of the control protein GAPDH. D. IFC staining shows reduced membrane 
staining for p-catenin in the PC3 10312 exp cell line compared to the control PC3 pEF6. ( —  
= 10pm).
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Figure 6.2 Over-expression of matriptase-2 results in increased p-catenin 
expression in DU145 cells
A. PCR showing a slight increase in p-catenin mRNA levels. B. Western blot 
displaying increased p-catenin protein levels in the DU 145 mat2 ^  cell line compared to 
the control DU 145 pEF6 C. Western blot band quantification showing p-catenin levels 
normalised to the levels of the control protein GAPDH. D. IFC staining also shows an 
increase in membrane staining for P-catenin in the DU 145 111812 exp cell line compared to 
the control DU145 pEF6. ( , _  = 10pm).
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Figure 6.3 Over-expression of matriptase-2 results in no change in p-catenin 
expression in HECV cells
A. PCR showing no change in P-catenin mRNA levels. B. Western blot displaying no 
change in over-all P-catenin protein levels in the HECV exp cell line compared to the 
control HECV pEF6. C. Western blot band quantification showing p-catenin levels 
normalised to the levels of the control protein GAPDH. D. IFC staining also shows no 
change in membrane staining for p-catenin in the HECV 111812 exp cell line compared to 
the control HECV pEF6. ( —  = 10pm).
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Figure 6.4 Knockdown of matriptase-2 results in an increase in p-catenin 
expression in PZHPV7 cells
A. PCR showing no change in p-catenin mRNA with a knockdown of matriptase-2. B. 
Western blot displaying an increase in p-catenin protein levels in the PZHPV7 131312 nbl 
cell line compared to the control PZHPV7 pEF6. C. Western blot band quantification 
showing P-catenin levels normalised to the levels of the control protein GAPDH. D. 
IFC staining also shows an increase in membrane staining for P-catenin in the PZHPV7 
131312 nbl cell line compared to the control PZHPV7 pEF6 cells. ( —  = 10pm).
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Figure 6.5 Knockdown of matriptase-2 results in an increase in p-catenin 
expression in PNT2C2 cells
A. PCR showing no change in p-catenin mRNA levels in response to matriptase-2 
knockdown. B. Western blot displaying an increase in p-catenin protein levels in the 
PNT2C2 mat2 nbl cell line compared to the control PNT2C2 pEF6. C. Western blot band 
quantification showing p-catenin levels normalised to the levels of the control protein 
GAPDH. D. IFC staining also shows an increase in membrane staining for p-catenin in 
the PNT2C2 mat2ribl cell line compared to the control PNT2C2 pEF6. 10pm).
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Figure 6.6 Alteration of matriptase-2 expression affects the expression of E- 
cadherin and N-cadherin
A. Western blot showing decreased levels of N-cadherin protein in PC3 01312 exp and 
DU145 01312 exp cells. However, there is no change in HECV mat2 exp cells. The Western 
blot also shows an increase in N-cadherin protein in the matriptase-2 knockdown cells 
PZHPV7 01312 nbl and in PNT2C2 10312 nbl. B. Western blots displaying increased E- 
cadherin protein expression in PC3 01312 exp and DU145 m3t2 exp cells. The Western blot 
also shows a decrease of E-cadherin protein inmatriptase-2 knockdown cells PZHPV7 
01312 ribl and in PNT2C2 10312 ribl.
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Figure 6.7 Alteration of matriptase-2 expression influences p-catenin target gene 
and angiogenesis factor MMP-7
A. PCR showing decreased MMP-7 mRNA in PC3 mat2 exp and HECV raat2 exp cells. 
There was however an increase in MMP-7 mRNA in DU 145 113812 exp cells. The PCR also 
shows an increase in MMP-7 mRNA in PZHPV7 113812 ribl and in PNT2C2 111812 ribl. B. 
Western blots displaying decreased MMP-7 protein expression in PC3 133812 exp and 
HECV 113812 exp cells. As with the PCR the Western blot showed increased MMP-7 
protein in the DU145 111812 exp cell line. The Western also shows an increase of MMP-7 
protein in PZHPV7111812 ribl and in PNT2C2 111812 ribl.
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Figure 6.8 Matriptase-2 appears to regulate the levels of ECM modulator uPA.
A. PCR displaying no change in uPA mRNA expression in any cell line regardless of 
matriptase-2 status. B. Western blot analysis showed a reduction in uPA protein in the 
presence of matriptase-2 over-expression. It also showed an increase in uPA protein in 
cells with matriptase-2 knockdown.
6.4 Discussion
Matriptase-2 has been shown to potentially be a key player in preventing the 
progression of prostate and breast cancer not only in previously published data but 
throughout this project. It has been shown to reduce the aggressiveness of prostate 
cancer and breast cancer cells in vitro and tumour growth in vivo. It has also been 
shown to be a potential prognostic indicator for breast cancer patients (Parr et al., 2007; 
Sanders et a l, 2008). This project has also demonstrated that matriptase-2 may have a 
previously unknown role in prostate and breast tumour angiogenesis, an important 
process in allowing the further growth of primary and secondary tumours.
However, due to the relatively unstudied role of matripase-2 in cancer as it is a 
relatively newly discovered member of the TTSP family, there is little known about the 
mechanistic action of matriptase-2. In the last few years a crucial role for matriptase-2 
in iron homeostasis has been uncovered. It has been shown that matriptase-2 can 
proteolytically process m-HJV, more commonly known in cancer as RGMc (Folgueras 
et al., 2008; Silvestri et a l, 2008). As RGMc is a BMP co-receptor there is some scope 
for the involvement of matritpase-2 in the BMP pathway, a highly deregulated pathway 
in cancer. Investigating the effects of matritpase-2 cleavage of RGMc on the BMP 
pathway in cancer would be a worthwhile endeavour to give some insight into the 
proteases mechanism in cancer.
Unpublished work produced previously in the laboratory presented the possibility that 
there may be some link between the expression status of matriptase-2 and p-catenin. 
Given that Wnt/p-catenin signalling is another pathway that is highly aberrant in cancer
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development the fact that a regulatory link between matriptase-2 and p-catenin may 
exist was an exciting one. This project attempted to determine the definite existence of 
this link and consider the effects the link may have on the aggressiveness of prostate 
cancer.
To fully investigate the effect of matriptase-2 on p-catenin, two aggressive prostate 
cancer cell lines PC3 and DU 145 were utilised in the experiments along with the 
previously seen cell line HECV, PZHPV7 and PNT2C2. As both of these cell lines 
displayed low expression of matriptase-2 they were transfected with the matriptase-2 
expression plasmid that was also introduced to the HECV cells. Once matriptase-2 
over-expression was confirmed, experiments to investigate p-catenin were conducted.
The investigation started with examination of the mRNA levels of P-catenin in each of 
the five cell lines. The PCR results revealed that matriptase-2 expression status had no 
effect at all on the mRNA levels of p-catenin in any of the cell lines. In light of this the 
protein levels of p-catenin were then examined using Western blotting. The Western 
blots revealed that an over-expression of matriptase-2 greatly decreased the protein 
levels of p-catenin in the PC3 1X1312 exp cell line. Conversely in the matriptase-2 
knockdown cells PZHPV7 111812 nbl and PNT2C2 111812 nbl there was a large increase in p- 
catenin protein. The only exception was HECV111812 exp cells which showed no change in 
P-catenin protein levels. These results could indicate that in the normal prostate and 
prostate cancer cells matriptase-2 is potentially cleaving p-catenin. In the case of 
DU 145 111812 exp there was an increase in p-catenin levels. This could be due to the 
differing expression of E-cadherin in the DU 145 cell lines. The odd result with HECV
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mal2 exp cells may indicate that P-catenin is not involved in the mechanism of action in 
endothelial cells.
To further examine the protein expression of p-catenin immunofluorescent staining was 
conducted on all cell lines. This also revealed a decrease in p-catenin expression in the 
PC3 mat2 exp cells where the lack of fluorescence is clearly visible. The images from 
DU145 111812 exp also reveal the increase in protein seen with the Western blots. The 
HECV 111812 exp cells also showed no increase in p-catenin but may indicate a shift in 
location which would need to be further investigated. As with the Westerns the 
PZHPV7 111812 nbl and PNT2C2 111812 nbl also showed an increase in P-catenin protein 
staining. This change in p-catenin levels in the cells may account for the changes in 
motility and invasion seen in the cells as the P-catenin target genes are often involved in 
regulating such cellular processes.
There is evidence suggesting that during the process of prostate cancer progression, loss 
of E-cadherin expression or activation of the Wnt pathway can lead to an increase in the 
cytoplasmic levels of p-catenin. The excess free P-catenin proteins translocate to the 
nucleus and activate transcription of its target genes. As an AR co-activator, P-catenin 
may also play a critical growth-promoting role by compensating for decreased androgen 
levels in response to androgen ablation therapy (Verras and Sun, 2006). These two 
proteins obviously have a close relationship in the area of cancer progression; if 
matriptase-2 can indeed cleave P-catenin then this may in turn lead to a breakdown of 
the E-cadherin complex at the cell membrane. This would then lead to then cell 
becoming more aggressive in nature. Figure 6.6b showed that an over-expression of
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matriptase-2 increased the levels of E-cadherin in the PC3 mat2 exp and DU 145 111812 exp 
cell. It also showed a decrease in E-cadherin in the matriptase-2 knockdown cells 
PZHPV7 111812 nbl and PNT2C2 111812 nbl cells. This change in E-cadherin levels is also 
associated with a change in N-cadherin levels. Figure 6.6a showed that an increase in E- 
cadherin levels was twinned with a decrease in N-cadherin levels and the converse with 
a decrease of E-cadherin levels. This indicates that matriptase-2 not only cleaves p- 
catenin but has an effect on the EMT of the cells. In addition loss of E-cadherin would 
reduce cell to cell adhesion and promote motility of the cells. This could be a potential 
reason for the changes in motility seen in the cells with altered matriptase-2 levels. As 
EMT promotes a more cancerous phenotype this is another possible effect matriptase-2 
has in reducing the aggressiveness of prostate cancer cells.
In an attempt to investigate the anti-angiogenic nature of matriptase-2 the 
metalloproteinase MMP-7, which has previously been shown to be a p-catenin target 
gene in colorectal cancer (Brabletz et al., 1999; Crawford et a l, 1999), was investigated 
in the cells. MMPs have widely reported as being one of several angiogenic factors 
secreted by prostate cancer (van Moorselaar and Voest, 2002), if the accumulation of p- 
catenin also causes an increase in MMP-7 this could be one explanation to the anti- 
angiogenic nature of matriptase-2. Figure 6.7a reveals an increase in MMP-7 mRNA in 
response to matriptase-2 knockdown in the PZHPV7 mat2 nbl and PNT2C2 111812 nbl cells. 
The PC3 111812 exp cells showed a decrease in MMP-7 mRNA. The same trend is true for 
the MMP-7 protein in figure 6.7b. The only exceptions are DU145 mat2 exp in which 
MMP-7 increased in response to the increase in p-catenin levels. HECV111812 exp showed 
no change in MMP-7 levels corresponding to the unchanging p-catenin levels. This data
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indicates that MMP-7 may play some role in the anti-angiogenic role of matriptase-2 
but obviously cannot be the only player due to the results from DU 145 111812 exp and
mat2 exp
To further investigate the anti-angiogenic role of matriptase-2 a molecule unrelated to 
P-catenin was investigated. uPA is an extracellular matrix modulator that has been 
implicated in angiogenesis (Bajou et a l , 2001; Noel et a l , 2004; Morrissey et a l, 
2008). Figure 6.8a showed that there was no change in uPA mRNA irrelevant of 
matriptase-2 status. Figure 6.8b however, shows a decrease in uPA protein that is 
unrelated to the levels of p-catenin in the cells. An increase in uPA was also seen with a 
knockdown of matriptase-2. This could indicate that matriptase-2 directly cleave uPA 
which would contribute to the anti-angiogenic nature of matriptase-2 in a P-catenin 
independent manner. To further support this theory is has been shown that matriptase-1 
has the potential to cleave uPA (Takeuchi et a l, 2000). As matriptase-1 and -2 have a 
high sequence homology, it is likely that they share potential substrates (Hooper et a l, 
2003). Although both proteases may claim uPA as a substrate, due to the tumour 
progressing nature of matriptase-1 and the tumour suppressing nature of matriptase-2, 
the cleavage of uPA may potentially have very different effects in the cancer.
This chapter has revealed some interesting possibilities that will contribute to 
understanding the mechanism of action of matriptase-2. It is evident that the effect of 
matriptase-2 on p-catenin may play some role in reducing the aggressiveness of prostate 
cancer and potentially reducing angiogenic ability through regulation of MMP-7. 
Although due to the differing results seen between the cell lines the ability of
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Chapter 7 
General discussion
203
matripta$e-2 to alter t e  prQt^in expression of P-catenin may not be the major player in 
the meSmmsh^ diPhiatriptase-2. Also contributing to the anti-angiogenic nature of 
matriptase-2, uPA seems to play just as large a role as p-catenin. This reveals how 
complicated the mechanism of action of matriptase-2 actually is and it is possible that 
this project has only scratched the surface of the function of matritpase-2.
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7.1 Prostate cancer metastasis
Prostate cancer is the most commonly diagnosed cancer in men in the UK. 
Approximately a quarter of new cancer cases diagnosed in men are prostate cancer. In 
2007 around 36,000 men were diagnosed with prostate cancer in the UK. In 2008, there 
were 37,051 new cases of prostate cancer diagnosed in the UK, which is around 101 
men every day or one man every 15 minutes. The lifetime risk of being diagnosed with 
prostate cancer is 1 in 9 for men in the UK. The strongest known risk factor for prostate 
cancer is age, with very low risk in men under 50 and rising risk with increasing age 
thereafter. Very few cases are registered in men under 50 and around three-quarters of 
cases occur in men over 65 years. The largest number of cases is diagnosed in those 
aged 70+. As prostate cancer is typically a slow growing cancer, most never grow to the 
point of causing symptoms. Because of this the majority of men die with prostate 
cancer rather than of it. Due to this lack of symptoms, prostate cancer is often 
diagnosed in an already advanced state. Around 75% of patients exhibit locally 
extensive or metastatic disease, resulting in a poor prognosis of less than 15% surviving 
over 5 years (Foster, 1990).
The metastasis of cancer to secondary sites in the body is responsible for the 
majority of cancer related deaths. There is however, no curative treatment for cancer 
metastasis. Due to this fact metastasis is the subject of intense research in the hope of 
producing treatments to delay or even prevent the process of metastasis. Prostate 
cancer metastasis is a complex multi-stage process that involves several crucial steps 
that facilitates the spread of the cancer cells to secondary sites. The steps involve
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mutation of cells, epithelial to mesenchymal transition (EMT), degradation of the 
extracellular matrix (ECM), invasion, angiogenesis, intravasation, extravasation and 
colonisation of secondary sites. Angiogenesis is particularly important as it not only 
provides the tumour with the nutrients needs to grow larger; it also provides a means 
of escape for metastasising tumour cells. There is intense research into developing 
therapeutics targeting angiogenesis as a means to treat prostate cancer. .As most cells 
are not actively relying on angiogenesis, treatment with angiogenesis inhibitors will 
be more accurately targeted to cancer cells than a cytotoxic compound and will have 
a lower level of toxicity to normal non-cancerous cells.
7.2 Matriptase-2 and cancer
Cell surface proteolysis has become known as an important mechanism for the 
activation of proteins involved in managing a wide range of cellular functions. 
Matriptase-2 is a relatively newly discovered member of the Type II transmembrane 
serine protease (TTSP) family. The TTSP family is of great scientific interest due to 
the differing expression of TTSPs in normal and cancerous tissues and cells 
(Wallrapp et a l, 2000; Lang and Schuller, 2001; Magee et al., 2001; Netzel-Arnett 
et al., 2003; Lee et a l, 2005). Matriptase-2 was identified in 2002 when screening 
for sequences common to the TTSP family. Matriptase-2 shares a high homology 
with matriptase-1, which is also over-expressed in different human cancers (Shi et 
al., 1993). However, where the over-expression of matriptase leads to cancer 
progression (Uhland, 2006; Tsai et a l, 2008) matriptase-2 over-expression 
significantly reduces breast and prostate cancer growth and reduced levels correlate
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with poor patient outcome (Parr et a l , 2007; Sanders et al., 2008). Altered 
expression of matriptase-2 in cancer has been reported in several studies. Matriptase- 
2 transcript was detected in mouse Leydig tumour cells (Odet et a l, 2006) and 
elevated levels of matriptase-2 have been reported in invasive ductal cell carcinoma 
(Overall et a l, 2004). Studies from within our laboratories showed that there were 
reduced levels of matriptase-2 immunostaining in cancerous breast tissue sections 
compared to normal tissue sections with the majority of matriptase-2 staining being 
confined to the epithelial sections (Parr et a l, 2007). In contrast to this quantitative 
PCR showed that matriptase-2 levels were up-regulated in tumour compared to 
normal tissues, however matriptase-2 levels were significantly higher in lower NPI 
and TNM stages and correlated with positive patient outcome and the over­
expression of matriptase-2 reduced aggressive in vitro and in vivo traits of MDA- 
MB-231 breast cancer cells (Parr et a l, 2007). An additional study using the 
invasive prostate cancer cell lines PC-3 and DU-145 showed that increased 
expression of matriptase-2 reduced the invasiveness and motility of the cells 
(Sanders et a l, 2008). When the same cells were implanted into CD-I athymic nude 
mice, the resulting tumours developed very poorly in vivo compared to control cells 
and significant reductions in tumour volume were observed between matriptase-2 
over-expressing and control groups (Sanders et al., 2008).
The molecular mechanisms involved in the activation of matriptase-2 remain largely 
unknown. There is very little information concerning the specific involvement of 
matriptase-2 in cancer currently in the literature.
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7.3 Aims of thesis
As there is such a small amount of knowledgein the literature about matriptase-2 this 
project aimed to provide more information about the function of matriptase-2 and the 
mechanism by which it exerts its effects. This would provide much needed 
information about matriptase-2. Using methods well established within the 
laboratory matriptase-2 was over-expressed and knockdown in several cell lines. 
These altered cell lines were then used to conduct functional assays, in vivo mouse 
model trials and used in assays to examine the mechanistic action of matriptase-2.
7.4 The role of matriptase-2 in prostate cells
Using the ribozyme transgene technology to knockdown matriptase-2 in the normal 
prostate cell lines PZHPV7 and PNT2C2 allowed the effect of a removal of 
matriptase-2 to be examined. This revealed that matriptase appears to have no effect 
on the growth or adhesion of these two prostate cell lines. It also showed a 
significant increase in the motility and invasiveness of these cells. The ability of a 
cell to become motile and invasive is a mark of a developing cancer cell that will 
gain the ability to metastasise. The fact that a loss of matriptase-2 increases these 
cancerous characteristics in these cells suggests that matriptase-2 may prevent the 
development and/or progression of prostate cancer. These findings correlate with 
those found by Sanders et al 2006 and Parr et al 2007. In these studies it found that 
an over-expression of matriptase-2 in the aggressive cell lines PC3, DU 145 and 
MDA-MB-231 significantly reduced the motility and invasiveness of all three of 
these cell lines. Due to the scarcity of research involving the possible cellular
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functions matriptase-2 it is very difficult to hypothesize how the protease may be 
regulating the motility and invasiveness of prostate and breast cells. It is clear 
however, that matriptase-2 exerts its effects on key regulators of motility and 
invasion to prevent the cells from progressing to a more cancerous phenotype.
Due to the potential tumour suppressive role that these results suggest for matriptase- 
2 there is some discrepancy with the findings of Velasco et al 2002 who 
demonstrated the capacity of the matriptase-2 catalytic domain to degrade ECM 
components such as fibronectin, fibrinogen and type I collagen (Velasco et al., 
2002). This would suggest that matriptase-2 should promote the degradation of the 
artificial matrigel basement membrane as it contains a large portion of collagen, 
laminin, and fibronectin. A possible explanation for the opposite trends 
demonstrated in this chapter may be that Velasco et al only examined the catalytic 
domain of matriptase-2. This domain shows a large degree of homology to the 
catalytic domain of matriptase-1 (approximately 50%) and contains motifs and 
sequences which are characteristic of all members of the serine protease family. This 
would indicate that the catalytic domain of matriptase-2 would demonstrate the 
potential to degrade similar substrates to matriptase-1. However, the full length 
protein must be taken into account, not just the catalytic domain, as the large number 
of non-catalytic domains will undoubtedly contribute to protein folding and also 
interaction of the protease with substrates. Indeed the modular domains of the stem 
region of the TTSPs have been proposed to be involved in protease-substrate 
interaction (Netzel-Amett et al., 2003). Determining how matriptase-2 reduces the 
aggressive nature of prostate and breast cancer will be an important step in future 
research given the obvious importance of the protective capability of matriptase-2.
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7.5 The role of matriptase-2 in tumour angiogenesis
It was decided to investigate any impact of matriptase-2 on HECV endothelial 
cells due to the fact that the mRNA screen showed no expression of matriptase-2 in 
the HECV cells. This allowed the investigation as to whether matriptase-2 had any 
effect on angiogenesis. An over-expression of matriptase-2 in these cells revealed 
results similar to those seen in the PC3 and DU 145 cells over-expressing matriptase- 
2. As seen with the normal prostate cell lines, there was no change in the growth or 
adhesion of the HECV111812 exp cells. There was however, a significant decrease in the 
motility of the cells. This correlates perfectly with the results obtained from the other 
four cell lines examined. As the HECV cells are endothelial cells a tubule formation 
assay could be performed. An over-expression of matriptase-2 significantly reduced 
the HECV cells ability to form tubules in an artificial basement membrane. This 
revealed that matriptase-2 significantly reduced the angiogenic ability of the HECV 
cells.
These results show that matriptase-2 is likely to have a role in tumour 
angiogenesis. The results from this study clearly show a reduction in angiogenic 
potential in the presence of matriptase-2 over-expression. How matriptase-2 exerts 
its effect on the angiogenic process remains unknown. Several studies have 
suggested that fibrinogen and components of the uPA system can facilitate tumour 
angiogenesis and are possibly up-regulated in cancer (Bajou et al., 2001; Noel et al, 
2004; Morrissey et a l, 2008). As matriptase-2 has been shown to proteolytically
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process these proteins this may have some impact of the angiogenic ability of these 
cells.
These findings have shown that matriptase-2 is proving to be an incredibly 
important molecule in the area of preventing tumour metastasis. As matriptase-2 has 
been shown to reduce the aggressive nature of well known prostate and breast cancer 
cell lines and to reduce tumour volume in vivo it could have a significant impact on 
metastasis. As the cells over-expressing matriptase-2 are significantly less motile and 
invasive they are far less likely to become actively metastasising cells. Combined 
with matriptase-2 being capable of reducing the angiogenic ability of endothelial 
cells, it appears that matriptase-2 has significantly reduced the likelyhood that cells 
expressing matriptase-2 will be able to metastasise. This is an incredibly important 
fact as most prostate tumours are already found to be metastasising and matriptase-2 
could potentially be utilised to reduce the chance of further metastases and to reduce 
the possibly aggressive nature of the cancer.
7.6 The importance of p-catenin in the mechanistic action of 
matriptase-2
The p-catenin nuclear signalling molecule, a key component of the Wnt signalling 
pathway, has been widely implicated as an oncogene in human cancer and current 
research is greatly interested in deepening the understanding of the role of P-catenin 
in the development of cancer in the hope of providing possible therapeutic stratagies 
for the treatment of cancer. The reduction of P-catenin degradation upon wnt
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stimulation leads to greater p-catenin participation in two major cellular processes, 
nuclear signaling and cell-cell adhesion. P-catenin accumulation results in its 
translocation into the nucleus and interaction with DNA-binding transcription 
factors, the most prominent of which are those of the TCF/lymphoid enhancer factor 
(LEF) family. Once localized to the nucleus, p-catenin complexed with its DNA- 
binding transcription factors, initiates the transcription of its target genes. These 
target genes are highly involved in the regulation of many proteins that are involved 
in maintaining the proper functions of the cell. These target genes include c-MYC 
(He et al., 1998), MMP-7 (Brabletz et al., 1999; Crawford et al., 1999), VEGF 
(Zhang et al., 2001), MET (Boon et al., 2002). Because of the importance of these 
target genes in maintaining the correct function of the cell the balance between the 
degredation and activation of P-catenin must remain tightly controlled. Deregulation 
of this pathway plays a huge role in the progression and possibly the development of 
cancer.
P-catenin was chosen to investigate in this study due to data (unpublished) gained 
during a previous study involving matriptase-2. This study was trying to determine 
how matriptase-2 mediated the reduction in migration seen in PC3 and DU 145 cells 
over-expressing matriptase-2 and the reduction in adhesion seen in PC3 cells 
(Sanders, 2008 #225}. A screen of molecules involved with cell:cell and cell:matrix 
adhesion was performed using cells over-expressing matriptase-2. During this screen 
P-catenin was seen to be altered in response to matriptase-2 expression status. It was 
decieded that this result needed a further investigation. In this chapter PC3 111312 exp 
and DU 145 111312 exp cells were used to provide a comprehensive examination of the
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effect of matriptase-2 on p-catenin. The investigation started with examining the 
mRNA levels of p-catenin in each of the five cell lines. The PCR results revealed 
that matriptase-2 expression status had no effect at all on the mRNA levels of P- 
catenin in any of the cell lines. In light of this the protein levels of P-catenin were 
then examined using Western blotting. The Western blots revealed that an over­
expression of matriptase-2 greatly decreased the protein levels of P-catenin in the 
PC3 111812 exp cell line. Conversely in the matriptase-2 knockdown cells PZHPV7 mat2 
nbl and PNT2C2 111812 nbl there was a large increase in p-catenin protein. The only 
exception was HECV 111812 exp cells which showed no change in p-catenin protein 
levels. These results could indicate that in the normal prosate and prostate cancer 
cells matriptase-2 is potentially cleaving p-catenin. In the case of DU 145 111812 exp there 
was an increase in p-catenin levels. This could be due to the differing expression of 
E-cadherin in the DU 145 cell lines. The odd result with HECV 111842 exp cells may 
indicate that P-catenin is not involved in the mechanism of action in endothelial 
cells.
IFC conducted on the cells also revealed a reduction in P-catenin staining at the 
cell membrane in the PC3 111842 exp cells, an increase in DU 145 111842 exp and the HECV 
111312 exp cells also showed no increase in p-catenin but may indicate a shift in location 
which would need to be further investigated. As with the Westerns the PZHPV7 111842 
ribl and PNT2C2 111842 nbl also showed an increase in p-catenin protein staining at the 
cell membrane.
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This change in p-catenin levels in the cells may account for the changes in motility 
and invasion seen in the cells as the P-catenin target genes are often involved in 
regulating such cellular processes. It has also been shown that LNCaP cells stably 
transfected with a stabilised p -catenin mutant showed no significant advantage in 
cell growth either in the presence or absence of androgens in comparison to the 
parent line (Verras and Sun, 2006). Because of the importance of these target genes 
in maintaining the correct function of the cell the balance between the degradation 
and activation of P-catenin must remain tightly controlled. Deregulation of this 
pathway plays a huge role in the progression and possibly the development of 
cancer. If matriptase-2 does have a potential regulatory role for p-catenin at the cell 
membrane this could a huge impact on reducing the aggressiveness of prostate 
cancer. If the transcription o f genes promoting a more aggressive phenotype are 
prevented this would cause the cells to shift toward a less cancerous nature.
In an attempt to investigate the anti-angiogenic nature of matriptase-2 the 
metalloproteinase MMP-7, which has previously been shown to be a p-catenin target 
gene in colorectal cancer (Brabletz et al., 1999; Crawford et a l, 1999), was 
investigated in the cells. The expression of MMP-7 is correlated with tumour 
progression, metastasis, and unfavourable prognosis in the human oesophageal 
carcinoma, colon, and gastric carcinoma (Mori et al., 1995; Honda et al., 1996; 
Szarvas et al., 2010). MMPs have widely reported as being one of several 
angiogenic factors secreted by prostate cancer (van Moorselaar and Voest, 2002), if 
the accumulation of p-catenin also causes an increase in MMP-7 this could be one 
explanation to the anti-angiogenic nature of matriptase-2. It was shown that the
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mRNA and protein levels of MMP-7 increased or decreased according to the 
changes seen in P-catenin protein levels in each of the cell lines. This data indicates 
that MMP-7 may play some role in the anti-angiogenic role of matriptase-2 but 
obviously cannot be the only player due to the results from DU 145 mat2 exp and HECV
mat2 exp
To further investigate the anti-angiogenic role of matriptase-2 a molecule 
unrelated to P-catenin was investigated. uPA is an extracellular matrix modulator 
that has been implicated in angiogenesis (Bajou et al., 2001; Noel et al., 2004; 
Morrissey et al., 2008). This investigation revealed that there was no change in uPA 
mRNA levels in any of the cell lines. However, when the protein levels were 
examined it was seen that matriptase-2 over-expression reduced the levels of uPA 
protein in all three over-expression cell lines irrespective of the change in p-catenin 
levels. The trend continued with an increase in uPA protein in the matriptase-2 
knockdown cell lines, again irrespective of p-catenin levels. This could indicate that 
matriptase-2 directly cleave uPA which would contribute to the anti-angiogenic 
nature of matriptase-2 in a p-catenin independent manner.
To further support this theory is has been shown that matriptase-1 has the 
potential to cleave uPA (Takeuchi et al., 2000). As matriptase-1 and -2 have a high 
sequence homology, it is likely that they share potential substrates (Hooper et al., 
2003). Although both proteases may claim uPA as a substrate, due to the tumour 
progressing nature of matriptase-1 and the tumour suppressing nature of matriptase- 
2, the cleavage of uPA may potentially have very different effects in the cancer.
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7.7 Future work
Further investigation into the relationship between matriptase-2 and p-catenin is 
essential. The findings from this study have added further weight to the theoiy that 
matriptase-2 is a potential tumour suppressor and its mechanism of action must be 
fully investigated. It would be ideal to break down matriptase-2 and examine the 
components of the protein to determine which areas are needed to produce these 
results. If only a small section is actually needed to produce the described effects 
recombinant protein could be generated and the effects of exogenous matriptase-2 
can be investigated. This would be beneficial to the possible therapeutic application 
of matriptase-2. From the results of this study and previous studies any therapeutic 
treatment of matriptase-2 would involve increasing its expression. If only a small 
section of matriptase-2 is needed to produce the results seen in this study it would 
be far easier to administer. Although the involvement of matriptase-2 in iron 
metabolism would have to be taken into account if matriptase-2 was to be used as a 
therapeutic treatment. The association of matriptase-2 and p-catenin could be further 
investigated by examining P-catenin phosphorylation status, using TCF reporter 
assays to determine p-catenin activity. Potentially p-catenin could be knocked down 
in the cells or even use a Wnt inhibitor to further investigate the effect of matriptase- 
2 on Wnt/p-catenin signalling. Another aspect that must be considered is the 
potential involvement of the BMP pathway. As matriptase-2 has been irrefutably 
shown to cleave RGMc, a BMP co-receptor, there is scope for matriptase-2 to have 
an influence over the BMP signalling pathway. As the BMP pathway is highly 
important in driving prostate cancer progression this would be a highly relevant area 
to research.
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There is also the potential to further investigate the involvement of matriptase-2 in 
prostate cancer. As DU145 cells appear to have a small amount of endogenous 
matriptase-2 there is the potential to knockdown this endogenous matriptase-2 and 
perform the functional assays again to asses the functional effect of knowcking down 
matriptase-2 in this cell line. To also further investigate the involvement of 
matriptase-2 in prostate cancer is to use databases containing clinical data. These 
data bases include microarray data derived from clinical samples of patients with 
prostate cancer. This could provide some insight into the expression of matriptase-2 
throughout the different grades of prostate cancer and how that has affected patient 
outcome. Matriptase-2 is continuing to show itself as an important player in prostate 
cancer progression and fully determining its mechanistic actions will only increase 
the possibility of producing potential therapeutics that would be used to treat prostate 
cancer.
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